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ABSTRACT
Excessive fat deposition in the form of obesity is now a major health problem 
worldwide leading to an increased risk of a number of diseases, including type II 
diabetes, coronary heart disease and cancer. Adipose tissue was originally thought to 
be used by the body solely as an energy store. In recent years, increases in the 
prevalence of obesity and ongoing research, has shown that lipid storage is not the 
only function of white fat. The discovery of leptin, which was followed by the 
identification of other protein factors, termed ‘adipokines’, secreted by white adipose 
tissue (WAT), indicated that WAT is major endocrine organ.
The gastrointestinal tract is the portal for the entry of dietary nutrients and a number 
of intestinal hormones such as glucagon-like peptide-1 (GLP-1) and glucose- 
dependent insulinotropic polypeptide (GIP), known as incretin’s, and ghrelin, are 
involved in their absorption and storage. Recently, it was found that the gene 
precursor of ghrelin encoded another secreted and bioactive peptide named obestatin, 
and was shown to have actions opposite to that of ghrelin. Thus, if specific receptors 
for these peptides are present in adipocytes one can infer that it is likely that they may 
have a direct effect on adipose tissue function.
The work presented in this thesis has demonstrated that genes encoding the receptors 
for ghrelin (GHS-R), obestatin (GPR39-putative), glucagon-like peptide-1 (GLP-1 R) 
and glucose-dependent insulinotropic polypeptide (GIPR) are expressed in the main 
WAT depots of mice and humans, and indeed are expressed in cell systems of both 
mouse and human adipocytes. Moreover, the receptor protein was detected in adipose 
tissues and in differentiated adipocytes by western blotting. In addition, receptor 
mRNA was detected in subcutaneous adipose tissue of obese human subjects. 
Importantly, while GPR39 gene expression was found in subcutaneous fat of obese 
subjects no expression was evident for GPR39 in lean subjects.
The work has suggested that both GIP and ghrelin serve as regulatory agents that may 
have a role in the inflammatory response in human adipocytes. In addition, treatment 
with different gut hormones like the incretins, GIP and GLP-1, or ghrelin has a 
selective effect on the production of a number of adipokines in human adipocytes.
XIX
This might constitute an important element in the pathogenesis of obesity. Moreover, 
obestatin (1-23) and obestatin (11-23) may have regulatory effects on the release of 
key adipokines, such as adiponectin, IL-6, MCP-1 and in the case of obestatin (11- 
23), leptin.
Finally, 24 h treatment with GLP-1 and ghrelin in the absence or presence of insulin 
in fully differentiated SGBS adipocytes showed significant stimulatory effects on 
glucose uptake. Although it was not possible to identify the precise mechanism of this 
effect, it would not appear to be through induction of the insulin-sensitive glucose 
transporter, GLUT4.
In conclusion, these studies indicate that the receptors for gut hormones are expressed 
in WAT and are indeed present in differentiated adipocytes. They also suggest that in 
differentiated human adipocytes, the incretins, obestatin and ghrelin regulate the 
expression and release of key adipokines and thereby play a significant role in the 
cross-talk between the gut and adipose tissue.
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CHAPTER 1 
INTRODUCTION
Introduction
1.1 Historical
The physiology, origin, chemistry, pharmacology and clinical aspects of 
gastrointestinal (GI) hormones, or gut hormones as they have been more succinctly 
labelled, has become one of the most rapidly expanding and interesting fields in 
contemporary endocrinology and gastroendocrinology. One of the more eloquent 
pictures of the ever growing field of gut hormones was painted by G.B.J Glass
“ This territory is reminiscent of a subtropical forest full of proud and established 
trees, jungle-like bushes inter-woven with each other, beautiful flowers not yet 
classified in the Linnaen code, and also frail and weak growths struggling for survival. 
In this new territory the steps of the explorer are both risky and highly rewarding, but 
certainly full of excitement.” (Glass, 1980)
The study of gut hormones as we now know them, dates back to the very beginning of 
last century. Bayliss and Starling published a paper entitled “On the causation of the 
so called peripheral reflex secretion of the pancreas.” (Bayliss and Starling, 1902).
The “ peripheral reflex” referred to in their paper was that propounded by Popielski 
(1901) who claimed that the secretions of the pancreas were under nervous control. 
However, with Balliss and Staeling’s discovery of secretin the age of “endocrinology” 
had begun and any serious thoughts of the involvement of the central nervous system 
(CNS) in the secretions of the pancreas were set aside for decades.
In 1905 Edkins described the chemical mechanism of gastric secretion with the 
discovery of gastrin (Edkins, 1905). More than twenty years later it was discovered 
that yet another hormone contributed to the normal function of the gut, when it was 
shown that introduction of fat into the small intestine resulted in the secretion of a 
hormone which caused gall bladder contractions. This hormone was named 
cholecystokinin (CCK) (Ivy and Oldberg, 1928), and thus the entire workings of the 
gut were apparently explained by the actions of these three hormones; gastrin 
controlled gastric acid secretion, secretin that of pancreatic bicarbonate, and 
cholecystokinin-pancreozymin (as it became known) gall bladder contraction and 
pancreatic enzyme output. Even as late as 1970 it was argued that the hormonal 
regulation of the digestive tract and pancreas could be totally explained by these same 
three hormones (Grossman, 1970).
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Although the fuse was lit in 1902 the explosion in interest and “ understanding” in the 
working of the gut did not occur until sixty to seventy years later, for example, the 
amino acid sequence of gastrin was not determined until 1964 (Gregory et al., 1964)
A wealth of published studies have supported the hypothesis that more than one 
peptide can be involved in the regulation of GI function, for instance gastric and 
pancreatic secretion, and GI motility, acting as stimulants or inhibitors. However, 
more recently researchers have turned their attention to possible roles for GI 
hormones outside the GI tract.
1.2 The Gut
The primary function of the gut is the uptake of water and nutrients. Most of the 
nutrient molecules present in food are large polymeric molecules that must be 
mechanically and enzymatically broken down into smaller molecules before they can 
be absorbed.
Digestion, absorption, and secretion take place in different components of the GI tract 
and specific functions tend to be localized to the main regions of the gut, namely the 
stomach, the small intestine, and the distal and proximal colon.
There is a continuous back and forth passage of information between the GI tract, and 
the brain, known collectively as the brain-gut axis. In the CNS, complex circuitries 
process incoming signals and control metabolically active organs such as the liver, 
skeletal muscle, and adipose tissue (Spiegelman and Flier, 2001; Horvath et al, 2004). 
These interrelated circuits can influence the functions, sensitivity, secretion, 
inflammatory responses and motility of the gut (Fig 1.1).
Many peptides are synthesised and released from the GI tract. Whilst their roles in the 
regulation of GI function have been known for some time, it is now evident that they 
also influence eating behaviour and thus can be potential anti-obesity targets. Several 
peptides which affect food intake have been identified including ghrelin, obestatin, 
incretins [glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP)] and many other peptides. Several physiological factors may be 
involved in the development of obesity. These include altered adipose tissue 
metabolism, hormonal changes, and changes at sites in the brain that control satiety, 
particularly in the hypothalamus. There may be some kind of abnormal signal that 
affects adipose tissue metabolism and alters fuel partitioning, directing increased
3
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storage in adipose tissue instead of use in muscle. This abnormal signal has not been 
identified. However, lipoprotein lipase has been found to be increased in obesity, and 
this enzyme can increase the storage of triglycerides in adipose tissue. The molecular 
mechanisms of specific gut hormones supporting effect on lipogenesis are widely 
unclear apart from an increase of the insulin receptor affinity in adipocytes (Hauner et 
al., 1988 and Bassil et al., 2007). Despite evidence for GIP effects on fat metabolism 
in humans, the role of specific gut hormones in the pathogenesis of human obesity and 
insulin resistance has not been investigated in detail. However, specific receptors for 
GIP have been identified on adipose tissue, studies have been inconclusive with 
regard to GLP-1 and nothing is known with regards to ghrelin and obestatin. A direct 
effect on adipose tissue is highly likely if specific receptors for these peptide 
hormones are present in adipose tissue.
1.2.1 Incretins
The idea of regulation of the endocrine pancreas by signals from the gastrointestinal 
tract was proposed in 1929 by Zunz and La Barre. They termed this regulator an 
'incretin'. Further support for this theory came with the observation by two 
independent groups in 1964 that glucose given orally led to a much greater increase in 
insulin than when an equivalent amount of glucose was given intravenously (Elrick et 
al., 1964; McIntyre, Holdsworth and Turner, 1964). The explanation for this effect 
was that insulinotropic factors, incretins, were released from the gastrointestinal tract 
in response to nutrient (most notably glucose) absorption. A comparable experiment 
revealed that oral as opposed to intravenous amino acid loads caused a similar effect 
(Dupré et al., 1968).
In order to be considered as incretin candidates peptides need to fulfill certain criteria: 
they must be released in response to ingestion of nutrients, especially glucose, and 
should reach postprandial concentrations in vivo that are of a sufficient magnitude to 
elicit an insulinotropic response at elevated glucose concentrations (Creutzfeldt, 
1979).
Although several gut peptides and neurotransmitters exhibit incretin-like activity, 
evidence from experiments employing immunoneutralizing antisera, antagonists, and 
genetic loss-of function studies in mice suggests that GIP and GLP-1 are the dominant
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Fig 1.1 The brain integrates peripheral signals relating food intake and
energy balance
Adaptedfrom Konturek et al., 2006
A schematic diagram of the brain integrating the peripheral signals produced by adipose 
tissue, pancreas and the gut, Feedbacks are related to the absorbed nutrients, gut 
peptides, adipose-derived protein factors and neural signals which balance the appetite, 
satiety and energy expenditure. PYY, peptide YY; CCK, Cholecystokinin; GLP-1, 
glucagon-like peptide 1; GIP, glucose-dependent insulinotropic peptide; DVC, dorsal 
vagal complex.
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peptides involved in nutrient stimulated insulin secretion and account fully for the 
incretin effect (Fehmann et al., 1989 and Nauck et al., 1993).
1.2.1.1 Glucagon-like Peptide -1 (GLP-1)
Glucagon and the glucagon-like peptides are encoded in a much larger precursor 
known as proglucagon. Tissue-specific post translational processing leads to the 
production of the many forms of these peptides (Conlon, 1988; Drucker, 1990).
The sequence of human preproglucagon was determined (Bell et al., 1983) and found 
to contain the sequence of glucagon and of two glucagon-like peptides referred to as 
glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2). From 
examination of the gene sequence it was predicted that GLP-1 would contain 37 
amino acids corresponding to proglucagon (Pederson et al., 1975, Woods et al., 
2000). The presence of the glycine residue at the C-terminal suggested that the 
peptide is likely to be amidated by decarboxylation of glycine as is seen in other 
gastrointestinal hormones (Tatemoto and Mutt, 1980). This amidation is often found 
to be necessary for most hormones to be biologically active (Rehfeld et al., 1980).
Thus two structures of GLP-1 were predicted corresponding to GLP-1 (1-37) and 
GLP-1 (1-36) amide. It was then demonstrated that GLP-1 undergoes further 
processing in the intestine whereby the 6 N-terminal amino acids are cleaved 
producing GLP-1 (7-37) or GLP-1 (7-36) amide (Mojsov et al., 1986). Once this was 
discovered GLP-1 (7-36) amide was then isolated from the intestine of pigs (Holst et 
al., 1987), rats (Kreymann et al., 1988) and humans (Orskov et al., 1989). The 
predominant form of GLP-1 in the intestine was shown to be the amidated form 
(Orskov et al., 1989).
GLP-1 has been found to be localised in the distal regions of the intestine, most notably 
the ileum and colon (Kreymann et al., 1988). The endocrine cells in which GLP-1 is 
synthesised and secreted are also responsible for the secretion of enteroglucagon, GLP- 
2, glicentin (Orskov et al., 1986) and peptide YY (PYY) (Ali-Rachedi et al., 1984) and 
are termed L cells. GLP-1 is also localised in the A-cells of the pancreas (Uttenthal et 
al., 1985; Mojsov et al., 1986; Orskov et al., 1986; Vaillant and Lund, 1986).
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Glucose has been shown to stimulate the release of GLP-1 (7-36) amide (Kreymann 
et al., 1987; Orskov et al., 1991). Also a mixed meal results in increased secretion of 
GLP-1 (7-36) amide (Kreymann et al., 1987). Studies have demonstrated increases in 
circulating concentrations of GLP-1 (7-36) amide following the ingestion of glucose, 
protein, fat or a mixed meal in humans (Elliott et al., 1993; Ranganath et al., 1996).
It is interesting to note that the postprandial peak in plasma GLP-1 (7-36) amide 
concentrations occurs within 30 minutes of the ingestion of the meal. Since the 
peptide is released from distal regions of the intestine it is unlikely that the nutrients 
have come into contact with the lumen or are absorbed here; thus the release may be 
stimulated by neural (Roberge and Brubaker, 1991) or hormonal signals from the 
upper gut (Brubaker, 1991). It has been established that GIP is not responsible for the 
stimulation of GLP-1 (7-36) amide secretion since it has been shown not to increase 
GLP-1 (7-36) amide concentrations when physiological concentrations of GIP was 
administred (Nauck et al., 1991). The most documented action of GLP-1 (7-36) 
amide is its ability to stimulate the release of insulin during hyperglycaemia from the 
perfused pancreas (Holst et al., 1987; Mojsov, Weir and Habener, 1987). This action 
is discussed in greater detail in section 1.4.1.2.
GLP-1 (7-36) amide has been demonstrated to inhibit pentagastrin-stimulated gastric 
acid secretion in humans (O'Halloran et al., 1990) suggesting a role for this peptide 
as an enterogastrone. GLP-1 (7-36) amide has been shown to stimulate the release of 
somatostatin from perfused pig pancreas (0rskov, Holst and Nielsen, 1988), perfused 
rat pancreas (Schmid et al., 1990) and perfused rat stomach (Eissele, Koop and 
Arnold, 1990). Receptors for GLP-1 (7-37) have been discovered on a somatostatin 
secreting cell line (Fehmann and Habener, 1991). Receptors for GLP-1 (7-36) amide 
have also been found in the rat brain and lung (Kanse et al., 1988). The presence of 
binding sites in the brain suggest that GLP-1 (7-36) amide may have a role as a 
neurotransmitter.
GLP-1 receptor (GLP-1 R) is a protein belonging to the family B of the seven 
transmembrane G-protein coupled receptors (Mayo et al., 2003). Structure-activity 
studies suggest that the N-terminal comprises the activation domain and the C- 
terminal binding domain. GLP-1 R is found on B- and D-cells of the pancreas,
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parietal cells of the stomach, pylorus, lungs and the brain. The existence of receptors 
in the liver and skeletal muscle has not been confirmed.
The expression of the GLP-1R in adipocytes has been a matter of debate. Several 
studies have observed the expression of the GLP-1R in vitro by receptor-binding 
studies in human (Merida et al., 1993), rat (Valverde et al., 1993), and 3T3-L1 
adipocytes (Egan et al., 1994). However, in rat adipose tissue, others did not find 
GLP-1 receptors (Bullock et al., 1996). Moreover, an alternative form of the receptor 
has been proposed (Montrose-Rafizadeh et al., 1997). This alternative form may 
lower intracellular cAMP levels (Miki et al., 1996), contrary to the conventional form, 
which stimulates formation of this second messenger.
1.2.1.2 Glucose-dependent insulinotropic polypeptide (GIP)
GEP is a 42 amino acid hormone originally discovered by its action of potent inhibition 
of gastric acid secretion (Brown et al., 1970). It is localised in the duodenum and 
jejunum (Bloom and Polak, 1980) in cells termed K cells.
Secretion of GIP is stimulated by the ingestion of glucose in man (Cataland et al., 
1974) and in particular it is necessary for there to be active transport of glucose and 
other monosaccharides for this stimulation to occur (Sykes et al., 1980). The other main 
stimulus for the secretion of GIP in man is ingestion of fat (Falko et al., 1975) which is 
a more potent stimulant than glucose in man. Absorption of fat is a prerequisite for GIP 
secretion (Ebert and Creutzfeldt, 1980). Digestion of fat is necessary in order to elicit 
the response as GIP secretion is proportional to the quantity of long-chain fatty acids, 
which are the end product of triglyceride hydrolysis, in the gastrointestinal tract (Ross 
and Shaffer, 1981). It appears that chylomicron formation is a prerequisite for GIP 
secretion since blocking the formation of chylomicrons using a detergent (Tso et al., 
1981) results in inhibition of GIP release (Creutzfeldt and Ebert, 1988).
The first documented action of GIP was its ability to inhibit gastric acid secretion 
(Brown et al., 1970), but this effect is weak in humans since increases in circulating 
concentrations of GIP caused by feeding were insufficient to cause any significant 
inhibition of acid secretion (Maxwell et al., 1980). However, there is considerable 
evidence that GIP can inhibit the secretion of gastric acid and this action may be 
mediated by locally released somatostatin (Brown et al., 1989).
8
Introduction
The major biological activity of GIP is its potent stimulation of the secretion of insulin. 
It was observed that the infusion of GIP in humans together with an infusion of glucose 
resulted in potentiation of insulin release and improvement in glucose tolerance (Dupre 
et al., 1973). This action of GIP is covered more extensively in section 1.4.1.1.
It has recently become apparent that GIP may have direct effects on lipid metabolism 
(Beck, 1989).
The GIP receptor (GIPR) belongs to the seven-transmembrane domain family of 
receptors. It is widely distributed in peripheral organs of animals (Usdin et al., 1993). 
Although the GIP receptor is expressed in various regions of the brain, the actions of 
GIP in the central nervous system remain uncertain. Functional GIPR has also been 
identified in rat adipocytes (Yip et al., 1998). In addition; studies reported that GIPR 
has alternative modes of action, both dependent and independent of cAMP, in rat 
adipocytes (Ehses et al., 2002) and in non-adipose cell lines (Oben et al., 1991, Beck 
et al., 1983 and Beck et al., 1988). Although GIPR is expressed in primary cultures of 
rat adipocytes (Yip et al., 2000) and differentiated 3T3-L1 adipocytes (Kubota et al., 
1997), the functions of the hormones in fat cells, including whether it may affect 
adipokine production has not been established.
1.2.2 Ghrelin
Ghrelin is a 28 amino acid peptide that was originally identified as an endogenous 
ligand for the growth hormone secretagogue receptor (Horvath et al., 2001). Ghrelin 
is acylated on serine-3, a modification observed for the first time in mammalian 
physiology, and this acylation appears to be necessary for its biological activity 
(Kojima et al., 1999). Ghrelin is produced predominately by the stomach (Ariyasu et 
al., 2001), but also in lesser amounts by the GI tract (Date et al., 2000; Rindi et al.,
2002) kidney and in the hypothalamus and plays a role in the short-term regulation of 
energy homeostasis (Mori et al., 2000; Gnanapavan et al., 2002; Guan et al., 1997). 
Recently, adminstration of ghrelin to rodents was shown to induce obesity by 
increasing food intake and reducing fat utilization (Kojima et al., 1999). In human 
studies of ghrelin effects on growth hormone (GH) release, feelings of hunger were 
noted as a side effect in a majority of the test subjects (Arvat et al., 2000). Serum 
ghrelin is reduced in obese humans and following acute overfeeding (Kim et al.,
2003) . Circulating ghrelin is increased with fasting in humans. Ghrelin regulates food
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intake by binding specific receptors in the hypothalamus and activating well- 
characterized arcuate nucleus neurons, which produce neuropeptide Y (NPY) and 
agouti related peptide (AGRP) to stimulate feeding (Morton et al., 2001). Ghrelin has 
also been reported to act on other signalling pathways in the hypothalamus and much 
work is underway to fully understand the signalling pathways and role of ghrelin in 
the regulation of food intake (Nakazato et al., 2001). Ghrelin receptor, or GHS-R, is a 
typical G-protein coupled receptors (GPCR) with seven transmembrane domains (7- 
TM) (Howard et al., 1996; McKee et al., 1997; Smith et al., 1999). Two distinct 
ghrelin receptor cDNAs have been isolated (Howard et al., 1996). The first, GHS-R 
type la, encodes a 7-TM GPCR with binding and functional properties consistent with 
its role as ghrelin's receptor, and another GHS-R type lb, is produced by an 
alternative splicing mechanism (Howard et al., 1996). The ghrelin receptor occurs in 
several CNS sites such as arcuate and ventromedial nuclei (Howard et al., 1996), as 
well as in many peripheral regions including heart, lung, stomach, kidney (Kojima et 
al., 2001) and adipose tissue (Kim et al., 2004), indicating that ghrelin is likely to 
have multiple functions in these tissues.
1.2.3 Obestatin
Obestatin is a 23 amino acid peptide produced in the stomach that appears to be 
involved in the regulation of energy balance (Zhang et al., 2005). Obestatin is 
transcribed from the preproghrelin gene and C-terminal amidation is a prerequisite for 
biological activity (Zhang et al., 2005). Several of the actions of obestatin appear to 
oppose the actions of ghrelin (Szentirmai and Krueger 2006; Tremblay et al., 2007). 
Most notably, obestatin appears to be a potent appetite-suppressant causing reductions 
in food intake, body weight and jejunal contraction in rodents (Zhang et al., 2005). 
Also, recent information indicates that obestatin reduces fluid intake by altering of 
thirst mechanisms within the brain (Samson et al., 2007).
The G-protein coupled receptor, GPR39, has been proposed to be the target receptor 
of obestatin (Zhang et al., 2005). However, this has not been confirmed by other 
studies (Holst et al., 2007; Lauwers et al., 2006). One study showed that the GPR39 is 
present in many regions of the brain including the pituitary gland, hypothalamus and 
cerebral cortex (Zhang et al., 2005). However, this conflicts with recent evidence of 
the absence of both GPR39 in the hypothalamus (Jackson et al., 2006) and obestatin
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in the brain (Pan et al., 2006). More puzzlingly, it would appear that obestatin is not 
transported across the blood-brain barrier (Pan et al., 2006). Although some studies 
agreed that GPR39 is expressed in various regions of the brain, the actions of the 
obestatin peptide in the central nervous system remain unconfirmed. GPR39 appears 
to be strongly expressed in the jejunum, duodenum, stomach, ileum and liver, but has 
also been found to a lesser extent in the pancreas (Zhang et al., 2005). Although the 
presence of GPR39 in pancreatic tissue has not been confirmed by others (Jackson et 
al., 2006), significant levels of obestatin immunoreactivity were recently reported in 
perinatal rat pancreas (Chanoine et al., 2006). Furthermore, obestatin 
immunoreactivity positively correlated with insulin concentrations, and since acylated 
ghrelin, which is also found in the pancreas, inhibits insulin secretion, it has been 
suggested that obestatin may potentiate insulin release (Chanoine et al., 2006).
1.3 ROLE OF GASTROINTESTINAL HORMONES IN OBESITY
Treatment of obesity is likely to be eventually revolutionised by greater understanding 
of the disease. Knowledge in this field is still limited to a few “culprit factors” that 
might be involved in the perpetuation of the disease, while less is known about the 
precise role of the individual factors in the causation or initiation of obesity. 
Discovery of various peptides including, ghrelin, leptin and obestatin has given 
obesity research a boost, opening up areas for further studies.
1.3.1 Obesity
Obesity has become a major public health issue in western countries, and is starting to 
spread to developing countries. According to the figures provided by World Health 
Organization (WHO), globally, more than 1 billion adults are overweight; among 
them, at least 300 million are clinically obese. In England, a recent figure has shown 
that about two-thirds of its population are overweight or obese (House of Commons 
Health Committee, 2003). Even more seriously, the “epidemic” of obesity has rapidly 
spread to children and adolescents. The high proportion of obesity in a population not 
only reduces the quality of life since obese individuals are more likely to develop type 
2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, sleeping apnoea,
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osteoarthritis and certain cancers, but also results in a high economic burden to 
societies.
1.3.1.1 Prevalence and causes of Obesity
Obesity is caused by an imbalance between energy intake and energy expenditure. 
More precisely, obesity can only develop when energy intake is in excess of energy 
expenditure (Trayhum, 2005). Generally, overweight and obesity are defined by a 
criterition based on calculation of the body mass index (BMI), which is assessed by 
dividing an individual’s body weight measured in kilograms by his/her height in 
metres squared (kg/m2). The accepted classification ranges are; BMI> 17.5 kg/m2 and 
< 24.9 kg/m2 as normal, >25-29.9 kg/m2 as overweight, > 30 kg/m2 as obesity and > 
40 kg/m as morbid obesity. However, in some circumstances, BMI > 25 kg/m 
cannot necessarily be considered as overweight or obesity, for instance, in athletes 
and muscular individuals, who have more skeletal muscle than normal subjects; 
muscle mass is heavier than fat mass, and therefore, the enhanced proportion of 
muscle mass leads to an increased body weight. Another shortcoming of BMI is that 
it is unable to illuminate fat distribution in the body; in other words, BMI cannot 
distinguish the precise location of the extra body fat. Based on the previous 
approaches, a high accumulation of visceral fat is thought to be more highly linked to 
obesity-associated complications than subcutaneous fat (Bray, 2004). Thus, additional 
methods, including waist:hip ratio, computed tomography (CT) and magnetic 
resonance imaging (MRI), can be supportively used to diagnose obesity together with 
BMI.
Obesity is the consequence of unbalanced food intake and energy expenditure. It is 
believed that obesity is trigged by an interplay of genetic and environmental risk 
factors. Although a monogenic mutation occasionally can be traced in some obese 
families, it is more likely that multiple genes are involved in the underlying 
development of obesity in humans. In addition, environmental risk factors are major 
contributors to the pandemic of obesity. Foods with high fat are supplied routinely in 
the Western diet. Reduced physical activity also has a key role in weight gain. The 
sedentary life style markedly decreases metabolic rate. Overall, increased food intake 
and reduced energy expenditure results in extra energy stored as fat in white adipose
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tissue (WAT).
1.3.1.2 Obesity associated diseases
Obesity is one of the components that is part of the metabolic syndrome, diagnosis of 
which requires the presence of at least three out of the following five criteria: 
impaired insulin sensitivity, hyperglycaemia, dyslipidaemia (elevated blood 
triacyglycerols with depressed HDL-cholesterol), abdominal obesity and 
hypertension. The syndrome represents a group of metabolic and vascular disorders 
that increases the risk of developing type 2 diabetes and cardiovascular disease (Shaw 
et al., 2005).
Obesity itself is linked to a greater than 10-fold higher risk of developing type II 
diabetes (previously called non-insulin-dependent diabetes), which results from an 
inability of the tissues in the body to respond appropriately to insulin produced by the 
pancreas (WHO, 2002). This risk of developing the condition increases with the 
degree of obesity (Diabetes UK, 2005).
Cardiovascular disease is also strongly associated with obesity, with higher rates of 
coronary heart disease, hypertension, atherosclerosis and dyslipidaemia present in 
the obese (Shaw et al., 2005). A meta-analysis that collated data from 26 separate 
studies found that coronary heart disease is the most common cause of premature 
death in obese people (McGee, 2005). A 16-year prospective study in the USA 
linked obesity with an increased risk of death from cancer, with a higher incidence of 
certain cancers, including breast, ovarian and prostate occurring in the obese (Calle 
et al., 2003), and obesity is also associated with a greater risk of developing certain 
orthopaedic conditions such as osteoarthritis, respiratory diseases (including sleep 
apnoea) and a range of renal disorders (Formiguera & Canton, 2004).
The location of fat stores is also important in determining the susceptibility to 
obesity associated diseases, due to functional differences between visceral and 
subcutaneous fat (Wajchenberg, 2000; Atzmon et al., 2002). Increased adiposity in 
the upper part of the body, corresponding to visceral or abdominal fat accumulation, 
has been linked to the development of glucose intolerance, hyperinsulinaemia,
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hypertriglyceridaemia, hypertension and sleep apnoea (Wajchenberg, 2000; 
Vgontzas et al., 2003; Bray, 2004). Contrastingly, those with gluteal-femoral or 
peripheral adiposity (lower body obesity, or female-type fat distribution), have been 
found to be less susceptible to these morbidities (Wajchenberg, 2000).
1.3.1.3 Obesity and white adipose tissue
Extra energy is largely stored as lipid within adipocytes. The enlarged size of 
adipocytes in obesity is an initial compensation to buffer the increased content of 
triacylglycerol (TAG) in cells. However, in the long term, the extra lipid may exceed 
the storage capacity of adipocytes, which results in the differentiation of 
preadipocytes in the stromal vascular (SV) fraction into adipocytes and finally 
increases total adipocyte numbers (Spiegelman & Flier, 1996).
Obesity has emerged as a low grade inflammatory state. According to the description 
given in section 1.6, overproduction of several cytokines and acute-phase proteins by 
WAT, such as Tumour necrosis factor-a (TNFa), plasminogen activator inhibitor-1 
(PAI-1), monocyte chemoattractant protein-1 (MCP-1) and Interleukin-6 (IL-6), 
together with the inhibition of adiponectin, an anti-inflammatory adipokine, is 
proposed to be an important feature in obesity (Trayhum & Wood, 2004). It is still 
unclear whether adipocytes or the SV fraction in WAT has a more prominent role in 
the secretion of these proinflammatory factors (Fain et al., 2004). A remodelling of 
WAT by cross-talk between these two fractions is likely to mediate the low-grade 
inflammatory response in obesity. Evidence indicates that the infiltration of 
macrophages into WAT is an important phenomenon in obesity (Weisberg et al., 
2003; Xu et al., 2003). These recruited macrophages derived from bone marrow 
appear to be a response to the increased production of MCP-1 by both adipocytes and 
the SV fraction in WAT and contribute to the development of obesity-associated 
systemic inflammation (Weisberg et al., 2003; Xu et al., 2003). Recently, a study has 
shown that in WAT, the majority of macrophages are located around dead adipocytes 
scavenging debris by phagocytosis (Cinti, 2005).
Enhanced lipolytic activity is another characteristic aspect of obesity and infection 
(Wellen & Hotamisligil, 2005). The activation of lipolysis in WAT is likely to be 
partly due to the systemic inflammatory response in obesity as TNF-a and leptin 
stimulate lipolysis locally in adipocytes (Kawakami et al., 1987; Ryden et al., 2004;
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Ahima, 2006). In addition, the increased output of free fatty acids (FFA) leads to the 
accumulation of lipid droplets in other metabolic organs, such as liver, skeletal 
muscle, heart and pancreas, an event termed lipotoxicity (Lelliott & Vidal-Puig, 
2004).
Overall, the elevated levels of inflammatory markers and dyslipidaemia are involved 
in the development of a low-grade systemic inflammation in obesity. This directly or 
indirectly leads to insulin resistance and disorders of metabolic activity, which 
eventually result in the complications of obesity, such as type 2 diabetes and 
atherosclerosis.
1.3.2 GLP-1 and Obesity
GLP-1 decreases appetite in healthy (Flint et al., 1998), obese (Naslund et al., 
1999) and diabetic humans (Gutzwiller et al., 1999a). Whether this is mediated 
through direct action on central pathways or predominantly through peripheral actions 
(gastric distension due to delay in gastric emptying) remains to be clarified. The fact 
that GLP-1 reduces appetite even in fasted patients (Gutzwiller et al., 1999b) argues 
for a significant role for central mechanisms. Yet, the fact that the half-life of active 
GLP-1 is less than 2 minutes makes it likely that peripheral mechanisms such as 
delayed gastric emptying play a significant role.
One study showed that intraventricular administration of GLP-1 in fasted rats inhibits 
food intake (Tang-Christensen et al; 1996). This inhibition in food intake seemed to 
be a short-term effect rather than a long-term meal regulation effect as shown by 4- 
day infusion studies in rats (Donahey et al., 1998). The inhibitory effects of GLP-1 
on food intake may involve direct or indirect effects on hypothalamic feeding centres, 
and may be mediated in part through inhibition of gastrointestinal motility. The 
actions of GLP-1 on food intake may also be due in part to induction of a conditioned 
taste aversion response and activation of CNS aversive signaling pathways (Kinzig, et 
al., 2002, Seeley et al., 2000).
Exendin-4 is a novel 39-amino acid peptide isolated from the venom of the Gila 
monster Heloderma suspectum. It shares 53% sequence homology with GLP-17-36 
amide and interacts with the same membrane receptor. Exendin-4 has a significantly 
greater half-life in human serum compared to GLP-1. Exendin-4 has recently been 
shown to significantly lower fasting plasma glucose, delay gastric emptying, and
15
Introduction
reduce food intake in healthy human volunteers (Edwards et al., 2001). Exendin-4 
may potentially be useful in the future in the treatment diabetes and obesity.
1.3.3 GIP and Obesity
A recent study in GIPR-deficient mice has linked GIP to the development of obesity 
through an effect on adipose tissue triggered by ovemutrition (Miyawaki et al., 2002). 
GIP receptor knock-out prevents the development of obesity and insulin resistance in 
ob/ob mice despite high fat feeding. Despite the decreased insulin response and 
hyperglycaemia the feeding behaviour in these rodents was unaffected. Obese subjects 
have increased fasting concentrations of GIP as well as an early-enhanced 
postprandial GIP response compared to lean subjects (Vilsboll et al., 2003). In fact, 
GIP receptor antagonists may have a part to play in future obesity treatment (Gault et 
al., 2003), although the implications of GIP-blockade on carbohydrate and lipid 
metabolism might well restrict its evolution into a therapeutic agent for obesity in the 
near future.
1.3.4 Ghrelin and Obesity
Ghrelin is produced primarily in gastrointestinal organs in response to hunger and 
starvation, and circulates in the blood, serving to signal the central nervous system to 
stimulate feeding.
Recent identification of appetite-regulating humoral factors reveals regulatory 
mechanisms not only in the central nervous system, but also mediated by factors 
secreted from peripheral tissues (Neary et al., 2004; Ukkola et al., 2004). Leptin, 
produced in adipose tissues, is an appetite-suppressing factor that transmits satiety 
signals to the brain (Friedman, 2002); Hunger signals from peripheral tissues, 
however, had remained unidentified until the recent discovery of ghrelin. When 
ghrelin is injected into the cerebral ventricles of rats, their food intake is potently 
stimulated (Kamegai, et al., 2001; Nakazato, et al., 2001; Tschop et al., 2000).
Among all discovered orexigenic peptide, ghrelin has been found to be the most 
powerful. Chronic intracerebroventricular injection of ghrelin increases cumulative 
food intake and decreases energy expenditure, resulting in body weight gain. 
Ghrelin-treated mice also increase their fat mass, both absolutely and as a percentage 
of total body weight. Not only intracerebroventricular injection, but also intravenous
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and subcutaneous injection of ghrelin has been shown to increase food intake 
(Nakazato, et al., 2001;Tschop et al., 2000; Wren, et al., 2001).
1.3.5 Obestatin and Obesity
Initial studies showed that obestatin has opposing effects to ghrelin. When given 
centrally and peripherally to mice, it resulted in decreased food intake and suppressed 
gastric emptying. Given chronically over 8 days, obestatin also decreased weight gain 
in mice, as compared to vehicle (Zhang et al., 2005). Unlike with ghrelin, fasting 
rodents for 48 h and then re-feeding has no effect on obestatin levels (Zhang et al., 
2005). Since the original publications two groups have partially confirmed the effects 
of obestatin on food intake and gastric emptying, (Bresciani et al., 2006; Moechars et 
al., 2006), but two other groups have failed to replicate these findings (Nogueiras et 
al., 2007; Seoane, et al., 2006). The significance of obestatin in the short-term 
regulation of food intake therefore remains uncertain.
1.4 ROLE OF GASTROINTESTINAL HORMONES IN THE REGULATION 
OF INSULIN SECRETION
1.4.1 Enteroinsular axis
The term 'enteroinsular axis' was suggested by Unger and Eisentraut (1969) to 
describe the regulation of endocrine secretion from the pancreas. This included 
regulation by hormones, neural factors and substrate stimulation originating from the 
alimentary tract and the pancreatic islets, which promotes insulin release in response 
to feeding. The pancreas has an abundant supply of autonomic nerve fibres which 
enter the organ with the arteries (Woods and Porte, 1974), suggesting that nervous 
control of pancreatic secretions is important. Cholinergic, adrenergic and peptidergic 
neurons have all been demonstrated.
The role of cholinergic nerves in the control of endocrine secretion from the pancreas 
appears to be in the early (cephalic) insulin response to a meal and not associated 
with the absorption of nutrients. It has also been proposed that cholinergic control 
may be involved in some models of animal obesity and in the regulation of basal and
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postprandial insulin secretion (Ahren et al., 1986).
The role of adrenergic neurones in the control of endocrine secretion appears to be 
related to stress states. In this case there is dual control; a-adrenergic activity inhibits 
insulin secretion and (3-adrcnergic activity leads to stimulation of insulin secretion 
(Ahren, Taborsky and Porte, 1986). These opposing adrenergic influences make the 
net effect on insulin secretion very difficult to assess.
There are many peptides that have been shown to be present in nerve terminals in the 
pancreas, which may be involved in peptidergic regulation of pancreatic endocrine 
secretion. These include vasoactive intestinal peptide (VIP), cholecystokinin, gastrin 
releasing polypeptide, galanin, neuropeptide Y (NPY), calcitonin gene-related 
peptide, substance P and enkephalin.
Observation of a change in the circulating concentrations of insulin is not necessarily 
a result of variation in the rate of its secretion, but may occur in response to 
modification of the rate of hepatic extraction of this hormone. Creutzfeldt and Ebert 
(1985) proposed that the alteration in the rate of hepatic extraction of insulin plays a 
major part in the incretin effect. It is possible to estimate the rate of insulin secretion 
by measuring the plasma concentration of C-peptide. This peptide is co-secreted with 
insulin in equimolar amounts, but unlike insulin is not subject to hepatic extraction 
and so can be used to quantify insulin secretion rates.
Intravenous glucose was found to be associated with higher rates of hepatic insulin 
extraction than oral glucose (Nauck et al., 1986; Shuster et al., 1988) and it was 
suggested that this difference may be due to the action of gastrointestinal hormones or 
neural signals released in response to the absorption of nutrients.
1.4.1.1 Role of GIP in the enteroinsular axis
Soon after the isolation of GIP, its insulinotropic actions were demonstrated in 
humans (Dupre et al., 1973; Anderson et al., 1979; Elahi et al., 1979). When human 
subjects were given intravenous porcine GIP simultaneously with intravenous 
glucose there was a greater insulin response and improved glucose tolerance 
compared with glucose infusion alone (Dupre et al., 1973). This effect could be 
reduced in rats by the infusion of anti-GIP antiserum (Holst, Lauritsen and Moody, 
1980; Ebert and Creutzfeldt, 1982).
The potent ability of GIP to stimulate insulin secretion was demonstrated to be
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glucose-dependent in the perfused rat pancreas (Pederson and Brown, 1978). This 
was confirmed in humans where ingestion of an oral fat load stimulated the release 
of GIP but not insulin. When the fat load was ingested together with intravenous 
administration of glucose the insulin response was greater than when the infusion of 
glucose was given alone (Crockett et al., 1976). This observation confirmed the 
insulinotropic action of GIP to be glucose-dependent. Also, when the fat load was 
ingested during the infusion of intravenous glucose the GIP response was smaller 
than that observed when the fat meal was ingested alone suggesting feedback 
inhibition by insulin (Crockett et al., 1976).
Since the insulinotropic effect was not totally abolished by the administration of anti 
GIP antiserum in rats it was thought likely that GIP is not the only incretin (Holst et 
al., 1980; Ebert and Creutzfeldt, 1982).
1.4.1.2 Role of GLP-1 in the enteroinsular axis
GLP-1 (7-36) amide was demonstrated to be a physiological incretin, possibly more 
powerful than GIP (Kreymann et al., 1987).
GLP-1 (7-36) amide was considered to be a gastrointestinal hormone of physiological 
significance following the discovery of specific binding sites for GLP-1 (7-36) amide 
on pancreatic B-cells (Goke and Conlon, 1988). It was also confirmed that GLP-1 (7- 
36) amide had potent insulinotropic effects (0rskov et al., 1988; Shima et al., 1988). 
The insulinotropic effect of GLP-1 (7-36) amide is glucose-dependent as 
demonstrated from studies using perfused porcine pancreas (Holst et al., 1987) and 
perfused rat pancreas (Mojsov et al., 1987).
1.4.1.3 Role of other gastrointestinal hormones in the enteroinsular axis
Cholecystokinin has been shown to stimulate the release of insulin from the endocrine 
pancreas (Unger et al., 1967; Dupre et al., 1969).
The identification of the pancreatic ghrelin-expressing cells is a matter of controversy, 
and the role of ghrelin in insulin secretion is likewise under debate. Ghrelin has been 
shown to inhibit insulin secretion in some experiments and stimulate insulin release in 
others (Adeghate and Ponery 2002, Broglio et al., 2001, Lee et al., 2002, Reimer et al. 
2003).
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These discrepancies may be due to species differences and/or experimental design. 
Plasma ghrelin and insulin concentrations are affected by blood glucose level; high 
glucose suppresses ghrelin secretion and stimulates insulin secretion, thus the glucose 
level in experiments may be important. Date et al. 2002 reported that ghrelin stim­
ulates insulin release in the presence of high levels of glucose that could release 
insulin from cultured islet cells. In contrast, ghrelin had no effect on insulin release in 
the context of a basal level of glucose.
The recent discovery of obestatin in 2005 means that many of its biological actions 
remain to be identified, including whether this peptide influences in vivo/vitro glucose 
homeostasis or insulin secretion. Since ghrelin raises blood glucose and lowers insulin 
secretion, a number of studies are still investigating whether obestatin administration 
might exert opposite effects on glucose homeostasis and insulin secretion. However 
Green et al., (2007) observed that obestatin peptide has direct and indirect effects on 
food intake, but no direct actions on glucose homeostasis or insulin secretion were 
indicated in mice.
1.5 WHITE ADIPOSE TISSUE
White adipose tissue (WAT) is very important to maintain energy homeostasis. WAT 
contains adipocytes, which are filled with a large lipid droplet that is surrounded by 
cytoplasm. The nucleus is always flattened and is found on the periphery. The lipid is 
stored in a semi-liquid state, and is composed primarily of triacylglycerols. WAT was 
known to have a simple structure that stores large amounts of triacylglycerols (TAGs) 
when there was extra energy, and delivered fatty acids to other tissues and organs. 
Thus, the size of the adipose tissue stores increases in periods of positive energy 
balance and declines when energy expenditure is in excess of intake (Trayhum and 
Beattie, 2001). The SNS is the major regulator of lipolytic activity in WAT, although 
there is also regulation by nutrient and hormonal signals, including glucose and 
insulin (Ahima & Filer, 2000; Bartness et al., 2001)
WAT is also an insulator, which can help in regulating the body temperature of 
mammals (for example, blubber in whales) (Klaus, 2001). Adipose tissue also affords 
a degree of mechanical protection when interposed between bony structures and soft 
tissue (Klaus, 2001). WAT secretes certain hormones that affect energy homeostasis,
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which includes inflammatory development for example cytokines, regulators of 
lipoprotein metabolism and growth factors, among others (Mohamed-Ali et al., 1998). 
Moreover, since the discovery of leptin in 1994 (Zhang et al., 1994), there has been an 
appreciation of WAT as an endocrine organ, and these endocrine functions of adipose 
tissue will be described in section 1.6.
1.5.1 Anatomy of WAT
WAT contains mature adipocytes and the stromal-vascular (SV) fraction, which 
comprises macrophages, fibroblasts, vascular endothelial cells and preadipocytes 
(Hausman, 1985). Mature adipocytes account for about one-third to 50% of the 
cellular components in WAT (Avram et al., 2005). A single white adipocyte has a 
spherical shape with one large 'unilocular' lipid droplet in the cytosol, which pushes 
the cytoplasm and the nucleus into a thin rim (Cinti, 2002). The size of white 
adipocytes normally ranges from 30 to 70 pM in diameter (Napolitano, 1963). 
Adipocytes will become hypertrophied in an obese state; an enlarged fat cell can be 
greater than 150 pM in diameter (Chen et al., 2006). Increased adipocyte numbers, 
known as hyperplasia, may also take place in morbid or childhood obesity due to the 
differentiation of preadipocytes into mature adipocytes (Spiegelman & Flier, 1996). 
In addition, it has been observed that the number of macrophages is markedly 
increased in WAT in obesity (Weisberg et al., 2003; Cinti et al., 2005). In contrast, 
reduced size of adipocytes has been seen in WAT in cancer cachexia; adipocytes lose 
their spherical shape and the lipid content is depleted (Bing et al., 2006). 
Histologically, adipocytes are not isolated since they are adjacent to capillaries (Cinti 
et al., 2005). Although WAT is not as highly innervated as brown fat, the tissue is 
innervated by nerve fibres from the sympathetic nervous system (SNS) (Bartness & 
Bamshad, 1998). In view of this, the autonomic nervous system may also play 
fundamental roles in modulating the metabolism of WAT, particularly lipolysis 
and/or lipogenesis (Romijn & Fliers, 2005).
WAT is generally divided into subcutaneous and visceral depots according to the 
different location and function (Avram et al., 2005). In rodents, subcutaneous fat 
depots are mainly located at the base of the forelimbs and hind legs (Cinti, 2005), 
whereas visceral depots are present in the thorax and abdominal cavity, which are 
further categorised as perigonadal, perirenal and mesenteric depots (Cinti, 2005). In
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humans, subcutaneous depots are the predominant fat and account for up to 80% of 
total body fat (Amer, 1997). Subcutaneous fat pads are located beneath the layer of 
skin and play an important role in preventing heat loss in a cold environment. 
Visceral fat pads can be subdivided into intraperitoneal and retroperitoneal WAT 
according to the anatomy (Smith et al., 2001). Intraperitoneal WAT includes omental 
and mesenteric fat depots, which account for the majority of the visceral fat (Smith et 
al., 2001). Studies suggest that the highest metabolic activities occur in visceral fat 
and visceral obesity is closely linked to metabolic disorders (Amer, 1997). 
Additionally, expression of several adipose tissue-derived proteins varies between 
subcutaneous and visceral WAT (Gesta et al., 2006), which may partly explain the 
presence of unequal development of adipocytes between the two depots; moreover, it 
may also be the molecular mechanism underlining the difference in pathogenetic 
contribution between visceral fat and subcutaneous fat in obesity.
1.5.2 Development of adipose tissue
The development of WAT begins in embryos in humans (Poissonnet et al., 1988). 
Foetal fat is minimal in the first two trimesters of pregnancy, but starts to substantially 
accumulate in the third trimester (Ziegler et al., 1976). The proportion of fat accounts 
for about 15% of total body mass after birth in humans (Fomon et al., 1982).
1.5.3 Adipogenesis
Studies of the development of white adipose tissue focus on adipogenesis, a process 
by which the multipotent mesenchymal stem cells differentiate into mature 
adipocytes under appropriate stimuli (Rosen & Spiegelman, 2000). Convincing 
evidence suggests that adipogenesis occurs both in the foetus and after birth, and 
continuously throughout life (Rosen & Spiegelman, 2000). Adipogenesis includes 
two stages: firstly, the multipotent mesenchymal stem cells are induced to the 
preadipocyte lineage; secondly, adipogenic signals further trigger the differentiation 
of fibroblastic-like preadipocytes into spherical shaped adipocytes with lipid 
accumulation inside the cells (Gregoire et al., 1998). In addition to morphological 
alterations, adipogenesis is also associated with biochemical changes, such as the 
expression of specific genes in the early stage of adipocyte differentiation, which in
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turn are used as markers to reflect the differentiation (Ailhaud, 1996).
The molecular mechanisms which determine how the mesenchymal precursor cells 
undergo the transformation to the adipocyte lineage and further differentiation of 
preadipocytes into mature adipocytes have not been fully established. However, based 
on previous studies, a key development of adipogenesis research is the identification 
of two major transcription factors, the CCAAT/enhancer binding protein a (C/EBP a) 
and the peroxisome proliferator-activated receptor y (PPARy) (Gregoire et al., 1998). 
It has been demonstrated that in vitro and in vivo activation of these two transcription 
factors play a fundamental role in mediating adipocyte differentiation and is 
necessary to initiate the transduction of differential signalling cascades. C/EBPa is a 
family member of the basic-leucine zipper class of transcription factors and has 
predominant roles in the induction of preadipocytes and fat accumulation (Rosen & 
Spiegelman, 2000). PPARy has two isoforms, PPARyl and PPARy2, due to 
differential splicing near the 5'end in the gene encoded sequence (Fajas et al., 1997). 
PPARy2 is abundantly expressed in adipose tissue, and is the most likely isoform 
influencing adipogenesis in the tissue (Fajas et al., 1997). It has been shown that 
incubation of preadipocytes with PPARy ligands leads to a remarkable stimulation of 
adipogenesis (Gumell et al., 2003). In contrast, depletion of the PPARy receptor 
encoded gene in mouse embryos results in the death of the embryo (Barak et al.,
1999) , suggesting that the PPARy receptor is necessary for the development and 
survival of embryos. However, a functionally mutated PPARy gene causes a 
significant reduction of fat mass and lipodystrophy in mice (Rosen & Spiegelman,
2000) . In addition to stimulating adipogenesis, the PPARy receptor has roles in the 
modulation of insulin sensitivity, hypertension and dyslipidaemia (Gumell et al.,
2003).
1.5.4 Apoptosis of adipocytes
Apoptosis is the self-regulated deletion of a dysfunctional cell or 'programmed cell 
death'. It involves a large number of molecules and is governed by several integrated 
pathways. Although body weight loss primarily comes from the reduced size of 
adipocytes and not the number of cells, apoptosis is still present in adipocytes and is 
correlated with the depletion of fat cell numbers in WAT during weight loss 
(Gullicksen et al., 2003); for instance, apoptosis of adipocytes has been observed in
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WAT of cancer cachectic patients and human immunodeficiency virus (HIV) 
patients treated with protease inhibitors (Prins et al., 1994; Domingo et al., 1999). 
Leptin and TNF-a, two adipocyte-derived protein factors, have been shown to link 
with adipocyte programmed cell death (Gullicksen et al., 2003; Wame, 2003).
1.5.5 Studies of WAT
1.5.5.1 In vivo study of WAT
In vivo investigation is a very powerful tool to explore the specific environmental 
effects or the effects of foods on metabolism. For example, the influence of a certain 
chemical compound or the activity of a pharmacological drug can be examined by 
being given to live animals through oral administration or direct injections. In vivo 
knock out of a specific gene in a live animal is an extremely useful method to clarify 
the functions of the encoded protein. However, the major shortcoming of an in vivo 
study is that it is unlikely to precisely identify the exact molecules affected by the 
treatment. Thus, at some point, in vitro studies and particularly using cultured cells 
are a key way to examine the potential signalling pathways and the downstream 
molecules in response to a certain treatment.
1.5.5.2 In  vitro cell culture models to study adipocytes
Currently, at least three types of in vitro culture models have been employed for 
studying adipocytes: i) mature adipocytes isolated from white fat pad, ii) 
preadipocyte primary culture, and iii) preadipocyte clonal cell lines (Grégoire et al., 
1998). These culture models provide effective tools for studying adipogenesis and 
the functions of adipocytes.
1.5.5.2.a Mature adipocytes isolated from fat pads
Collagenase digestion is a straightforward way to separate mature adipocytes directly 
from a fresh fat pad. The isolated mature adipocytes are seeded and maintained in 
media with essential nutrients or salt solution. Mature adipocytes are able to be
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maintained for a period of time but normally no longer than 24 h. It is thought that 
mature adipocytes isolated by this method are closer to in vivo adipocytes since they 
are immediately separated from WAT of an intact animal. However, caution should 
be exercised in data analysis since excision and mincing of tissues are disruptive 
procedures that may influence the outcome of the experimental results. For example, 
induced expression of tumour necrosis factor-a (TNF-a) and hypoxiainduced factor- 
la (HIF-la) was observed in mature adipocytes prepared from minced adipose tissue 
(Gesta et al., 2003; Ruan et al., 2003).
1.5.5.2.b Preadipocyte primary culture
Primary culture is a method to obtain adipocytes from the isolated preadipocytes in 
the SV fraction of fresh WAT. The cultured preadipocytes are maintained in a 
medium with all the necessary nutrients. Following confluence, preadipocytes are 
then induced to differentiate into adipocytes by exposure to a medium containing 
components of an adipogenic cocktail. In comparison with the clonal aneuploid cell 
lines, it reflects the in vivo situation more closely because primary preadipocytes are 
diploid (Gregoire et al., 1998). Another key advantage of preadipocyte primary 
culture is that preadipocytes can be derived from a variety of fat depots, such as 
subcutaneous and visceral. This property raises the possibility of analysing the 
difference between subcutaneous and visceral fat depots in term of their capacity to 
differentiate and differences in biochemical activity. However, one problem of 
primary preadipocyte culture is the purity of this culture system since there may be 
trace amounts of other cell types in the SV fraction, such as fibroblasts. Another 
shortcoming is that primary culture needs a large amount of fresh adipose tissue to 
collect sufficient preadipocytes. Moreover, primary culture is unable to be repeated 
since the preadipocytes have a limited capability to undergo passage; in other words, 
the preadipocytes lose their ability to be induced into adipocytes after culturing for a 
couple of generations.
Zen-Bio cells are a commercially available primary culture derived from the 
preadipocytes in the SV fraction from human WAT (Gregoire et al., 1998; Wang et 
al., 2005). However, as discussed above, these preadipocytes are only able to 
differentiate in limited passages and their differentiation ratio is largely dependent on 
donor age.
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1.5.5.2.C Preadipocyte cell lines
Clonal cell lines have been characterized into three types according to the origin of 
the cells (Ailhaud, 1997). Firstly, the totipotent embryonic stem cells (ES cells) are 
the cell lines, which are capable of generating all cell lineages. Secondly, the 
generated multipotent stem cells are the cell lines, which are able to be further 
differentiated into myogenic, chondrogenic and adipogenic lineages. Finally, the 
adipoblasts are the adipogenic lineage which are the only precursors induced to 
adipocytes. Theoretically, clonal cells can be passaged and subcultured indefinitely 
(Ntambi & Young-Cheul, 2000). The clonal cells are likely to be homogeneous and 
can be induced at the same stage. Moreover, the clonal adipocytes are histologically 
and functionally similar to mature adipocytes derived from fresh adipose tissue. 
However, clonal cell lines are of aneuploid lineage, and this will not make them 
entirely the same as adipocytes derived directly from adipose tissue (Gregoire et al., 
1998).
3T3-L1 and 3T3-F442 are the most well-characterized murine clonal adipocyte cell 
lines at present. They are derived from the heterogeneous Swiss T3 cells obtained 
from mouse embryos (Green & Meuth, 1974). Cultured preadipocytes have an ability 
to constantly proliferate until reaching confluence, a stage termed as growth arrest 
(Rosen & Spiegelman, 2000). Differentiation of cultured preadipocytes is initiated 
after the postconfluent cells are exposed to a combination of agents including insulin, 
isobutylmethylxanthine (IBMX) (a cAMP phosphodiesterase inhibitor) and 
dexamethasone (a synthetic glucocorticoid agonist) (Rosen & Spiegelman, 2000).
The development of a human clonal adipocyte cell line has not been as successful as 
in the mouse. To date, there is still a lack of a well-characterized human preadipocyte 
cell line. Currently, a valuable resource is the SGBS cell strain which is developed 
from the SV fraction within the subcutaneous adipose tissue of an infant with 
Simpson-Golabi-Behmel syndrome (SGBS) (Wabitsch et al., 2001). It is a rare X- 
linked genetic disorder with multiple abnormalities and overgrowth including adipose 
tissue (Wabitsch et al., 2001). The fibroblast-like SGBS preadipocytes have a high 
capacity to be induced to adipocytes after incubation with adipogenic compounds 
(Wabitsch et al., 2001). More importantly, the differentiated adipocytes 
biochemically and functionally mimic the primary adipocytes originated from 
adipose tissue which makes them useful as an alternative tool of primary culture
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(Wabitsch et al., 2001). In this thesis, the 3T3-L1 and SGBS cell strains were 
employed to perform most of the in vitro work. However, it should be pointed out 
that SGBS cell strain cannot be fully regarded as a cell line because it is not immortal 
and its differentiation capacity diminishes after 70 generations (Wabitsch et al., 
2001) .
Differentiation of the mesenchymal stem cells into adipocytes has also been 
examined under in vitro conditions. The mesenchymal stem cells are primarily 
isolated from bone marrow and are able to differentiate into multiple cell types 
including osteoblasts, chondroblasts and adipocytes (Vaananen, 2005). Several 
studies suggest that bone marrow is not the only place where the mesenchymal stem 
cells are present because similar types of cells have been identified in many other 
tissues (Vaananen, 2005). Recently, a study has reported that the multipotent stem 
cells isolated from the SV fraction of WAT of an infant, termed hMADS cells, 
appear to be able to enter into an adipose lineage which is further induced to fat cells 
under appropriate stimuli. It is also suggested that the preadipocytes preserve their 
ability to be differentiated into adipocytes over 160 generations (Rodriguez et al.,
2004). However, due to the absence of follow-up studies, the utility of hMADS cells 
is still uncertain.
1.6 Endocrine function of WAT
It has only been over the last decade that the prevalent view of white adipose tissue 
has changed from that of it being a relatively inactive tissue, storing and releasing 
nutrients, as and when required, to that of an active endocrine organ with pleiotropic 
roles affecting a range of physiological processes. Adipose tissue is now recognised 
as the source of a wide range of secreted proteins and other factors (Trayhum & 
Beattie, 2001; Trayhum & Wood, 2004). The proteins released from adipocytes are 
referred to as adipokines; a previously used term, adipocytokines, is potentially 
misleading as it might be inferred that all adipocyte-secreted proteins are cytokines. 
A key feature of adipokines is that they are secreted proteins, and the term should 
therefore not be employed to describe cytosolic or membrane proteins that are not 
released by adipocytes. The description is also restricted to proteins secreted by 
adipocytes themselves, rather than adipose tissue as a whole, since this would 
otherwise include protein signals emanating from other cell types present within
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WAT (such as macrophages) that may also be present in other tissues (Trayhum & 
Wood, 2004). The secretory products of WAT are summarised in Fig. 1.2, and 
several will be presented in more detail below.
It should first be mentioned, however, that fatty acids are quantitatively the primary 
secreted products from WAT, being the result of TAG lipolysis mediated by HSL. 
Cholesterol is also released into the circulation by WAT, and although the tissue is 
unable to synthesise steroids de novo, WAT expresses the enzymes necessary for the 
conversion of oestrone into oestradiol, androstenedione into testosterone and 
androgens into oestrogens; these are therefore also secretory products of WAT 
(Trayhum & Beattie, 2001).
1.6.1 Leptin
Leptin is the product of the ob gene, and its discovery in 1994 (Zhang et al., 1994) 
has been pivotal in the development of the current understanding of the endocrine 
function of WAT (Trayhum & Beattie, 2001). The ob gene encodes an 18 kDa 
molecule, and mature leptin is a 16 kDa cytokine-like protein (Considine & Caro,
1996) . Although WAT is the primary source of leptin production, reflected by the 
close correlation between the degree of adiposity and basal leptin level, other tissues 
are known to synthesise and secrete the protein, including placenta (Hoggard et al.,
1997) , BAT (Moinat et al., 1995), stomach (Bado et al., 1998) and skeletal muscle 
(Wang et al., 1998).
Along with insulin, leptin fulfills the criteria laid out for a satiety factor as described 
by the lipostatic theory of energy balance referred to earlier (Kennedy, 1953). The 
parabiosis studies of Coleman in the 1970s also foreshadowed the discovery of 
leptin. Grafting of a lean control mouse to an ob/ob mouse led to normalisation of the 
latter’s phenotype (Coleman, 1973; Coleman, 1978). This was interpreted as 
evidence that the ob gene encoded a humoral factor that regulated nutritional status, a 
mutated version of which was present in the ob/ob mouse. In a parallel study, 
Coleman demonstrated that parabiosis of a db/db mouse with a lean control had no 
effect on the former's phenotype, suggesting that the db/db mouse possessed a 
defective gene that encoded a receptor for the putative circulating satiety factor.
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Fig 1.2 Products released by white adipocytes
Energy Homeostasis 
Hormones
Leptin, Adiponectin
Proteins of lipid 
Metabolism
LPL, adipsin , ZAG
Haemostatic & Haemodynamic 
Factors
PAI-1, Angiotensinogen
The secretory and endocrine function of white adipose tissue. The figure shows a range 
of adipose tissue derived factors in energy balance, blood pressure regulation, 
angiogenesis, insulin sensitivity, immunity and inflammation. TNFa, tumour necrosis 
factor-a; IL, interlukin; PAI-1, plasminogen activator inhibitor-1; SAA, serum amyloid 
A; MCP-1, monocyte chemoattractant protein-1; NGF, nerve growth factor; VEGF, 
vascular endothelial growth factor; MIF, macrophage migratory inhibitory factor; LPL, 
lipoprotein lipase; ZAG, zinc-a2-glycoprotein.
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The control animal died of starvation, indicating that in response to the lack of a 
functional receptor, the db/db mouse was over expressing the satiety factor, leading 
to anorexia in the lean mouse (Coleman, 1973; Coleman, 1978).
Although examples of human obesity due to mutations in the ob gene have been 
documented (Montague et al., 1997; Strobel et al., 1998; Farooqi et al., 1999), these 
are rare occurrences and in the vast majority of cases leptin levels are actually 
increased in human obesity (Considine et al., 1996), leading to the concept of'leptin 
resistance' in which increasing leptin levels fail to reduce food intake or increase 
energy expenditure. The mechanisms underlying this postulated resistance to the 
actions of leptin in human obesity have not been established, but two possible 
explanations are a failure of circulating leptin to reach its targets in the brain, and 
inhibition of the intracellular leptin receptor signalling cascade (Mtinzberg & Myers,
2005).
1.6.2 Proteins of lipid and lipoprotein metabolism
Lipoprotein lipase (LPL), the first protein to be identified as being secreted by 
adipocytes, hydrolyses circulating TAGs to release fatty acids for uptake by 
adipocytes. Its expression is stimulated by insulin and glucocorticoids (Trayhum & 
Beattie, 2001). WAT is also an important source of cholesteryl ester transfer protein 
(CETP; required for accumulation of cholesteryl esters by adipose tissue), 
phospholipid transfer protein (PLTP; involved in cholesterol and HDL metabolism) 
and apolipoprotein E (ApoE; involved in cholesterol and VLDL metabolism) (Jiang 
& Bruce, 1995; Trayhum & Beattie, 2001; Westerterp et al., 2006).
Adipocytes secrete adipsin and acylation-stimulating protein (ASP), enabling them to 
regulate TAG synthesis. Adipsin is equivalent to complement D, the rate-limiting 
enzyme of the alternative complement pathway, and its expression is regulated by 
glucocorticoids and insulin (Choy et al., 1992; Ahima & Flier, 2000). It is required 
for the synthesis of ASP, which is derived from the end product of the alternative 
complement pathway, complement C3a (Trayhum & Beattie, 2001). ASP is involved 
in the uptake and esterification of fatty acids to TAGs for storage by adipocytes, and 
has an additive effect with that of insulin by allowing adipose tissue to self-regulate 
its lipid-storage capacity (Cianflone et al., 1999). Plasma concentrations of both 
adipsin and ASP are increased in human obesity (Cianflone et al., 1999; Ahima &
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Flier, 2000).
Zinc-a2-glycoprotein (ZAG) is overexpressed in several types of malignant tumour, 
and has been used as a cancer marker. ZAG mRNA and protein have recently been 
shown to be detectable in murine and human WAT, with mRNA levels in 3T3-L1 
adipocytes being increased by administration of the p3-adrenoceptor agonist BRL 
37344 and the synthetic glucocorticoid dexamethasone. Furthermore, ZAG mRNA 
and protein levels were shown to be selectively elevated in the WAT of mice with 
cancer cachexia. Together with evidence that ZAG administration increases free fatty 
acid levels in vivo, and stimulates lipolysis in vitro, it has been suggested that ZAG 
may be involved in lipid metabolism and the marked loss of adiposity that occurs in 
the presence of certain malignancies (Bing et al., 2004).
Retinol binding protein (RBP) is highly expressed by WAT, although liver and 
kidney are the major contributors to the circulating level of this protein, required for 
the transport of retinol (vitamin A) from the liver and adipose tissue to target tissues 
(Trayhum & Beattie, 2001). It has recently been reported that elevated serum RBP 
levels in humans and mice may contribute to the development of insulin resistance in 
obesity and type II diabetes (Yang et al., 2005). Fasting-induced adipose factor 
(FIAF) is an angiopoietin-like protein which was originally identified as a result of it 
being a target gene for PP/l7?a. Although the functions of FIAF are not yet well 
understood, circulating levels generally increase on fasting (Kersten et al., 2000; 
Dutton and Trayhum, 2007), and it has been shown to inhibit lipoprotein lipase 
activity, with implications for TAG accumulation by adipocytes (Backhed et al., 
2004). Fasting also causes increased expression of FIAF mRNA in the pituitary, 
suggesting a possible central regulatory role in energy balance (Wiesner et al., 2004).
1.6.3 Insulin sensitivity and insulin resistance
Adiponectin (also referred to as Acrp30, GBP28, AdipoQ and apMl) is one of the 
most abundantly expressed adipose-specific proteins (Maeda et al., 1997). Unlike 
most adipokines, adiponectin levels are inversely related to body weight, with 
reduced expression occurring in obesity and type II diabetes (Arita et al., 1999). 
There also appear to be inverse correlations between the plasma adiponectin 
concentration and risk factors for cardiovascular disease, such as blood pressure 
(Adamczak et al., 2003; Matsuzawa, 2005). Adiponectin acts as an insulin sensitiser,
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stimulating glucose utilisation and fatty acid oxidation in mice (Yamauchi et al., 
2002). Administration of TZDs has been shown to increase adiponectin levels, and it 
has been proposed that adiponectin may be mediating the insulin-sensitising effects 
of these PPARy agonists (Maeda et al., 2001). Several anti-inflammatory and anti­
atherogenic effects have been demonstrated for adiponectin, including inhibition of 
NFkB activation and direct effects on vascular endothelial cells to inhibit monocyte 
adhesion (Ouchi et al., 2000; Diez & Iglesias, 2003; Matsuzawa, 2005).
Resistin (also described as FIZZ3 and ADSF) is a recently discovered adipokine that 
was initially proposed to act as a strong link between obesity and diabetes by 
inducing insulin resistance (Steppan et al., 2001). This was based on observations 
that genetically obese and diet-induced obese mice had raised resistin levels and that 
immunoneutralisation of resistin in these animals had a corrective effect on their 
insulin resistance and hyperglycaemia. In addition, when resistin was administered to 
normal mice, glucose tolerance and insulin sensitivity were impaired, and treatment 
of 3T3-L1 adipocytes with TZDs decreased resistin gene expression (Steppan et al., 
2001). In humans, administration of resistin results in the development of hepatic, 
but not peripheral, insulin resistance (Rajala et al., 2003). Other reports however, 
have failed to establish either clear mechanisms by which resistin expression is 
regulated, or a definite physiological role for the protein (Stumvoll & Haring, 2002; 
Yang et al., 2003). A study in 2001 showed that resistin was barely detectable in 
human adipocytes, and no differences were found in resistin gene expression when 
comparing cells from normal, insulin-resistant or type II diabetic individuals 
(Nagaev & Smith, 2001). Other work reported that resistin levels were actually 
decreased in obese hyperinsulinaemic db/db mice compared to lean controls, and that 
administration of metformin (an anti-diabetic agent with insulin sensitising effects) 
stimulated resistin expression (Fujita et al., 2002). It has been suggested that mouse 
and human resistin may exert divergent effects, and that the physiology of one may 
not be pertinent to the other, although identification of the molecular target of resistin 
may improve understanding of its function (Steppan & Lazar, 2004).
Visfatin (also known as PBEF) is another novel adipokine which has a proposed role 
in glucose homeostasis. This protein was found to be highly expressed in the visceral 
WAT of both humans and mice, with the circulating level increasing with adiposity 
(Fukuhara et al., 2005). It was also determined that visfatin is a ligand for the insulin
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receptor, and that it has insulin-like effects; glucose uptake was enhanced in 3T3-L1 
cells, and plasma glucose concentrations were suppressed in mice, although unlike 
insulin, visfatin levels were unaffected by fasting or feeding (Fukuhara et al., 2005).
1.6,4 Tumour necrosis factor-a
Tumour necrosis factor-a (TNFa) was first isolated in 1984 and is so named due to 
its ability to regress tumour masses in patients with bacterial infections of their 
tumours (MacEwan, et al., 2002). It is a pleiotropic cytokine expressed as a 26 kDa 
transmembrane protein that can be cleaved to release a 17 kDa soluble form that has 
roles in cell apoptosis, proliferation, differentiation, inflammation and immunity 
(MacEwan, et al, 2002). TNFa has been implicated in the pathogenesis of a range of 
disorders including rheumatoid arthritis, asthma, septic shock and cancer cachexia 
(MacEwan, et a i, 2002). The primary source of production is activated 
macrophages, but TNFa production in WAT is well documented (Hotamisligil et al, 
1993). However, whilst TNFa is recognised as an adipokine, being synthesised and 
released from adipocytes themselves, it may be that, at least in humans, the majority 
of the production occurs in the stromal vascular cells of adipose tissue (Fain et al, 
2004).
The circulating level of TNFa is increased in obesity, and it has been implicated in the 
development of insulin resistance, (Hotamisligil et a l, 1993; Hotamisligil et a l, 
1995). This has been suggested to occur at the level of the adipocyte itself, through 
autocrine and paracrine actions of TNFa resulting in changes to the way adipocytes 
metabolise glucose and lipid. It has been shown in human adipocytes that TNFa 
treatment results in decreased GLUT4 mRNA and protein levels, thereby inhibiting 
insulin-mediated glucose uptake, and also reduces LPL mRNA levels (Hauner et al, 
1995). TNFa may also increase insulin resistance by elevating plasma free fatty acid 
concentration, not only by reducing LPL activity to decrease uptake, but also via a 
lipolytic effect to stimulate fatty acid release from adipocytes (Feingold et a l, 1992; 
Souza et a l, 2003; Ryden et al, 2004).
Further evidence of the role of TNFa in inducing insulin resistance is provided by 
studies involving the use of TNFa-deficient mice. Mice deficient in TNFa activity due 
to a targeted mutation of the TNFa gene displayed significantly improved insulin 
sensitivity and reduced circulating free fatty acids in response to diet-induced obesity
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compared to their controls (Uysal et al., 1997). By eliminating TNFa signalling in 
ob/ob mice (by targeted deletions in the two TNFa receptor genes), improvements 
were observed in hyperglycaemia, hyperinsulinaemia and insulin sensitivity (Uysal et 
al., 1997).
Within adipose tissue itself, TNFa is a key regulator of the expression of other 
adipokines. It has been shown to stimulate leptin production, leading to increased 
circulating leptin levels in both rodents and humans (Sarraf et al., 1997; Zumbach et 
al., 1997), and also increases synthesis of IL-6 (Wang et al., 2005), PAI-1 (Birgel et 
al., 2000) and haptoglobin (Chiellini et al., 2002; Oiler do Nascimento et al., 2004) in 
adipocytes. In addition, TNFa has been proposed as a key regulator of adipose tissue 
mass (Wame, 2003), since as well as its lipolytic actions it is recognised to induce 
apoptosis in mature adipocytes (Coppack, 2001), and appears to have anti-adipogenic 
effects via suppression of C/EBPa and PPARy expression (Sethi & Hotamisligil, 
1999).
1.6.5 Interleukins
Adipose tissue is recognised as the source of a range of interleukins, which are key 
regulators of the inflammatory response and modulate the expression of a range of 
other adipokines. IL-6 has a ubiquitous tissue distribution, and is a major cytokine 
with effects on cell growth, acute phase responses and carbohydrate and lipid 
metabolism (Mohamed-Ali et al., 2001). It is expressed and secreted by adipocytes, 
and although it has local effects, it is released into the circulation and may also act 
centrally in the hypothalamus to regulate energy balance (Trayhum & Wood, 2004). 
Circulating IL-6 levels are elevated in obesity and insulin resistance, and sympathetic 
stimulation has been shown to increase plasma IL-6 concentration in both humans 
and mice, with administration of sympathetic agonists elevating production of the 
interleukin by human and murine adipocytes (Mohamed-Ali et al., 2001). Adipose 
expression of IL-6 is stimulated by insulin (Krogh-Madsen et al., 2004) and TNFa 
(Wang et al., 2005), and the cytokine induces insulin resistance in adipocytes, which 
can be prevented by the TZD rosiglitazone (Lagathu et al., 2003; Rotter et al., 2003). 
Other interleukins synthesised within WAT include IL-ip, IL-8, IL-10 and IL-18 
(Trayhum & Wood, 2004). EL-ip has been shown to mediate leptin induction in mice 
administered inflammatory stimuli (Faggioni et al., 1998), and also stimulates IL-6
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release from human adipocytes (Flower et al., 2003). IL-8 may be involved in 
atherogenesis, and circulating levels are correlated with obesity; its release from 
adipose tissue is stimulated by IL-ip and TNFa, but inhibited by dexamethasone 
(Bruun et al., 2001; Trayhum & Wood, 2004). The anti-inflammatory cytokine IL-10 
is secreted by human WAT explants, where it is upregulated by LPS and TNFa, and 
its expression in WAT is raised in both human and rodent obesity (Juge-Aubry et al., 
2005). The plasma concentration of IL-18, a pro-inflammatory cytokine, is also 
elevated in obesity, and has been shown to fall in response to weight reduction 
(Esposito et al., 2002). It has recently been established that WAT is indeed a site of 
IL-18 expression, with mRNA levels in cultured human adipocytes markedly 
stimulated by treatment with TNFa, although no evidence was found for the release 
of IL-18 from these cells (Wood et al., 2005). Another study has, however suggested 
that IL-18 is released from human adipocytes (Skurk et al., 2005)
1.6.6 Haemostatic and haemodynamic factors
The pro-thromboembolic factor plasminogen activator inhibitor-1 (PAI-1) is a key 
regulator of vascular haemostasis; by inhibiting plasminogen activation, it suppresses 
the formation of plasmin which is involved in fibrinolysis (Mutch et al., 2001). 
Plasma PAI-1 concentrations are elevated in obesity, and production of the factor in 
WAT has been demonstrated in both rodents and humans. The increased production 
of PAI-1 in obesity has been linked to higher levels in WAT of several factors known 
to stimulate PAI-1 expression, including TNFa, TGFp and IL-6, and PAI-1 has been 
implicated in the increased risk of cardiovascular and atherosclerotic complications 
associated with obesity (Mutch et al., 2001; Trayhum & Wood, 2004).
Tissue factor (TF) is the main cellular initiator of the coagulation cascade and also 
acts as a cell-surface receptor for the activation of factor VII. Abnormal expression of 
TF may promote thrombotic events through activation of the coagulation cascade. TF 
gene expression is raised in the adipose tissues of ob/ob and db/db mice compared 
with their lean controls, and TF mRNA levels are increased in adipocytes by 
administration of TGFp and insulin. It has therefore been proposed that the 
hyperinsulinaemia associated with obesity may induce TF expression in WAT, and 
that elevated TF levels may contribute to the prothrombotic state existing in the obese 
(Samad et al., 1998; Samadef a/., 2001).
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The renin-angiotensin system (RAS) is an important regulator of systemic blood 
pressure and renal electrolyte homeostasis, with local RAS activity implicated in 
pathological changes of organ structure and function by modulation of gene 
expression and inflammatory responses (Engeli et al., 2000). Angiotensinogen (AGT) 
is converted by renin to angiotensin II (Ang II), which is a potent vasoconstrictor and 
key regulator of vascular tone. Although the liver is the main source of AGT, it is 
produced and secreted by adipose tissue, with adipocyte expression and secretion of 
AGT stimulated by glucocorticoids but inhibited by insulin and TNFa (Aubert et al., 
1997; Aubert et al., 1998; Wang et al., 2005). AGT levels have been shown to be 
elevated in rodent models of obesity, and weight reduction in humans resulted in 
reduced circulating AGT, as well as a fall in AGT expression in adipose tissue 
(Engeli et al., 2005). The increased plasma AGT concentration seen in obesity may 
thus be a significant contributor to the hypertension associated with this condition 
(Engeli et al., 2000; Engeli et al., 2005).
1.6.7 Acute phase proteins
The main source of acute phase proteins is the liver, but several are also synthesised 
and secreted from adipose tissue. Haptoglobin is expressed in both human and mouse 
white adipocytes, with expression being stimulated by TNFa and IL-6, and inhibited 
by TZDs (Chiellini et al., 2002; Oiler do Nascimento et al., 2004). Circulating levels 
of haptoglobin are elevated in obesity, which may contribute to the state of chronic 
mild inflammation (Chiellini et al., 2002). It is capable of binding haemoglobin, thus 
preventing iron loss and renal damage, and also acts as an antioxidant and angiogenic 
factor, which may be its main roles in adipose tissue (Oiler do Nascimento et al.,
2004). Antioxidant and angiogenic functions have also been proposed for 
metallothionein, a metal-binding stress-respone protein which is expressed and 
secreted in WAT (Trayhum et al., 2000), and whose expression is stimulated by 
TNFa in human white adipocytes (Wang et al., 2005).
WAT has recently been identified as a significant source of serum amyloid A (SAA), 
an acute phase protein recognised as an independent risk factor for coronary artery 
disease, as well as contributing to the development of amyloidosis. Serum SAA 
levels have been reported to be correlated with BMI, adiposity and adipose tissue
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SAA mRNA levels (Sjoholm et al., 2005). WAT expression of the gene, and 
circulating levels of the protein, were also shown to be under nutritional regulation, 
with decreases in both occurring in response to weight loss, thus indicating that SAA 
could be a link between obesity and cardiovascular disease (Poitou et al., 2005; 
Sjoholm et al., 2005). Another acute phase protein whose circulating level is 
correlated with BMI is C-reactive protein (CRP) (Bullo et al., 2003), recognised as a 
marker of inflammation and atherosclerosis (Lind, 2003). It has been thought that the 
elevated serum levels of CRP present in obesity are in part due to increased secretion 
from WAT. Moreover it has recently been suggested that human adipocytes secrete 
CRP and inflammation may modulate its gene expression (Memoli et al., 2007).
1.6.8 Chemokines
It has been reported that obesity is associated with an increased level of macrophages 
infiltrating WAT, leading to the increased expression of many inflammation and 
macrophage-specific genes within the tissue (Weisberg et al., 2003; Xu et al., 2003). 
This infiltration process may be regulated by chemokines secreted from adipocytes, 
one of which is macrophage migratory inhibitory factor (MIF), an important mediator 
of inflammatory responses. Human adipocytes express and secrete MIF, and as the 
level of production is correlated to BMI it has been proposed that MIF may be an 
obesity-dependent regulator of macrophage infiltration into adipose tissue (Skurk et 
al., 2005; Trayhum, 2005).
Another factor which may play a key role in the infiltration of WAT by macrophages 
is monocyte chemoattractant protein-1 (MCP-1). In vivo studies have demonstrated 
that MCP-1 is overexpressed in obese (ob/ob) mice compared with their lean controls, 
and that WAT is a major source of MCP-1 (Sartipy & Loskutoff, 2003). Recent work 
has shown MCP-1 mRNA levels and protein secretion to be stimulated by TNFa in 
human adipocytes (Wang et al., 2005). Insulin stimulates MCP-1 release from 3T3-L1 
adipocytes, and also increases circulating levels of MCP-1 in ob/ob mice, which may 
link the chemokine with the pathologies seen in obesity and hyperinsulinaemia 
(Sartipy & Loskutoff, 2003).
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1.7 PHYSIOLOGICAL ROLE OF GASTROINTESTINAL HORMONES IN 
THE CONTROL OF ADIPOSE TISSUE METABOLISM
Little is known of any physiological role of gastrointestinal hormones in the control 
of lipid deposition and mobilisation in adipose tissue. However, a limited number of 
investigations have demonstrated that these hormones may have an important role in 
the control of pathways of lipid metabolism. The control may be consequent to 
changes in the secretion of insulin or directly by controlling lipogenesis, lipolysis or 
the activity of lipoprotein lipase. Most of this knowledge comes from in vitro studies 
and the problems associated with tissue viability and pharmacological doses of 
hormones need to be considered in the interpretation of data obtained.
1.7.1 White adipose tissue Metabolism
1.7.1.1 Glucose metabolism
Glucose, the substantial energy source within the body, fluctuates in a narrow range 
in the bloodstream during fasting and feeding. Dysregulation of the balance between 
glucose intake and output leads to a high glucose level in the circulation. Muscle and 
WAT are the crucial peripheral organs to reduce the increased circulating glucose 
level after a meal by uptake of glucose into the cells. In fact, glucose is unable to be 
independently transported into the cells. It must be supported by a group of 
facilitative glucose transporters (GLUTs) - to cross the cell membrane. To date, at 
least 14 GLUT family members have been identified, and many of them, such as 
GLUT 1, GLUT3-5, GLUT10, GLUT12, and HMIT, are present in white adipocytes 
(Wood & Trayhum, 2003; Trayhum et ah, 2006). GLUT1, which is found 
ubiquitously, is located on the plasma membrane of adipocytes and probably 
mediates basal, non-insulin mediated glucose uptake (Khan & Pessin, 2002). 
GLUT4, the most important insulin-responsive glucose transporter, is expressed in 
skeletal muscle, heart muscle and adipocytes (Khan & Pessin, 2002). Under basal 
conditions, GLUT4 is stored as intracellular vesicles; however, the activation of the 
insulin signalling pathway triggers the translocation of GLUT4 from its storage 
vesicles in the cytosol to the plasma membrane, and hence facilitates increased
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glucose uptake into the cells (James et al., 1994).
Normal function of the insulin signal transduction pathway in target cells is essential 
to maintain the circulating glucose at a stable level. However, in type II diabetes, 
impaired insulin sensitivity results in an enhanced glucose concentration in the 
bloodstream. The precise mechanism of insulin resistance remains to be fully 
understood. However, obesity has been indicated to be a major risk factor for type II 
diabetes.
1.7.1.2 Lipid metabolism
Triglycerides, also known as triacylglycerols (TAGs), are the core energy sources 
stored in WAT originally derived from foods (Trayhum & Beattie, 2001). The 
formation of chylomicrons after a meal facilitates the transportation of TAGs from the 
small intestine to adipose tissue for storage. Also, the liver synthesizes TAGs which in 
turn are exported and stored in adipose tissue. In addition, TAGs in adipocytes can be 
derived and synthesized from glucose taken up by adipocytes.
If energy intake is insufficient for requirements, TAGs are broken down to supply 
the extra energy by a process known as lipolysis (Amer, et al., 2005). TAGs are 
hydrolysed by activation of the hormone sensitive lipase (HSL) to release free fatty 
acids (FFAs) and glycerol (Fig 1.3). Both FFAs and glycerol can cross the plasma 
membrane of adipocytes and be secreted into the circulation. FFAs loosely combine 
with serum albumin in the bloodstream. Glycerol is unable to be taken up by 
adipocytes after it is released; thus, to measure the amount of glycerol in the 
circulation or the culture medium of the cells is a useful method to estimate the 
lipolytic activity of the cells.
HSL is a rate-limiting enzyme activating lipolysis through the cyclic adenosine 
monophosphate (cAMP) dependent protein kinase pathway (Amer, et a l, 2005). 
Evidence strongly suggests that catecholamines, the neurotransmitters released by 
the nerve endings of the SNS, may be the key mediators of lipolysis (Amer, et al.,
2005). The binding of catecholamines to p-adrenoceptors on the cell membrane 
activates the adenylate cyclase, an enzyme having an ability to convert adenosine 
triphosphate (ATP) to cAMP (Carmen & Victor, 2006). The increased cAMP further 
stimulates activation of the cAMP-dependent kinase (PKA), which further 
phosphorylâtes its downstream molecules, such as perilipin A (Peri A), the most
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prevalent substrate of PKA (Carmen & Victor, 2006). The phosphorylation of 
perilipin is an essential process for translocation of the HSL from the cytosol to lipid 
droplets, and finally the breakdown of lipid (Souza et ah, 2002; Miyoshi et ah,
2006).
It is believed that there are metabolic and functional differences between 
subcutaneous and visceral fat depots (Amer et al., 2005). Catecholamine-induced 
lipolysis is higher in visceral fat than in subcutaneous fat, but the basal lipolytic 
activity is opposite (Amer et ah, 2005). It is thought that a high rate of hormone- 
stimulated lipolysis in visceral fat leads to a large amount of free fatty acid release 
reaching the liver and other metabolic organs, such as the heart and skeletal muscle, 
which is the major cause of the impairment of glucose tolerance in obesity (Klein et 
ah, 2004).
As discussed above, lipolysis is mainly regulated by the neurotransmitter 
nonadrenaline released from the SNS. In addition to the SNS, lipolysis is also 
influenced by several other factors, such as the reduced plasma glucose 
concentration during fasting, increased growth hormone and glucocorticoids, which 
all stimulate free fatty acid release by adipocytes whereas lipolysis is inhibited by the 
elevated insulin (Ahima & Flier, 2000).
HSL has long been regarded as the only lipase mediating lipid hydrolysis in cells. 
However, recent studies have shown that the hormone-mediated-lipolytic activity 
still exists at cellular levels in HSL-knockout mice (Osuga et ah, 2000). This finding 
indicates that there may be other unidentified intracellular triacyglycerol lipase(s). 
This hypothesis has been confirmed following the discovery of a novel adipose- 
expressed triacyglycerol lipase (ATGL) (Zimmermann et ah, 2004). ATGL, also 
known as patatin-like phospholipase domain containing protein 2 (PNPLA 2) or 
desnutrin, is highly expressed in adipose tissue and has a specific role to break down 
lipid by removing fatty acids from TAGs (Zimmermann et al., 2004). Subsequent 
studies suggest that ATGL is downregulated in white adipocytes in obesity and 
likely to mediate the basal lipolysis activity (Langin et ah, 2005). Knockout of the 
ATGL gene in mice leads to enlarged fat depots, including gonadal, inguinal WAT 
and BAT; moreover, TAGs have been found to accumulate in cardiac muscle, testes 
and kidney (Haemmerle et ah, 2006), indicating that ATGL has an essential role in 
the regulation of lipolysis.
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Fig 1.3 Fatty acid and glucose metabolism in WAT
Lipoprotein particles 
(chylom icrons, VLDL)
Vttiite Adipose Tissue
Glycerol ► Glycerol
-----------------------V------------
Fat Storage Fat Mobilization
Adaptedfrom Frayn,et al.,1996
A schematic pathway of how the dietary fat digested and then re-synthesised into TAG 
is carried in the circulation as lipoproteins. Lipoprotein molecules are transported in to 
bloodstream. Fat then enters adipose tissue and is hydrolysed by lipoprotein lipase, the 
activity of which is stimulated by insulin. When required, the stored TAG is mobilised 
by HSL, which is stimulated by adrenaline and glucagon. When the fatty acids are 
released from adipose tissue, they are transported and attached to the major protein in 
the circulation, which is albumin. HSL, hormone-sensitive lipase; LPL, lipoprotein 
lipase; TAG, triacylglycerol
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1.7.2 Functions of gastrointestinal hormones in WAT metabolism
1.7.2.1 Indirect control via regulation of insulin secretion
Insulin is known to stimulate lipogenesis (Stansbie et al., 1976), the activity of 
lipoprotein lipase (Cryer et al., 1976; Sadur and Eckel, 1982; Eckel, 1987) and to 
have an antilipolytic effect (Denton et al., 1981). Therefore, any hormones that affect 
the secretion of insulin will indirectly affect adipose tissue metabolism via these 
mechanisms. Several gastrointestinal hormones are known to stimulate the release of 
insulin and their role in the enteroinsular axis is well established. The most important 
hormones fulfilling this role are GIP (Dupre et al., 1973; Anderson et al., 1979; Elahi 
et al., 1979) and GLP-1 (7-36) amide (Kreymann et al., 1987). GIP increases insulin 
binding and insulin-dependent glucose uptake (Starich et al., 1985; Hauner et al., 
1988). GLP-1 potently increases insulin-dependent glucose uptake in adipocytes at 
low concentrations (Egan et al., 1994; Miki et al., 1996; Perea et al., 1997). It also 
rescues the downregulation of glucose transporter-4 (GLUT-4) brought about by 
prolonged insulin exposure (Wang et al., 1997).
Other hormones that have been demonstrated to stimulate insulin release include 
cholecystokinin (Unger et al., 1967; Dupre et al., 1969). Neurotensin (Brown and 
Vale, 1976) and somatostatin (Pederson, Dryburgh and Brown, 1975) have also been 
shown to inhibit the secretion of insulin.
In 3T3-L1 adipocytes, ghrelin enhances insulin sensitivity (Kim et al., 2004) as 
measured by glucose transport. However in a diverse study, using brown adipocytes, 
insulin-induced glucose uptake was not altered by ghrelin treatment (Ott et al., 2002).
1.7.2.2 Control of lipogenesis
Recently, it has become apparent that GIP may have direct effects on metabolism, in 
particular anabolic effects, and not solely indirectly via its stimulation of insulin 
release (Beck, 1989).
GIP has been found to exert a direct influence on the insulin sensitivity of rat 
adipocytes. The incubation of isolated adipocytes with GIP led to increased insulin 
receptor affinity. An increase in the sensitivity of insulin-stimulated glucose transport 
was also demonstrated (Starich, et al., 1985) which is the first step in the synthesis of
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triglycerides from this precursor.
It has been reported that GIP is capable of stimulating the transport of glucose into 
isolated rat adipocytes and the incorporation of glucose into extractable lipids 
(Hauner et al., 1988/
Studies showed that GIP increased basal lipogenesis in rat (Oben et al., 1991a) and 
lamb adipose explants (Baba et al., 2000). Consistent with these findings, GIP has 
been noted to increase insulin induced lipogenesis in primary cultures of rat 
adipocytes (Beck and Max, 1983; Beck and Max, 1988) and to boost the activity of 
lipoprotein lipase in cultured murine preadipocytes (Eckel et al., 1979). Moreover, 
GIP suppresses P-adrenergic and glucagon-mediated lipolysis in isolated rat 
adipocytes (Dupre et al., 1976; Hauner et al., 1988). However, GIP alone has also 
been reported to increase basal lipolysis in primary rat adipocytes (Beck and Max, 
1983; Hauner et al., 1988). Furthermore, an inhibition of insulin-induced lipogenesis 
has been described in lamb adipose explants (Baba et al., 2000).
Another study has shown GIP to stimulate the incorporation of glucose into 
saponifiable fatty acids by explants of rat adipose tissue (McCarthy, 1993) and a 
weak lipogenic effect of GIP has also been demonstrated in ovine adipose tissue 
using acetate as a precursor (Haji Baba and Buttery, 1991; McCarthy, 1993).
An investigation into the effects of GLP-1 on human adipose tissue concluded that it 
exerts differential, concentration-dependent effects on lipid metabolism in human 
adipocytes. This was attributed to the existence of different GLP-1-binding receptors. 
At low concentrations, GLP-1 was found to act synergistically with insulin to 
increase lipogenesis in human adipocytes, whereas, at higher concentrations, it 
augmented glucagon-dependent lipolysis (Villanueva-Penacarrillo et al., 2001). 
Recently, Ghrelin has been found to activate the mitogen-activated protein kinase 
pathway in vitro (Kim et al., 2004; Zhang et al., 2004), which stimulates cellular 
proliferation and differentiation in cultured white adipocytes (Choi et al., 2003; Kim 
et al., 2004; Zhang et al., 2004). This has been confirmed in rats in vivo (Thompson et 
al., 2004). In brown adipocytes, however, ghrelin does not seem to affect adipocyte 
differentiation (Ott et al., 2002).
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1.7.2.3 Control of lipolysis
The stimulatory effect of glucagon on lipolysis has long been known after first being 
demonstrated in rat adipose tissue (Hagen, 1961; Vaughan, 1961). Secretin, which is 
related to glucagon in structure, has also been shown to stimulate lipolysis in isolated 
rat adipocytes (Rudman and Del Rio, 1969). This action was confirmed in a similar 
study where it was shown that secretin also causes an increase in cyclic AMP levels 
in the adipocytes (Butcher and Carlson, 1970).
The effect of GIP on lipolysis was investigated in adipocytes isolated from rat 
adipose tissue and was found not to stimulate lipolysis itself but was capable of 
inhibiting the lipolytic action of glucagon. GIP was without effect on the lipolysis 
stimulated by secretin. The antilipolytic effect appeared to result from competition for 
the glucagon receptor since GIP was able to bind non-functionally to the glucagon 
receptor (Dupre et al., 1976).
In a more recent study, GIP has been found to have a weak lipolytic effect in 
adipocytes isolated from rat adipose tissue (Hauner et al., 1988). This discrepancy 
with the previous study may arise from the different methods used to estimate 
lipolysis. By measuring the release of free fatty acids, GIP was shown not to stimulate 
lipolysis (Dupre et al., 1976) whereas by measuring glycerol release it was found to 
be weakly lipolytic (Hauner et al., 1988). It is possible that the free fatty acids 
released during lipolysis may become re-esterified in the adipocyte and therefore 
mask a weak lipolytic effect.
It has been reported that GLP-1 (7-36) amide and, to a lesser extent, GLP-1 (1-36) 
amide stimulated lipolysis in isolated rat adipocytes although the effect was very 
weak compared to that of glucagon (Ruiz-Grande et al., 1992). However, one study 
did not find any effect of GLP-1 on lipolysis in human subcutaneous adipocytes 
(Bertin et al., 2001). Likewise, reports on the lipolytic or lipogenic activity of GLP-1 
in rodent adipocytes have been contradictory, some supporting the notion of increased 
lipogenesis (Oben et al., 1991; Egan et al., 1994; Perea et al., 1997), and some the 
opposite (Ruiz-Grande et al., 1992).
A recent study on the role of ghrelin and GHS-R on rat adipogenesis showed that 
ghrelin suppresses isoproterenol-induced lipolysis (Choi et al., 2003).
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1.7.2.4 Control of lipoprotein lipase activity
In addition to its lipogenic effect, GIP has also been shown to stimulate the release of 
lipoprotein lipase activity from cultured 3T3-L1 preadipocytes into the medium and 
also the total amount of lipoprotein lipase activity within these cells in a dose- 
dependent manner (Eckel, et al., 1979). This was followed by demonstration that the 
infusion of GIP in dogs promoted the clearance of chylomicron triglycerides which 
had been administered in the form of chyle collected from donor dogs following a 
triglyceride rich meal (Wasada et al., 1981). This is presumed to occur via the 
stimulation of lipoprotein lipase activity by GIP, lipoprotein lipase being involved in 
the transfer of circulating lipoprotein triglycerides to adipose tissue. It is also possible 
that this effect results from increased transport of free fatty acids into the adipocytes. 
GIP has been shown to promote the insulin-stimulated incorporation of fatty acids 
into rat adipose tissue; this effect occurs using physiological doses of GIP and is 
dose-dependent. It was suggested that GIP might exert its effect by facilitating the 
passage of fatty acids through the membrane of the adipocyte (Beck and Max, 1983).
It has been demonstrated that GIP stimulates total cellular lipoprotein lipase activity 
in explants of rat adipose tissue whilst GLP-1 (7-36) amide was found to be without 
effect (Oben et al., 1991).
1.7.2.5 Endocrine activity (Secretion of adipokines)
Little is known in regards with the regulation of adipokine production by incretins. 
However, a recent study has now examined the possibility that specific actions of GIP 
are mediated through the direct regulation of resistin release in 3T3-L1 adipocytes, 
resulting in increasing the activity of both PKB and LPL pathways (Kim et al., 2007). 
On the other hand, ghrelin directly suppresses adiponectin mRNA expression (Ott et 
al., 2002). In one study, intra-peritoneal injection of ghrelin increased both 
adiponectin and leptin expression in adipose tissue, but these effects did not reach 
statistical significance (Asakawa et al., 2003). Any effect of obestatin in the 
regulation of adipokines has not been explored to date.
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1.8 AIMS AND SCOPE OF THE RESEARCH IN THIS THESIS
The survey of the literature indicates that gastrointestinal hormones released during 
the digestion and absorption of nutrients directly affect the partitioning of nutrients 
within the body. In particular gastrointestinal hormones appear to have regulatory 
roles in the complex lipogenic and lipolytic pathways that occur in white adipose 
tissue. Excessive fat deposition in the form of obesity, is now a major health problem 
worldwide leading to an increased risk of many diseases, including type II diabetes, 
heart failure and cancer. Adipose tissue was originally thought to be an organ solely 
for energy storage. In recent years, ongoing research has shown that lipid storage is 
not the only function of white fat. The discovery of leptin, which was followed by 
the identification of other protein factors, termed ‘adipokines’ secreted by white 
adipose tissue (WAT), indicated that WAT is major endocrine organ.
Elucidation of the roles of gastrointestinal hormones in adipose tissue function may 
lead to further understanding of the mechanisms of obesity which in turn could allow 
more effective approaches to the prevention and treatment of obesity. Thus, if 
specific receptors for gut peptides can be found in adipose tissue one may infer that 
it is likely that they may have a direct effect on adipose tissue function. While 
specific receptors for GIP have been identified, studies have been inconclusive with 
regard to GLP-1 and very little is known regarding ghrelin and obestatin.
The first objective of the work in this thesis was to establish whether the genes 
encoding the receptors for ghrelin (GHS-R), obestatin (GPR-39), glucagon-like 
peptide-1 (GLP-1 R) and glucose-dependent insulinotropic polypeptide (GIPR) are 
indeed expressed in adipocytes. The work then hoped to elucidate the nature of the 
interaction of these hormones with adipose tissue in the form of the alterations in the 
endocrine secretion of this organ. It was specifically hypothesised that the incretins 
may regulate the expression and release of key adipokines and thereby play a 
significant role in adipose tissue as part of the cross-talk between the gut and adipose 
tissue.
More specifically the aims of this research project were:
■ To employ RT-PCR was used to examine whether the receptors genes are 
expressed in different mouse tissues, and more particularly to screen for gene
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expression of these receptors in major fat depots of both mice and humans.
■ To compare receptor gene expression between lean and obese subjects to 
assess whether this is altered in white adipose tissue in human obesity.
■ To assess the gene expression for these receptors in adipocyte cell culture 
systems of both mouse (3T3-L1) and human (Simpson-Golabi-Behmel 
syndrome; SGBS), in order to establish whether these systems can be used to 
assess the affect of the gut hormones on adipocytes.
■ To employ Western blotting to determine whether receptor protein is 
expressed by adipose tissue and adipocyte cell culture system of humans.
■ To explore the effects of the gut peptides on the gene expression of key 
adipokines including leptin, adiponectin, IL- 6  and MCP-1 genes in human 
SGBS adipocytes.
■ Finally, to investigate the effects of a 24-h treatment of the gut peptides in the 
presence or absence of insulin, on glucose uptake using 2-deoxy-D-glucose 
(2-DG). This was to allow us to ascertain if prolonged exposure to these 
peptides had any modulatory effects by themselves or on insulin action in 
cultured fat cells.
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MATERIALS & METHODS
Materials and Methods
2.1 Reagents and Methods
2.1.1 Chemical reagents
Acetic acid 
Acrylamide 
a-linoleic acid 
Agarose
Ammonium persulphate 
Arachidonic acid 
ß-mercaptoethanol 
Bicinchoninic acid (BCA)
Biotin
Bovine serum albumin 
BRL-37344
Bromophenol blue (BPB)
Chloroform
Conjugated linoleic acid
Copper (II) sulphate solution
Cortisol
Dexamethasone
Disodium hydrogen phosphate
Docosahexaenoic acid
Dulbecco's modified Eagle's medium/Ham's F12 (1:1)
Eicosapentaenoic acid
100% Ethanol
Ethidium bromide
Foetal calf serum
Fluorescein anti-mouse IgG
Free glycerol reagent
GeneRuler ™ 100 bp DNA ladder
Glucose
Glycerol
Glycerol standard solution 
Glycine
Guanidine hydrocholoride 
HEPES
Human recombinant Ghrelin protein 
Human recombinant GIP protein 
Human recombinant GLP-1 protein 
Human recombinant Obestatin protein 
Human recombinant Des 1-10 Obestatin protein
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
T ocris
Sigma
Fisher
Sigma
Sigma
Sigma
Sigma
Sigma
Fluka
Invitrogen
Sigma
Sigma
Sigma
Biosera
Vector
Sigma
Helena BioSciences
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
ALEXIS
PolyPeptide Laboratories 
PolyPeptide Laboratories 
ALEXIS, PeptaNova, Peptides I 
Peptides International
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Human polyclonal antibody to human GHS-R Novus Biologicals
Human polyclonal 1 antibody to human GIP R MBL International
Human polyclonal antibody to human GLP-1R MBL International
Human polyclonal antibody to human GPR 39 Novus Biologicals
Human transferrin Sigma
I-methyl-3 -isobutylxanthine (IBMX) Sigma
Insulin Sigma
Isoprénaline Isopropanol Sigma
Linoleic acid Sigma
Lipopolysaccharide Sigma
Magnesium sulphate Sigma
Methanol VWR
Myristic acid Sigma
Noradrenaline Sigma
Normal horse serum Vector
Oleic acid Sigma
Palmitic acid Sigma
Pantothenate Sigma
Penicillin/Streptomycin Invitrogen
Photographic developer Sigma
Photographic fixer Sigma
Potassium chloride Sigma
Potassium dihydrogen orthophosphate Ponceau Sigma
Ponceau S Sigma
Rainbow molecular weight maker Amersham
RNase AWAY Molecular BioProd
Rosiglitazone GlaxoSmithKline
Saponin Sigma
Sheep anti-rabbit conjugated to horseradish peroxidase Sigma
Sodium chloride Sigma
Sodium citrate Sigma
Sodium dodecyl sulphate Sigma
Sodium dihydrogen orthophosphate Sigma
Sodium EDT A Sigma
Sodium hydroxide Sigma
Stearic acid Sigma
Sucrose Sigma
lOxTBE buffer Fisher
Trichloroacetic acid Sigma
Triiodothyronine (T3 ) Sigma
Tris-Base Sigma
Tris-hydrochloride Sigma
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Trizol
Trypsin/EDT A
Tween 20 (polyoxyethylene sorbitan monolaurate)
Ultra-pure water
Vectashield
2.1.2 Kits
DNA-free Kit
ECL Western Blotting detection reagents 
QPCR Core Kit
ReddyMix ™ Master PCR Master Mix Kit 
Reverse-iT ™ 1st Strand synthesis Kit
2.1.3 Equipment
2011 Macrovue UV transilluminator
ABI Prism 7700 real-time PCR machine
Beckman Preparative Ultracentrifuge
Benchmark™ Plus microplate spectrophotometer
Biophotometer
Centrifuge 5415 D
Centrifuge 5417 R
Coming filter system (0.22 pm membrane)
Glass homegenizers (borosilicate)
HB-1000 hybridisation oven 
Horizontal Gel Electrophoresis units 
Hybond ™ ECL 
Hyperfilm ECL
Kodak Digital Science DC 120 digital camera
Mx3005P™ QPCR System
Nitrocellulose membrane
PCR Express thermal cycler
PhotoEnhancer
3310 pH meter
Polytron Ultra- Turrax T25 electric homogenizer 
Reichert Polyvar Met 
Real-time PCR plates 
Rocker
TV 400 vertical gel electrophoresis units 
UVette® plastic disposable cuvettes
Invitrogen
Invitrogen
Dakocytomation
Sigma
Vector
Ambion
Amersham
Eurogentec
Abgene
Abgene
Ultra-Violet Products
Applied Biosystems
Beckman
Bio-Rad
Eppendorf
Eppendorf
Eppendorf
Fisher
Fisher
Ultra-Violet Products
SC1E-PLAS
Amersham
Amersham
Kodak
Stratagene
Amersham
Hybraid
Kodak
Barloworld
Janke& Kunkel
Reichert
Abgene
Bibby Sterilin
SCIE-PLAS
Eppendorf
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Water bath 
6 -well plate 
1 2 -well plate 
96-well microplate
Grant Instruments
Fisher
Fisher
Fisher
2.1.4 Software
Beacon Designer
GraphPad InStat version 3.00 for Windows 95 
Kodak Digital Science ID 1 image analysis software
MXPro™ QPCR Software 
Primer Express Software 
Primer Premier 5 software 
SDS version 1.7a software
Premier Biosoft 
GraphPad Software 
Kodak 
Stratagene
Applied Biosystem 
Premier Biosoft 
Applied Biosystems
2.1.5 Address and URLs 
Addresses:
Abgene UK,ABgene House, Blenheim Road, Epsom KTI9 9AP, UK.
ALEXIS Biochemicals Coporation, AXXORA (UK) LTD.PO Box 6757, Bingham, 
Nottingham, NG13 8 LS.
Ambion Ltd, Spitfire Close, Ermine Business Park, Huntingdon, Cambridgeshire, 
PE29 6 XY, UK.
Amersham PLC, Amersham Place, Chalfont, Buckinghamshire, HP7 9NA, UK. 
Applied Biosystems, Kelvin Close, Birchwood Science Park North, Warrington, 
Cheshire, WA3 7PB, UK.
Bechman Instruments Inc, Palo Alto, California 94304, USA.
Barloworld Scientific Ltd, T/As Jenway, Gransmore Green, Felsted, Dunmow, 
Essex, CM6  3LB, UK.
Bibby Sterilin Ltd, Stone, Staffordshire, ST15 OSA UK.
Biosera, I Acom House, the Broyle, Ringmer, East Sussex, BN8  5NN, UK. 
BioVendor Laboratory Medicine, Inc, CTPark Modrlce, Evropska 873, 664 42 
Modrlce, Czech Republic.
MBL International, Inc, 15B Constitution Way, Wobum, MA 01801, USA 
Dakocytomation, Dako Denmark NS, Produktionsvej 42, DK-2600 Glostrup, 
Denmark.
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Eppendorf UK Ltd, Endurance House, Chivers Way, Histon, Cambridge, CB4 9ZR, 
UK.
Eurogentec Ltd, P.C.House, 2 South Street, Hythe, Southampton, Hampshire S045 
6 EB, UK.
Fisher Scientific, Bishop Meadow Road, Loughborough, Leicestershire, LEU 5RG, 
UK.
Fluka, Industriestrasse 25, CH-9471 Buchs SG, Switzerland.
GlaxoSmithKline, Glaxo Wellcome UK Ltd., Stockley Park West, Uxbridge, 
Middlese, UB 11 IBT, UK.
Grant Instruments (Cambridge) Ltd, Shepreth, Royston, Hertfordshire, SG8  6 GB, 
UK.
Helena BioSciences Europe, Colima Avenue, Sunderland Enterprise Park, 
Sunderland, Tyne & Wear, SR5 3XB, UK.
Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley, P A4 9RF, UK. 
Janke & Kunkel, Janke-&-Kunkel-Str. 10, 79219 Staufen, Germany.
GraphPad InStat version 3.00 for Windows 95, GraphPad Software, San Diego 
California USA.
Kodak Ltd, P.O.Box 6 6 , Station Road, Hemel Hempstead, Hertfordshire, HPI 1W, 
UK.
Microsoft Corporation, One Microsoft Way, Redmond, WA98052-6399, USA. 
MWG-Biotech AG, Anzingerstr.7a, 85560 Ebersberg, Germany.
Norlab Instruments Ltd, Kirkhill Place, Kirkhill Industrial Estate, Dyce, Aberdeen, 
AB2 OES, UK.
Novus Biologicals, Inc, PO Box 802, Littleton, CO 80160, USA.
PeptaNova GmbH, Keplerstr. 26, 69207 Sandhausen, Germany.
Peptides International, Inc, PO Box 24658, Louisville, Kentucky 40224, USA. 
PolyPeptide Laboratories, Halchtersche Str. 49, 38304 Wolfenbüttel.
Premier Biosoft international, 3786 Corina Way, Palo Alto, CA 94303-4504, USA. 
R&D Systems, 4-10 The Quadrant, Barton Lane, Abingdon, OXON, OX14 3YS, UK. 
Reichert Ophthalmic Instruments, 3362 Walden Ave, Depew, NY 14043, USA. 
Roche Diagnostics Ltd, Bell Lane, Lewes, East Sussex, BN7 1 LG, UK.
Scie-Plas, Unit 3 Gainsborough Trading Estate, Old Road, Southam Warwickshire, 
CV47 HIP, UK.
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Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BH12 4QH, UK. 
Stratagene Europe, Gebouw California, Hogehilweg 15 1101 CB Amsterdam 
Zuidoost The Netherlands.
Tocris Cookson Ltd, Northpoint, Fourth Way, Avon Mouth, Bristol, BS1I 8 TA, UK. 
Ultra-Violet Products Ltd, Unit 1, Trinity Hall Farm Estate, Nuffield Road, 
Cambridge, CB4 1TG, UK.
Vector Laboratories, 30 Ingold Road Burlingame, CA 94010, USA.
VWR International, Hunter Boulevard, Magna Park, Lutterworth, Leicestershire, 
LE17 4XN, UK
Whatman PLC, Whatman House, St Leonards Rd, 20/20 Maidstone, Kent, ME 16 
OLS, UK.
URLs:
http://www .ncbi.nlm.nih.gov /entrez/
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2.2 Animals and Tissues
2.2.1 Mice
Adult male CD-I mice, aged 8  wk, were obtained from Harlan Olac (Bicester, UK). 
The mice were housed on receipt for 2 wk at 21°C with a 12:12-h light-dark cycle 
(lights on at 0700) and fed a commercial rodent diet (CRM Diet, Labsure, Witham, 
UK) containing 19.2% protein and 4.3% lipid (wt/wt). Both food and water were 
available ad libitum. The mice were killed by cervical dislocation, and the following 
tissues were rapidly removed and frozen in liquid nitrogen: muscle, small intestine, 
liver, kidney, brain and various white fat depots (gonadal, mesenteric, omental, and 
subcutaneous). The omental depot, which is small and can be hard to localise in lean 
mice, is located alongside the inferior surface of the stomach and is distinct from the 
mesenteric fat. All tissues were stored at -80°C until analysis.
2.2.2 Human tissues
Abdominal subcutaneous and omental WAT were provided by Dr S Wood 
(University of Liverpool) and were taken during gastroplasty from six obese male 
patients, aged 35-48 years with body mass index >33.5; the subjects did not exhibit 
any other ongoing diseases, such as infection or cancer. The studies were approved by 
Sefton Ethics Committee and all patients gave their informed consent. After removal, 
samples were immediately frozen in liquid nitrogen, and stored at -80°C until 
analysis.
Subcutaneous abdominal adipose tissue samples were also provided by Dr Monica 
Bullö (Universität Rovira I Virgili, Reus, Spain) and were obtained from 4 morbidly 
obese (BMI 40.1-49.3 kg/m2 ) and 4 lean or slightly overweight (BMI 23.5-26.5 
kg/m2). Subjects’ samples were obtained by biopsy or during surgery 
(cholecystectomy or abdominal hernia repair). The procedure of obtaining tissues and 
the study protocol were approved by the Ethics committee of the Sant Joan University 
Hospital (Catalunya, Spain); all subjects gave their informed consent. All samples 
were stored at -80°C until analysis.
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2.3 3T3-L1 Cell Culture
2.3.1 Reagents
1. Culture Medium
lxDMEM(25 mM glucose, 1.0 mM pyruvate, 4.02 mM L- 
alanyl-L-glutamine)
10% FCS
2. Induction Medium
lxDMEM
10% FCS
5 pg/ml insulin
0.25 pM dexamethasone
0.5 mM IB MX
3. Feeding Medium
lxDMEM 
10%FCS 
5 pg/ml insulin
All media were prepared using a Coming filter systems (incorporating a 0.22 pm 
sterilising filter membrane) in a cell culture hood. Prepared media were pre-warmed 
to 37°C in a water bath prior to use and stored at 4°C at other times. Culture and 
feeding media were used for up to 2  weeks after preparation; however, induction 
medium was always freshly prepared prior to actual use and any excess discarded 
thereafter.
4. lx  PBS
0.286 M sodium chloride
5.55 mM potassium chloride
16.4 mM disodium hydrogen phosphate
2.94 mM potassium dihydrogen orthophosphate
Autoclaved distilled water
5. Trypsin/EDTA
Autoclaved distilled water 
0.005%/0.002% trypsin/EDTA 
lx  PBS
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2.3.2 Culture method
3T3-L1 cells were obtained from the American Type Culture Collection 
(Manassas,Viginia, USA) and aliquots were stored in liquid nitrogen. Cells were 
cultured at 37°C in an incubator with a humidified atmosphere of 5% CO2 /95% air. 
Prior to each episode of cell culture work, the cell culture hood was thoroughly wiped 
with a 1% Virkon solution followed by 70% ethanol in order to maintain a sterile 
working environment; this wiping procedure was also performed after each episode of 
work was completed. All items were sprayed with 70% ethanol before being placed 
inside the hood, or packaging was opened, such that the sterile item within entered 
directly into the hood environment. Hands were sprayed repeatedly as necessary 
following removal from the hood and handling items outside of the hood.
To initiate cell culture, a frozen aliquot was removed from liquid nitrogen storage and 
thawed by placing it immediately into a water bath at 37°C. Prior to opening the 
cryovial inside a culture hood, it was thoroughly wiped with tissue sprayed with 70% 
ethanol to avoid contamination of the contents. One ml of pre-warmed culture 
medium was then added to the aliquot. The thawed cell suspension was transferred to 
a 25 cm2 flask containing 3 ml of culture medium and placed in an incubator until the 
cells were -80% confluent. The degree of confluency was checked using light 
microscopy. Cells were fed every 2-3 days with culture medium by aspirating the old 
media and replacing with 2  ml of fresh medium.
Once cells reached -80%  confluency (for 3T3-L1 cells, usually 5 days after being 
placed in the flask), the medium was removed and 1 ml of trypsin/EDTA was added 
to the flask which was then placed in the incubator for 1-2 min. The cells were then 
examined by light microscopy to establish that they detached once the flask was 
knocked gently against the bench. Nine ml of pre-warmed culture medium was added 
to the flask without delay (to neutralize the trypsin and prevent cell lysis) and then 
pipetted across the culture surface several times to wash off all the cells. The 
suspended cells were then pipetted up and down several times against the comer of 
the flask to break up any clumps.
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For the original flask (generated from a thawed aliquot), cells were passaged into new 
flasks to generate sufficient numbers for experimental use and also to ensure a 
homogeneous and healthy cell population. One ml of the cell suspension was 
transferred to each new flask containing 3 ml of culture medium. Cells trypsinised 
from these flasks were subcultured out to 6 - or 1 2 -well plates as required by adding 
(respectively) 300 or 150 pi of the cell suspension to 1.5 or 1 ml of culture medium 
per well. Cells were fed every 2-3 days with culture medium until confluent. 
Differentiation into adipocytes was examined under a light microscope by phase 
contrast at lOOx magnification. The phase contrast image of the accumulation of lipid 
droplets during the development of adipocytes was captured and photographed (Fig 
2 .1 ).
Differentiation of the cells was initiated 24-48 h after they reached confluence by 
incubation for 2  days in freshly-prepared induction medium; this was followed by 
maintenance in feeding medium (renewed every 2-3 days).
Time course studies during 3T3-L1 adipocyte differentiation were performed by 
collecting media samples every 2  days; cells were harvested at the appropriate time 
points.
2.4 SGBS Cell Culture
2.4.1 Reagents
1. Serum-containing medium (used in preadipocyte phase)
DMEM/Nutrient Mix F12 
33 pM Biotin 
17 pM Pantothenate 
100 units/ml Penicillin 
100 pg/ml Streptomycin 
10% FCS 2
2. Feeding Medium (used throughout the renewal o f  medium)
DMEM/Nutrient Mix F12 
33 pM Biotin 
17 pM Pantothenate
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100 units/ml Penicillin 
100 pg/ml Streptomycin 
10 pg/ml Human Transferrin 
10 nM Insulin 
100 nM Cortisol 
200 pM T3
3. Induction Medium (used once when cells are confluent (day 0)) 
DMEM/Nutrient Mix F12 
33 pM Biotin 
17 pM Pantothenate 
100 units/ml Penicillin 
100 pg/ml Streptomycin 
10 pg/ml Human Transferrin 
10 nM Insulin 
100 nM Cortisol 
200 pM T3
250 nM Dexamethasone 
500 mM IBMX 
10 mg/ml Rosiglitazone
All media were prepared using a sterilizing filter system in a cell culture fume 
cupboard. The media prepared was stored in a fridge with a temperature of 4°C. 
Before use, the media has to be warmed up to 37°C in a water bath. The culture and 
feeding media prepared can be used for up to 2 weeks. The induction medium, 
however, must be made freshly immediately before use.
2.4.2 Culture Method
SGBS preadipocytes were kindly supplied by Professor Martin Wabitsch (University 
of Ulm, Germany). They are a human preadipocyte cell “strain” derived from the 
stromal-vascular fraction of the subcutaneous white adipose tissue of an infant with 
Simpson-Golabi-Behmel syndrome. The cell strain found shows a high capacity for
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adipose differentiation, resulting in mature fat cells which are biochemically and 
functionally similar to human adipocyes (Wabitsch et al., 2001).
A frozen SGBS cell stock in a cryovial was taken out from the liquid nitrogen and 
quickly defrosted in a 37°C water bath. To entirely thaw the cells, 1 ml of pre-warmed 
culture medium was added to the cryovial and gently pipetted up and down several 
times. The thawed cell suspension was then transferred to a 25 cm2  flask containing 2 
ml of culture medium. The cells were maintained in an incubator at 37°C in a 
humidified atmosphere with 5% C(V95% air. The culture medium was changed two 
to three times a week until 80%-90% of the cells were confluent. At this point, the 
cells were ready to be passaged and subcultured. Prior to trypsinisation, the cells were 
briefly washed once with sterilized 1 xPBS. Then, 1 ml of trypsin/EDTA was added 
to the flask and the flask immediately put in a 37°C incubator for 1 min to help 
quickly detach the cells. To examine whether the cells were trypsinised completely, 
the flask was checked under a light microscope. After the cells were entirely 
detached, 9 ml of culture medium was added in a final volume of 10 ml. The cell 
suspension was gently pipetted up and down for several times to mix cells evenly. 
Equal density of preadipocytes was seeded in new flasks, and 6 -well or 12-well plates 
according to the experimental requirement. The culture medium was changed two or 
three times a week until cells were ready to be induced.
2.4.3 Differentiation of SGBS cells
Differentiation of the cells was initiated 24 h after 100% confluence in the plates. 
After aspiration of the old medium, the cells were gently washed with pre-warmed 
lx PBS for three times, and then incubated for 4 days in the FCS-free medium 
containing 0.25 pM dexamethasone, 500 pM 3-isobutyl-1-methyl-xanthine, 10 nM 
insulin, 200 pM triiodothyronine (T3 ), 1 pM cortisol and 2 pM rosiglitazone. 
Differentiation into adipocytes was examined under a light microscope by phase 
contrast at lOOx magnification. The phase contrast image of the accumulation of 
lipid droplets during the development of adipocytes was captured and photographed 
by a CCD video camera (UVP Inc., California, USA) (Figure 2.1). More than 90% of 
SGBS cells underwent full differentiation into mature adipocytes after day 10 post­
induction.
60
Materials and Methods
Fig 2.1 SGBS and 3T3-L1 cells cultured as in vitro models of human and mouse
white adipocytes respectively
SGBS Human cell models
Day -3 Day 0 Day 6 Day 20
The photographs shown above demonstrate the development of human SGBS and 
mouse 3T3-L1 adipocytes in culture medium at Day -3 , Day 0, Day 6  and Day 20 
or Day 0 Day 4 Day 7 and Day 10 respectively. Day -3 and Day 0 show a view of 
fibroblastic preadipocytes.
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2.4.4 Harvesting the Cells
The cells were maintained in the feeding medium containing insulin, cortisol and T3; 
which was renewed two or three times a week. According to the particular 
experimental design, the cells were collected at several time-points.
In the case of the time-course study of gut hormone receptor gene expression during 
differentiation, the cells were kept for up to 18 days and collected every 1-3 days in 
700 pi of Trizol per well. Samples were stored at -80°C until analysis. The cells were 
maintained in the feeding medium for 11-15 days for the studies on the regulation of 
GIP, GLP-1, ghrelin and obestatin treatment(s) on expression of various adipokine 
genes.
2.4.5 Time-Course Cells
A plan was organized to collect the cells and their medium, which was done every 
two days accordingly (starting from day -3 up to day 18) as shown below:
-3 -1 0 1 2 3 4 6 8 10 12 15 18
Cells and their medium were collected in 1.5 ml tubes on each of these days 
(preferably at the same time) and stored in a -80°C freezer until required for use.
2.5 RNA preparation
2.5.1 Total RNA isolation from cells and tissues
2.5.1.1 Reagents
Trizol (Invitrogen)
Chloroform (Sigma)
Isopropanol (Sigma)
75% Ethanol (Sigma)
Ultra-Pure water (0.1 pm filtered, DNase free & RNase free)
2.5.1.2 RNA Extraction Method
Scissors, tweezers and electric homogenizer blade attachments were treated with 
RNAse AWAY and rinsed with UV-irradiated distilled water prior to use to remove
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any RNAses present. If glass homogenizers were used, these were baked at 220°C for 
at least 2 h beforehand. For each group of samples, the glass homogenizer used was 
changed. If the electric homogenizer was used, the blade was rinsed twice with UV - 
irradiated distilled water between groups.
For RNA extraction from tissue, 50-150 mg of snap-frozen tissue were placed in a 
sterile tube. If necessary, the required quantity of tissue was cut from the frozen 
sample using a sterile scalpel, dissecting scissors and tweezers while on dry ice 
(alternatively, the tissue sample could be placed in a polythene sachet and broken into 
smaller pieces by hitting gently with a hammer). One ml of Tri-Reagent was added to 
the tube and the sample homogenized using either a glass or an electric homogenizer 
(Polytron Ultra-Turrax T25). The tissue homogenate was transferred into a 2 ml tube 
and centrifuged at 12,000xg for 10 min at 4°C. The clear supernatant was aspirated 
and transferred into a fresh 2 ml tube. Care was taken not to aspirate the cell debris 
pellet or any lipid layer overlying the supernatant. For RNA extraction from cells, the 
cells were first collected using Tri-Reagent as described and homogenised by 
triturating 10 times using a 1 ml syringe with a 23 gauge needle.
After incubating the tissue or cell homogenate at room temperature for 5 min, 200 pi 
of chloroform were added per ml of Tri-Reagent used. The tube was shaken 
vigorously for 15 sec by hand and then stood for 2-3 min at room temperature. This 
was followed by centrifugation at 12,000xg for 15 min at 4°C, leading to separation 
of three layers - a colourless upper aqueous phase containing RNA, a white interphase 
containing DNA and a red phenol phase containing protein. The aqueous layer 
containing the RNA was transferred into a fresh 2 ml tube, taking care to avoid 
contamination with either of the other two phases. If protein isolation was required the 
phenol phase was saved and stored at -20°C.
To minimise any possible genomic DNA contamination, an optional step 
(recommended by Sigma) was performed. Fifty pi of isopropanol were added to the 
sample per ml of Tri-Reagent used. This was vortexed, allowed to stand for 5 min at 
room temperature and then centrifuged at 12,000xg for 10 min at 4°C. The 
supernatant was transferred to a 1.5 ml tube, taking care not to aspirate in the area 
where any DNA pellet would have been precipitated.
Isopropanol was then added to the sample (450 pi per ml of Tri-Reagent used in 
sample preparation), followed by vortexing, incubation of the sample for 1 0  min at
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room temperature and centrifugation at 12,000xg for 10 min at 4°C. After this step the 
precipitated RNA pellet could usually be identified at the base of the tube.
Pure ethanol was diluted with distilled water to prepare a 75% ethanol solution. The 
supernatant was poured off and 700 pi of 75% ethanol added to the RNA pellet. This 
was followed by vortexing and centrifugation at 10,000xg for 10 min at 4°C. The 
supernatant was again poured off, and any remaining volume aspirated by pipette and 
discarded. The RNA pellet was allowed to air dry for 2-3 min and then dissolved by 
adding 10-15 pi of ultra-pure water, then vortexing briefly and centrifugating. 
Samples could be stored temporarily if required at -20°C prior to DNase treatment 
and/or quantification. Scissors, tweezers and glass homogenizers or electric 
homogenizer blade components were soaked in 1% Virkon solution for 1-2 h to 
decontaminate, then cleaned of any tissue debris prior to rinsing.
2.5.2 DNAse treatment of RNA
This treatment to further minimise any genomic DNA contamination was performed 
for all RNA samples that were to be analysed using real-time PCR. The efficacy of 
the treatment was established by DNase treating aliquots of two RNA samples known 
to contain genomic DNA. Treated and untreated RNA aliquots were then subject to 
PCR using a primer pair known to generate a band of a specific size if genomic DNA 
was present in the template. To check that the DNase treatment did not degrade the 
RNA, the treated and untreated samples were reverse-transcribed, and PCR performed 
using the cDNA.
2.5.2.1 Reagents
DNA-free Kit:
■ 1 Ox DNase I buffer
■ 2 units/ pi DNase (RNase free)
■ DNase inactivation reagent
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2.5.2.2 Method
One pi of DNAse I and 2.5 pi of lOx DNAse I buffer were added to a 25 jxl RNA 
sample, gently vortexed and incubated at 37°C in a hybridisation oven (HB-1000) for 
20-25 min. Five pi of DNAse inactivation reagent were added to the tube and 
vortexed gently. This was followed by an incubation step of 2 min at room 
temperature, flicking the tubes once during the incubation to redisperse the DNAse I 
inactivation reagent.
The sample was centrifuged at lOOOOxg for 1 min at room temperature to pellet the 
DNAse inactivation reagent and then stored temporarily if required at -20°C until 
quantification. Transfer of the RNA solution into a new 1.5 ml tube was usually not 
necessary, as the sample could be centrifuged prior to use so that the DNase 
inactivation reagent pellet was not disturbed when removing aliquots of RNA.
2.5.3 RNA Quantification
The RNA extracted samples were passed through a spectrophotometer machine 
(BioPhotometer) to read and calculate their concentration in pg/pl. First, the extracted 
RNA has to be diluted. This is done by adding 1 pi of the RNA to 69pl of pure water 
to new tubes to give a 1 in 70 dilution. Then, 70pl of pure water was added to a 
cuvette (spectrophotometer special sterile tube) to act as a blank. The RNA tubes were 
measured straight away making sure that the cuvette was rinsed with water before 
each use. The RNA concentration was determined from the absorbance at 260 nM 
(Yao et al., 2004), which has a coefficient number of 44. To determine the 
concentration of RNA; the Beer-Lambert law was used.
The Beer-Lambert law:
[RNA] pg/pl = A260 x 44 x 70 /1000
2.5.4 RNA integrity
RT-PCR was performed using the isolated RNA samples. Once the cDNAs had been 
synthesised, their quality was checked by performing PCR using primers for the 
housekeeping gene p-actin and running the products on a gel. The band intensity 
indicated the quality of the cDNA sample from which the integrity of the original
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RNA template could be inferred. Faint or undetectable bands suggested degradation 
of the isolated RNA or a failed RT reaction. The former could be investigated by 
checking the RNA integrity directly, and if found to be significantly degraded the 
sample was re-extracted from the tissue.
mRNA comprises 1-5% of a total RNA sample, whereas ribosomal RNA (rRNA) 
makes up >80% of total RNA, the majority of that consisting of 255 and 18S rRNA 
species (in mammals). The method used to directly check RNA integrity (denaturing 
gel electrophoresis) relies on the assumption that rRNA quality and quantity reflect 
that of the underlying mRNA population, with the caveat that there may be a degree 
of difference between the integrity of the longlived and abundant rRNA molecules 
and that of the underlying mRNA population, which turns over much more rapidly 
(Palmer & Prediger, 2005).
2.5.4.1 Reagents
Ultra-pure water
Sample buffer (1 ml 40% glycerol, 40 pi saturated BPB solution)
Reagents for agarose gel electrophoresis
2.5.4.2 Method
One pg of RNA was diluted with ultra-pure water to a total volume of 5 pi in a 0.2 ml 
tube and 2 pi of sample buffer added. The sample was mixed by vortexing briefly, 
loaded onto a 1 % agarose gel and run at 80-100 V for 30-40 min. An image of the gel 
was photographed. An intact RNA sample would have two clearly visible and well- 
defined bands representing 285 and 185 rRNA with little or no visible debris at the 
base of the gel. RNA degradation would be inferred from smudging or absence of the 
rRNA bands and a strong signal at the base of the gel.
2.6 Reverse Transcriptase Polymerase Chain Reaction (RT PCR)
2.6.1 Reagents
Reverse-iT 1st Strand Synthesis Kit (ABgene):
• Anchored Oligo-dT
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• 5x 1st Strand Synthesis Buffer
• 5 mM dNTP mix (each)
• Reverse-iT Rtase Blend
• DTT
• Pure RNA water
2.6.2 Method
Each tube had 1 pg of RNA and 1 pi of Anchored Oligo-dT, which is diluted with 
pure water to 12 pi. The tubes were incubated at 70°C for 5 minutes to denature the 
RNA. After that, the tubes were placed on ice to prepare the master mix. An RT-PCR 
standard master mix was prepared. Each tube contained 4pl of the buffer, 2pl of the 
dNTP, 1 pi of Reverse-iT RTase and 1 pi of DTT. So, for 12 samples, 48 pi of the 
buffer, 24 pi of the dNTP, 12 pi of Reverse-iT RTase and 12 pi of DTT were 
prepared.
The mixture was vortexed and pelleted down using a centrifuge. Then it was 
incubated at 47°C for 30 min to stretch the reverse transcription of the RNA along the 
cDNA. An incubation of 75°C for 19 min followed, which is performed to denature 
the RTase. Again, the mixture was pelleted down prior taking for PCR (if not, it was 
stored at -20°C).
2.7 Polymerase Chain Reaction (PCR)
The PCR generates multiple copies of a cDNA. A master mix was prepared that 
includes the DNA, which was placed in a PCR machine. Firstly, the temperature was 
increased to 94°C, which causes the DNA double helix to separate (denaturation). 
Secondly, the temperature was lowered, which causes the primers to anneal (attach) to 
the double strand DNA. Primers are specific RNA segments that match to specific 
DNA sequences, which initiate the process of making new DNA. Thirdly, an enzyme 
called TAQ polymerase (ready mix) was used to make new DNA chains. The 
temperature was again increased and the enzymes made new DNA to match the DNA 
strands that were separated. The cycles were repeated many times; after only 20 
cycles, there would be a million copies of the original DNA.
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2.7.1 Reagents
■ Ultra-pure water
■ 10 pM each sense and antisense primer mix
■ ReddyM ix PCR Master Mix Kit:
l.lxR eddyM ix
2.7.2 Method
This procedure was carried out using sterile 0.2 ml RNA/DNA-free tubes and filter 
tips and reactions were performed using a thermal cycler (PCR Express). A master 
mix containing 11.25 pi of l .lx  ReddyMix, 0.25 pi of primer mix and 0.5 pi of ultra- 
pure water per sample was prepared, vortexed and centrifuged. Twelve pi of this 
master mix were transferred into each tube and 0.5 pi of the appropriate cDNA added 
for a 12.5 pi final reaction volume (all volumes proportionately scaled up for a 50 pi 
reaction); ultra-pure water was used for the 'no template' control. The tubes were 
vortexed, centrifuged and placed into the cycler with the PCR program set as follows:
94°C, 2 min (denaturation)
20-38 cycles (specified cycle number for each primer pair) of:
i. 94°C, 20 sec (denaturation)
ii. 53-62°C, 30 sec (annealing; Ta optimized for each primer pair)
iii. 72°C, 30 sec (extension)
72°C, 5 min (final extension)
2.7.3 Primer Design and Optimisation
Primers were designed using Primer Premier 5 software and synthesized 
commercially (MWG Biotech, Ebersberg, Germany or Eurogentec, Romsey, UK). 
Primers were created by first pasting the mRNA coding sequence of the gene of 
interest into the software. This sequence was obtained from the NCBI PubMed Entrez 
Nucleotide database (www.ncbi.nlm.nih.gov/entrez)  and the most complete and up-to- 
date sequence of those available for the gene was selected. The locations on the
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mRNA coding sequence of any exon-exon boundaries, together with the start and end 
of the protein coding sequence (CDS) were identified.
Knowing the location of exon-exon boundaries was important as the primer pair could 
then be designed to span at least one intron in order to avoid the generation of PCR 
products from any genomic DNA contaminants present in the cDNA template 
solution. Intron locations were either established directly (for example using NCBI's 
Map Viewer utility) or calculated from the chromosomal exon locations when the 
sequence was subjected to a BLAST search against the genome. Ideally, the primers 
would be sited so as to generate a product from the CDS, but if it was necessary, one 
of the primers could be sited outside this region in order to span an intron.
Primers were designed according to several parameters. The primer length was chosen 
to be between 18 and 24 bases. Longer primers are more specific during amplification 
(allowing use of a lower Ta) but are more likely to form secondary structures 
including hairpins, dimers and self-complementation. If unavoidable, primers with the 
most unstable secondary structures were selected, as these structures would tend to 
disappear at a higher Ta. Dimers, or false priming sites involving the 3' end of the 
primer, were especially avoided as these could theoretically be extended by the DNA 
polymerase.
Ideally, the primer melting temperature (Tm) was between 60-65 °C (and within 2°C of 
each other for the pair), so that the Ta would not be below 55°C (Ta of a primer pair 
should be ~5°C lower than the average of their Tms; a low Ta promotes nonspecific 
binding). The guanine-cytidine (GC) content of the primers was generally 40-60%, 
and roughly equal between the two primers, as with increasing GC content the Tm 
increases. The amplicon size was ideally 180-600 bp; larger products would require 
longer annealing times in order to be fully extended. The primer sequences as well as 
the expected amplicon sequences were subjected to a BLAST search to ensure 
specificity prior to ordering.
Primers were tested on receipt by performing PCR with one or more cDNA samples 
in which a signal for that gene might be expected. A high cycle number (38 or more) 
and a low annealing temperature (53-55°C) were used initially to maximise the
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chance of obtaining a product. The optimal Ta of a primer pair was determined by 
performing PCR over a range of annealing temperatures and selecting the highest 
temperature at which a strong signal was obtained with no non-specific products. The 
cycle number was optimized by performing PCR over a range of cycle numbers and 
selecting the lowest cycle number for which a distinct signal could be detected. 
Primer sequences and optimal cycling conditions are detailed in Table 2.1.
2.8 Agarose gel electrophoresis
2.8.1 Reagents
■ Agarose
■ 5 mg/ml ethidium bromide
■ lOxTBE buffer
■ 100 bp DNA ladder (GeneRuler or ReddyRun Super-ladder low 100 bp)
■ Distilled water
❖  Distilled water was used to dilute lOx TBE buffer to prepare lx  TBE buffer for 
use.
❖  1 % agarose gel (final volume 50/60 ml):
0 .5/0.6 mg agarose 
50/60 ml lx TBE buffer
5/6 pi ethidium bromide (final concentration 0.5 pg/ml)
2.8.2 Method
The gel casting tray was prepared by sealing the ends with autoclave tape. The 
agarose was weighed directly into a 500 ml flask, the lx  TBE added and the flask 
heated for ~2 min in a microwave (flask taken out and swirled every 30 sec) until the 
agarose was completely dissolved. The solution was cooled by running the flask 
under cold water prior to adding the ethidium bromide, which was mixed by swirling 
the flask. The mixture was poured into the gel casting tray and any bubbles pushed
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Table 2.1 Sequences of PCR primers
P rim er Ta (°C) C ycles Product (bp) Sequence (5'- 3')
m f i -  actin s TGCTGTCCCTGTATGCCTCT
60 20 463
m/?-actin as AGGT CTTT ACGG AT GT C AACG
mResistin s G A AG AACCTTTC ATTT CCCCT CC
60 30 266
mResistin as CTTCACGAATGTCCCACGAGGC
mGLP-lR s TCCTCCG AG AGC ACT GT CCGT CTT
59.9 36 328
mGLP-lR as CAGCAGCCCTCGTCCTCATAGA
mGIPR s T AT GCCT GCT GGA ACT AC ACGG
57.5 36 489
mGIPR as GGT ACGGAAAT AGATGGGAAACG
mGHSR s TGGAGCACGAGAACGGCACAGA
63.3 36 217
mGHSR as GGGCAGCCAGCAGAGGATGAAA
mGPR39s GTCAGTTTGGCTTGTTCAGATA
55 35 355
mGPR39 as AGTT G AGTCCCTT GTGAGTGG
hf i -  actin s GT GGCAT CCACGAAACTACCTT
56.2 28 281
h/i-actin as GGACTCGTCATACTCCTGCTTG
hLeptin s GAACCCTGTGCGGATTCTTG
55 38 422
hLeptin as C ACCT CT GTGGAGT AGCCT G AA
hAdiponectin s AT GCTGTTGCT GGG AGCT GTTC
60 31 352
hAdiponectin as CCACACT GAATGCT GAGCGGTA
hGLP-lR s GCCGCCT GGT GTTT CT GCT CAT
62.5 36 268
hGLP-lR as GCGTGCTCGTCCATCACAAAGG
hGIPR s T AT CCGC ATT CTT GGC ATT CTCC
61 36 448
hGIPR as CTCCGACTGCACCTCCTTGTTG
hGHSRs CGCT CAGGGACCAGAACCA
55.8 36 320
hGHSR as GGCCCG AG AACTTT C ATCTTT C
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hGPR39 s 
hGPR39 as
58 33 453
CAGCCCGAGACCTCCAATA 
AAACT GCT GCGAGG AC ACC
This table shows the sequences of the primers used in PCR analysis. The PCR product 
sizes, the annealing temperatures (Ta) and amplification cycle numbers are those used 
unless otherwise indicated, p-actin was used as a housekeeping gene, m, mouse; h, 
human; s,sense primer; as, anti sense primer.
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aside using a comb. The combs were then placed into their slots and the gel allowed 
to set for at least 15 min. The autoclave tape was removed and the tray with the gel 
placed in the gel tank. The tank was filled with 1 x TBE until the gel was submerged 
in the buffer before removing the combs.
For analyzing the PCR products on the gel, 10 pi of each was pipetted sample into 
separate wells. Two pi of ladder was loaded near the samples as a reference to assess 
whether the PCR product was located at the expected size. The end wells were 
avoided if possible, as these are most likely to run aberrantly. The gel was run at 85- 
100 V for 30-60 min or until the samples had run far enough. For band detection, the 
gel was placed on a UV transilluminator (2011 Macrovue). The images were recorded 
using a DC 120 digital camera and analyzed using ID 1 image analysis software.
2.9 PCR product purification and sequencing
Correct primer design should ensure that the product obtained with PCR is the 
intended one. However, in order to confirm that the target cDNA has indeed been 
amplified, it is important to sequence the product obtained from the use of a new 
primer pair. The sequencing was performed commercially by MWG Biotech. (Table 
2.2)
2.9.1 Reagents
■ ReddyMix PCR Master Mix Kit (1. lx ReddyMix)
■ NucleoSpin Extract 2-in-l Kit:
Buffer NT1
Buffer NT2 Buffer NT3 
NucleoSpin columns 
NucleoSpin collecting tubes
■ Ultra-pure water
■ lOObp ladder GeneRuler
■ Sample buffer (1 ml 40% glycerol, 40 pi saturated BPB solution)
2.9.2 Method
PCR reactions using a single template cDNA, previously identified as strongly 
expressing the gene of interest, were performed to a total reaction volume of 1 0 0  pi
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(2 x 50 pi reactions) and using a high number of cycles (38-40) in order to generate a 
large quantity of the PCR product. After cycling, the reaction volumes were pooled 
and loaded onto a 1 % agarose gel, using a single composite well (obtained by taping 
several teeth of the comb together in advance). The gel was run at 100 V for 30 min. 
The band was examined under low-wavelength UV light, excised with a clean scalpel 
and the gel fragment transferred to a 2 ml tube and it’s mass determined. The PCR 
product was extracted from the gel using the standard protocol for the NucleoSpin 
Extract 2-in-l kit as follows:
For each 100 mg of the gel fragment, 300 pi of NT1 was added. A water bath was 
used to incubate the tube at 50°C until the gel had dissolved (~10 min) and was 
accompanied by vortexing the tube briefly every 2 min. A column was placed into a 
collecting tube, 700 pi of the sample loaded and centrifuged for 1 min at 8000xg.
The flow-through in the collecting tube was discarded. If the sample volume was 
above 700 pi, this procedure was repeated using further aliquots of up to 700 pi each 
time until the total volume had been processed. As a result of this step, the (impure) 
PCR product was bound to the silica membrane of the column. To remove inhibitors 
and contaminants resulting from the agarose, a recommended washing step was 
performed by adding 500 pi of NT2 to the column and centrifuging for 1 min at 
llOOOxg. The flow-through was discarded, 600 pi of NT3 added and the column 
centrifuged for 1 min at llOOOxg to wash the membrane. The flow-through was again 
discarded, 200 pi of NT3 added and the column centrifuged for 2 min at llOOOxg to 
dry the membrane. The column was then placed into a 1.5 ml tube and 30 pi of ultra- 
pure water added. The column was allowed to stand for 1 min at room temperature to 
allow full dissolution of the DNA. This was followed by centrifugation for 1 min at 
1 lOOOxg to collect the eluted DNA in the 1.5 ml tube.
In order to be accurately sequenced, 20 ng of DNA are needed per 100 bp of the 
product size. The concentration of the purified DNA solution was estimated by 
preparing a sample consisting of 1 pi of the purified DNA, 5 pi of ultra-pure water 
and 2 pi of sample buffer. This was loaded into a well of a 1 % agarose gel and run as 
described above alongside 2 pi of quantifying 100 bp ladder (GeneRuler). According 
to the brightness of the purified DNA band, the concentration of the solution could be 
estimated as described below. If the band was extremely faint or absent, the whole 
procedure was repeated from the PCR reaction onwards.
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The 100 bp GeneRuler ladder was prepared using 1 pi (0.5 pg) of ladder DNA, 1 pi of 
loading dye solution and 4 pi of ultra-pure water. The DNA was therefore diluted 1: 6  
in the final preparation (0.083 pg/ pi). Two pi of ladder, containing 0.17 pg of DNA, 
were loaded onto the gel. According to the manufacturer's protocol a specific quantity 
of DNA is present in each band when 1 pg of the ladder DNA is used. Thus, the 
amount of DNA present in each band when 0.16 pg of ladder are used could be 
determined.
When 1 pi of the purified DNA solution was run against the ladder, the brightness of 
the purified DNA band was compared to that of each of the ladder bands by eye and 
the nearest match identified. The DNA concentration of that ladder band was then 
taken to be the approximate concentration of the purified DNA solution. An aliquot of 
this solution containing the amount of DNA required for sequencing was then dried in 
a 1.5 ml tube using a vacuum centrifuge. This was then sent for sequencing together 
with a 10 pi aliquot of a 10 pM solution of either the sense or the antisense primer (to 
sequence both the sense and antisense strands, two DNA aliquots were sent together 
with an aliquot of each primer). The sequencing result was subjected to a BLAST 
search to confirm identity.
2.10 Real-time polymerase chain reaction
Real-time PCR can be used for absolute or relative quantitation of the initial amount 
of template in a sensitive, specific and reproducible manner. It is preferable to 
alternative forms of PCR quantification because it quantifies the initial template 
cDNA rather than the final amount of amplified PCR product. This is possible as real­
time PCR monitors the fluorescence emitted during the reaction as an indicator of 
amplicon production during each PCR cycle. The fluorescent signal increases in direct 
proportion to the amount of PCR product. During the exponential phase of the PCR 
reaction, there is a significant increase in the amount of PCR product. By monitoring 
the fluorescence, the cycle at which this phase commences can be determined. The 
more initial template there is, the earlier the fluorescent signal will be significantly 
increased.
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Real-time PCR also offers a wide dynamic range of up to 107 -fold, compared to only 
103 -fold in conventional PCR, which means that large variations in template amount 
can be quantified sensitively and accurately.
2.10.1 Taqman® system
The real-time PCR work performed in this study employed the Taqman system 
(Applied Biosystems), which involves the use of a primer pair and a Taqman probe. 
The probe is an oligonucleotide with a fluorescent (reporter) dye (usually FAM) on 
the 5' base, and a quenching dye (usually TAMRA) typically on the 3' base. When the 
probe is intact, energy is transferred from the reporter dye to the nearby quenching 
dye molecule (FRET - fluorescence resonance energy transfer) rather than emitted as 
fluorescence (Giulietti et al., 2001). During the annealing phase of the PCR cycle, the 
probe binds to an internal region of a PCR product and when the Taq polymerase 
replicates a template onto which a probe is bound, its 5' exonuclease activity cleaves 
the probe. This separates the reporter and quenching dyes and ends the FRET. The 
reporter dye now starts to emit fluorescence (at 518 nm for FAM) which increases in 
each cycle proportional to the rate of probe cleavage. Accumulation of PCR products 
is detected by monitoring the increase in fluorescence (AR) of the reporter dye 
(usually plotted as ARN after normalisation of the reporter dye signal to a reference 
dye (usually ROX) to correct for differences in reaction mix volumes between wells) 
(Giulietti et al., 2001).
2.10.2 Design of primers and Taqman probes
Human IL-ip primers and Taqman probe sequences were designed by Primer Express 
software and synthesised commercially (Eurogentec for primers and probes). 
Sequences and intron data were obtained as in section 2.7.3, and primers were again 
designed to span an intron. Primers and probes were designed to be 20-30 bases in 
length, with primer Tms of 58-60°C and the probe Tm 10°C higher. The product size 
was designed to be 50-150 bases as PCR is more efficient with smaller amplicons. 
One specific requirement for the Taqman probes was that there be no G at the 5' end, 
as a G adjacent to the reporter dye quenches reporter fluorescence even after the probe
77
Materials and Methods
Table 2.3 Real-time PCR primer and Taqman probe sequences
P rim er/P robe Product Final cone. Sequence (5'-3')
(bp) (nM )
qhB-actin s 900 TTGCCGACAGGATGCAGAA
qhB-actin as 101 900 GCCGAT CC AC ACGG AGT ACT
qhB-actin P 200 AGCACAATGAAGATCAAGATCATTGCTCCTCCT
qhLeptin s 300 CCAAAACCCTCATCAAGACAATT
qhLeptin as 93 300 AGT CC A AACCGGT G ACTTT CT G
qhLeptin P 250 TGACATTTCACACACGCAGTCAGTCTCCT
qhAdiponectin s 300 CCCAAAGAGGAGAGAGGAAGCT
qhAdiponectin as 73 300 T CCTTTCCATC AT AGT AAT ATTT CC AG AA
qhAdiponectin p 200 TT CCCAGATGCCCCAGCAAGTGTAAC
qh IL-6 s 300 GGTACATCCTCGACGGCATCT
qh IL-6 as 83 300 GTGCCTCTTTGCTGCTTTCAC
qh IL-6 p 200 TGTT ACTCTT GTT AC ATGT CT CCTTT CT C AGGGCT
qh MCP-ls 300 CAT AGC AGCC ACCTT C ATT CC
qh MCP-las 104 300 TCTGCACTGAGATCTTCCTATTGG
qh MCP-lp 200 CAGCCAG ATGCAATCAATGCCCC
This table shows the sequences of the primers and Taqman probes employed in real­
time (q)PCR analysis for (relative) quantitation of gene expression.; h, human; s, sense primer; 
as, antisense primer; P, Taqman probe
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has been cleaved. All other human primers and Taqman probes were kindly provided 
by Dr B Wang (University of Liverpool).
Primer and Taqman probe sequences are detailed in Table 2.3, together with the 
optimised final reaction concentrations. For a new primer/probe set, optimal primer 
concentrations were determined by performing an assay with final concentrations of 
sense and antisense primers ranging from 50 nM to 900 nM, in all possible 
combinations, with the probe concentration fixed at 200 nM. The resulting 
amplification plots were then examined and the combination with the lowest Ct and, 
the highest ARN was selected. Taqman probe optimisation was then performed at 
concentrations from 25-225 nM using the optimised primer concentrations and the 
amplification plots were used to select the optimal probe concentration.
2.10.3 Preparation of 96 well plates for real-time PCR
2.10.3.1 Reagents
qPCR Core Kit: 
lOx reaction buffer 
50 mM magnesium chloride 
5 mM dNTP mix 
5 U/pl Hot Goldstar enzyme
Sense primer, antisense primer and Taqman probe stock solutions 
Ultra-pure water
2.10.3.2 Method
Working solutions of the primers and probes were prepared at lOx concentration (e.g. 
9000 nM for a final reaction concentration of 900 nM) by diluting the stock solution 
with ultra-pure water. A master mix was made up which contained all the necessary 
components for the PCR, minus the cDNA template as follows:
10 x reaction buffer 2.5 pi per well (lx  final concentration)
50 mM MgCl 
5 mM dNTP
Sense primer
2.5 pi (5 mM)
1 pi (200 mM)
2.5 pi (SEE TABLE (2.3))
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Antisense primer 
Taqman probe 
5 U/pl Hot Goldstar enzyme 
Ultra-pure water
2.5 pi (SEE TABLE (2.3))
2.5 pi (SEE TABLE (2.3)) 
0.125 pi (0.025 U/pl) 
11.375 pi
Once the master mix had been made up, 25 pi were aliquoted to each well. One pi of 
the appropriate template cDNA was then added to each well for a total reaction 
volume of 26 pi and the plate sealed with an optical cover. All samples were run in 
duplicate, or triplicate if practical. No primer and no template controls were included 
on the plate for each set of primers and probe. The plate was spun at 1000 rpm for 20 
sec to ensure the reaction mix was not sticking to the well sides. If the assay was not 
to be performed immediately, the plate could be stored for up to 5 days at 4°C. If a set 
of samples (comprising several groups) required analysis over several plates, at least 
one group (usually the control group) was present on all plates. Data were normalised 
such that the mean ACt for the control group had the same value for each assay, 
enabling the data on the different plates to be directly compared.
2.10.3.3 Taqman system real time PCR setup
Reactions were performed using an Mx3005P cycler (Stratagene). Default conditions 
were used except that the reaction volume was specified as 26 pi. Once the cover 
temperature had reached 105°C, the plate was inserted into the heat block and an 
optical pad placed on top so that the holes aligned with the well positions. The cover 
was screwed into position and the run started.
Amplifications were performed commencing with a 2 min activation stage at 50°C, 
then a 10 min denaturation stage followed by 40 cycles consisting of a denaturation 
step of 15 sec at 95°C and a combined primer annealing and extension step for 60 sec 
at 60°C. Data were collected automatically by the software, and analysed once the run 
was complete (total mn time was ~ 2  h).
2.10.3.4 Analysis of real-time PCR data
The amplification plots were displayed in log scale using the Sequence Detector 
software and the threshold manually adjusted to ensure that it was clear of any noise.
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The software automatically recalculated the Cj value for each well (CT defined as the 
cycle number at which the fluorescence emitted from the well crossed the threshold). 
The results were exported as a Microsoft Excel file and gene expression analysed by 
relative quantitation with the 2'AACT method (Livak & Schmittgen, 2001). All samples 
were normalised to values of P -actin, the difference of Ct values between the control 
and treated samples were calculated and the relative fold changes obtained between 
the two groups. The formulae used for calculation are as follows:
ACt= Cj  (Target gene)- Ct (Reference gene)
AACt = Mean ACt (treated samples) - Mean ACT(control samples)
Fold Change=2'AACT
2.11 Western blotting
This technique enables the detection of a specific protein within a sample using a 
specific primary antibody. The protein samples are initially denatured using heat, SDS 
(to destroy hydrogen bonds and ionic interactions) and p-mercaptoethanol (to reduce 
disulphide bonds) to generate proteins with a linear structure. SDS also binds to the 
proteins (1.4 g of SDS per 1 g of protein) so that mass and charge are in equal 
proportion. The samples can then be separated according to their size by gel 
electrophoresis.
The negatively charged proteins are transferred from the gel to a membrane by 
electroblotting and a specific primary antibody used to bind with the antigen binding 
(Fab) part of the protein. A secondary antibody is used to bind to the constant region 
(Fc) of the primary antibody. The Fc of the secondary antibody is labeled with 
horseradish peroxidase (HRP); which in the technique employed here breaks down a 
chemiluminescent substrate in the presence of hydrogen peroxide and alkaline 
conditions. This chemiluminescent reaction emits light for up to 1 h. The maximum 
emission is at 428 nm and is detected by exposure of the membrane to a blue-light 
sensitive autoradiography film such as Hyperfilm ECL.
2.11.1 Protein isolation
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2.11.1.1 Protein isolation from snap frozen tissue
2.11.1.1.1 Reagents
SHE buffer:
250 mM sucrose 
1 mM HEPES 
0.2 mM EDTA 
Distilled water
Buffer PH adjusted to 7.2 and stored at 4°C.
2.11.1.1.2 Method
Between 100 and 200 mg of tissue were homogenized in 300-500 pi of SHE buffer 
using glass homogenisers, followed by centrifugation at 12000xg for 15 min at 4°C. 
The supernatant containing the protein was retrieved and the pellet discarded.
2.11.1.2 Protein isolation with Tri-Reagent
2.11.1.2.1 Reagents
Tri- Reagent
0.3 M guanidine hydrochloride in 95% ethanol (0.3M GHC1)
1 0 0 % ethanol
1% sodium dodecyl sulphate (SDS)
2.11.1.2.2 Method
As described in section (2.5.1.2), the phenol layer obtained after phase separation with 
Tri-Reagent was retained to perform protein extraction. The sample was mixed by 
inversion with 300 ml of 100% ethanol, allowed to stand for 3 min at room 
temperature and then centrifuged at 2000xg for 5 min at 4°C to pellet any remaining 
DNA. The supernatant containing the protein was transferred into 2 ml tube and 1.5 
ml isopropanol added to precipitate the protein.
The sample was allowed to stand for 10 min at room temperature and was then 
centrifuged at 12000xg for 10 min at 4°C. The protein was washed by discarding the
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supernatant, adding 2 ml of 0.3 M GHC1 and standing for 20 min at room temperature 
before centrifuging at 7500xg for 5 min at 4°C. This washing step was repeated twice 
more. After the final wash the protein was vortexed in a 2 ml of 100% ethanol and 
incubated for 20 min at room temperature. This was followed by centrifuging at 
7500xg for 5 min at 4°C. The supernatant was discarded and the protein dried for 5 
min under vacuum. The protein pellet was dissolved in 50-100 pi of SDS using a 
sonicator and stored at -80°C.
2.11.2 Protein quantification by BCA methods
The protein concentration was detected by the bicinchoninic acid (BCA) method. This 
assay involves initially the formation of a Cu+ 2  -protein complex under alkaline 
conditions, which is followed by the reduction of Cu+ 2  to Cu+1, and then combination 
with BCA to form a complex, which is a purple colour and has an absorption 
maximum at wavelength of 570 nm. The raw data were collected and calculated using 
the Microplate Manager 5.2 software (Bio-Rad).
2.11.2.1 Reagents
■ Bicinchoninic acid (BCA)
■ Copper (II) sulphate solution
■ Bovine serum albumin standard 2mg/ml(BSA)
- 1% SDS
■ 96-well microplate
2.11.2.2 Method
A standard curve was prepared with final protein concentrations of 0, 4, 8 , 12, 16, 20 
and 40 pg/well. This was performed by adding 0, 2, 4, 6 , 8 , 10 and 20 pi of protein 
standard in duplicate to the wells and making the volume up to 20 pi with 1% SDS. 
One pi of each sample was added in duplicate to the plate and 19 pi of SDS added to a 
final volume of 20 pi in each well. A 1:50 dilution of copper sulphate in BCA was 
prepared. Two hundred pi of this solution were added to each well. The plate was 
incubated for 2 h at room temperature and the extinction measured at 570 nm with a
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plate reader. Data were collected with Microplate Manger software, a standard curve 
was made and the protein concentrations of the samples determined.
2.11.3 SDS-PAGE
2.11.3.1 Reagents
1) Loading buffer (aliquots stored at -20°C)
125 mM tris-HCl 
2.5% SDS
2.5% P-mercaptoethanol 
6.25% glycerol
2.5 mg/ml BPB
2) Separating gel (10 ml) (8%/12%)
5.275/4.3 ml distilled water 
2.025/3 ml 40% acrylamide/bis 
2.5ml 1.5 M tris (pH 8 .8 ) 
lOOpl 10% SDS 
lOOpl 10%AP 
6/4 pi TEMED
3) 4% Stacking gel (5 ml)
3.732 ml distilled water 
498 pi 40% acrylamide/bis 
630 pi 1.0 M tris (pH 6 .8 )
50pl 10% SDS 
50pl 10% AP 
5 pi TEMED
4) Running buffer
25 mM tris-base 
192 Mm glycine 
0.1% SDS 
Distilled water
5) Transfer buffer (pH 8 .3)
25 mM tris-base 
192 mM glycine 
2 0 % methanol
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Distilled water
Rainbow recombinant protein molecular weight markers (10-250 kDa)
Water- saturated n-butanol
2.11.3.2 Method
To run the gel a vertical electrophoresis unit was used. Prior to use the glass plates 
and spacers were cleaned with ethanol, dried and then assembled. The separating gel 
was inserted between the glass plates using a 5 ml syringe and 21 gauge needle to 
prevent the development of bubbles. A few drops of n-butanol were pipetted on top of 
the gel to stop it drying out and to ensure that it was level. Once the separating gel had 
set (~30 min) the n-butanol was removed with filter paper and a 12-well (30 pl/well) 
comb inserted. The stacking gel was then poured using a needle and syringe between 
the glass plates and allowed to set (~20 min). Between 5 and 20 pg of protein were 
used as required. The samples were diluted 1:1 with sample buffer and heated at 95°C 
for 5 min. The gel apparatus was transferred into the gel tank which was filled with
1.5 1 of running buffer until the top of the wells were fully submerged. The comb was 
removed and the samples and 5 pi of protein marker were loaded into separate well. A 
maximum volume of 30 pi per well could be used. The gel was run for 1 h at 100 V or 
until the end of the run when the BPB line started to run off the gel. The 
electrophoresis unit was then disassembled and the gel transferred for electroblotting. 
The blotting procedure was performed using compact electroblotting units. Two foam 
pads, a nitrocellulose membrane and two squares of extra thick blotting filter paper 
were pre-soaked in transfer buffer. The blotting unit was assembled as follows:
White cassette clamp +ve side 
Pre- soaked foam pad
- Extra thick blotting paper
Pre-wetted transfer membrane (Hybond ECL)
- Gel
Extra thick blotting paper 
Pre-soaked foam pad 
Black cassette clamp -ve side
When the gel was laid on the membrane it was checked that no bubbles were 
trapped. The blotting unit was transferred into the blotting tank with the -ve
85
Materials and Methods
cassette clamp facing the -ve side of the tank. The tank was filled with transfer 
buffer until the membrane-gel assembly was fully submerged. The transfer was 
performed at 100 V for 1 h and the system was cooled with water during the ran.
2.11.4 Immunological detection of proteins
2.11.4.1 Reagents
1) Tris buffered saline (TBS; pH 7.5)
20 mM tris-base
500 mM sodium chloride
Distilled water
2) TTBS
TBS
0.05% Tween-20
3) Blocking solution
10% skimmed milk powder in TTBS
4) Antibody diluent
5% skimmed milk powder in TTBS
Primary antibody: Rabbit polyclonal antibody to human GLP-1, GEP, GHS 
and GPR39 receptors
Secondary antibody: sheep anti-rabbit IgG-HRP (horseradish peroxide)
ECL Western blotting detection reagents
Hyperfilm ECL
Developer
Fixer
2.11.4.2 Method
The membrane was removed from the blotting unit, placed in a container with 10 ml 
of blocking solution and incubated overnight at 4°C. The primary antibody solution 
was prepared by diluting 8  pi of primary antibody in 2  ml of antibody diluent for a
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final dilution of 1:250 or 1:500. The membrane was placed in a clean bottle container 
(with the protein coated surface innermost) together with the primary antibody 
solution and placed on a rocker, rotating at 4°C overnight. The membrane was then 
transferred to a clean container and washed with 10 ml of TTBS by incubating on the 
rocker for 15 min at room temperature. This procedure was repeated twice more, 
using fresh TTBS on each occasion.
After these washing steps the membrane was incubated with 2 ml of secondary 
antibody solution ( 1 : 1 0 0 0  dilution in antibody diluent), shaking for 1 h at room 
temperature. The membrane was washed 3 times in TTBS as before (5 min incubation 
only) followed by 3 further 5 min washes in TBS. The membrane was transferred to a 
clean container and incubated for 30 min in TBS, which was then poured off. For 
detection, 1 ml of each of the two ECL reagents was mixed, poured over the 
membrane and incubated for 1 min at room temperature. Excess reagent was then 
discarded and the membrane heat-sealed in Saran wrap.
The membrane was exposed within 5 min by placing it face up into an intensifying 
screen. A suitably sized piece of Hyperfilm ECL chemiluminescence film was placed 
on the membrane and intensifying screen shut. The exposure time was 5-10 min. the 
film was placed in developer for 2-3 min then transferred to fixer for at least 5 min. 
Finally, the film was rinsed in water for 10 min before being allowed to air dry.
2.12 Glucose uptake
Glucose transport is the process by which glucose is taken up into cells through a 
facilitated carrier process.
2.12.1 Materials
■ In vitro differentiated adipocytes in 12-well plates (SGBS cells are optimal at day 10-12)
■ KRH buffer (Krebs-Ringer-Hepes)
130 mM NaCl
10 mM HEPES 
10 mM MgS04 x7H20
2.5 mM NaH2 P 0 4 xH20
4.6 mM KC1
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2.5 mM CaCl2 x2H20
■ Adjust pH to 7.4
■ Freshly add: 1% BSA
■ 3 H-deoxyglucose -  Final concentration in 4.5 cm2 well (12 well) should be 0.2 pCi
■ PBS
■ Serum free basal medium
■ Insulin
■ 0.1 N NaOH
2.12.2 Working solution/ per well
- KRH/BSA 47.8 pi
■ 30mM 2-deoxy-D-glucose 2.0 pi
■ [3HJ2-DG 0.2 pi
2.12.3 Method
A modification of a method by Bernier et al. (1988) was used for the measurements of 
2-deoxy-D-glucose uptake. Briefly, SGBS fibroblasts were grown and differentiated 
in 12-well culture plates as described in section 2.4. After a 24 h incubation with 
pretreatment medium in the presence or absence of various concentrations of GLP-1, 
GIP, ghrelin or obestatin treatments, cells were washed twice and incubated with 950 
pi of KRH buffer containing 1% BSA for 3 h at 37 °C, 5% C 02. This was followed by 
the addition of different concentrations of insulin for 1 h at 37 °C (no insulin added 
for the basal uptake). 2-DG was added to a concentration of 60 pM containing 0.2 
pCi/well of 2-deoxy-D- [1-3 H] glucose (Sp. Act 315 GBq/mmol, GE Healthcare) for 5 
min at 37°C, 5% C 02. Uptake was stopped by the addition of 2 ml of ice-cold PBS 
containing 200 pM phloretin (Sigma). The cells were washed three times with PBS 
stop solution, and solubilised in 0.1 N NaOH for 10 min at 22 °C. The cell lysates 
were subjected to liquid scintillation counting using EcoScint A fluid (National 
Diagnostics). The uptake of 2-DG was measured in the absence and presence of 40 
pM cytochalasin B to correct for non-specific uptake.
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2.13 Electrospray ionization mass spectrometry (ESI-MS)
The technique is called Electrospray Ionisation Mass Spectrometry (ESI-MS). As its 
name implies, it measures the mass (molecular weight) of molecules, by producing 
singly or multiply charged molecular ions from an analyte solution by spraying it (the 
solution) under the influence of a strong electrical field. The mass spectrometer used 
for this work is called a tandem mass spectrometer. It consists essentially of an ion 
source followed by two mass analysers in series with a collision cell in between them. 
In general the stages within the mass spectrometer are:
■ Production of ions from the sample
■ Separation of ions with different masses
■ Detection of the number of ions of each mass produced
■ Collection of data to generate the mass spectrum
A mass spectrometer measures the mass-to-charge ratio (m/z) of each ion peak by the 
following equation: (m/z)= (Mr+ nH) / n
Where Mr molecular masses, H = proton mass = 1.00794 Da and n = number of 
protons (charges) for any particular ion peak.
2.13.1 Materials
■ 2 0  pi stock solution:
Obestatin amide solution (dissolved in DMSO)
De-ionised water
■ 180 pi denaturing solution which contains:
De-ionised water
50 % aqueous acetonitrile
0 . 2  % formic acid
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2.13.2 Method
The mass spectrometry study was kindly carried out by Mr Brian Green (VG 
BioTech/Fisons, Altrincham, England) using VG BioQ mass spectometer with 
electrospray (ES) ion source.
Initially, the obestatin amide sample is diluted 10-fold with water to give a stock 
solution. An aliquot of the stock solution made up into aqueous acetonitrile solutions 
(50:50 v/v)/ 2% formic acid, of final concentration 25-50 pmol/ pi. Generally, a 10 pi 
aliquot of the analyte solution is injected, via a loop injector, into a stream of the same 
solvent mixture flowing at a rate of 5 pi /min. The mass spectrometer is then routinely 
scanned over an appropriate m/z range, determined experimentally, generally several 
scans <15, are summed to obtain the final ESI-MS spectrum. Calibration of the m/z 
scale of the spectrometer is normally performed during each series of measurements 
using a solution of pure protein of known structure.
2.14 Statistics
The statistical significance of the difference between the means of two groups of 
samples was assessed by Student’s /-test using Microsoft Excel 2003. The statistical 
differences between more than two groups (treatments vs control) however were 
evaluated through one-way ANOVA (Analysis of Variance) with Dunnett's post-hoc 
test using the GraphPad InStat version 3.00 for Windows 95 {GraphPad Software, San 
Diego California USA}. Normality of the variables was tested and confirmed with the 
Kolmogorov and Smirnov method. Differences were considered to be significant 
when the P value was less than 0.05 (P<0.05). All results are presented as mean ± 
standard error of the mean (SE).
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GUT HORMONE RECEPTOR EXPRESSION IN MOUSE 
AND HUMAN ADIPOSE TISSUE
Chapter 3
3.1 Introduction
With obesity on the rise worldwide, studies have focused on investigation of the 
whole body mechanisms that govern weight gain and the abnormalities of both 
metabolic and inflammatory pathways. However, a potential role for gut peptides in 
white adipose function has been little considered and much of the current research on 
gut peptides is focused on circulating gut peptide levels but little work has been 
directed at studying receptors for gut peptides.
In general, the receptors for the peptide hormones are located in the plasma 
membrane. Receptor structure is varied: some receptors consist of a single 
polypeptide chain with a domain on either side of the membrane, connected by a 
membrane-spanning domain. Some receptors are comprised of a single polypeptide 
chain that is passed back and forth in serpentine fashion across the membrane, giving 
multiple intracellular, transmembrane, and extracellular domains. Other receptors are 
composed of multiple polypeptides. For example, the insulin receptor is a disulfide- 
linked tetramer with the (3-subunits spanning the membrane and the a-subunits located 
on the exterior surface. The hormone-binding signal of most, but not all, plasma 
membrane receptors is transduced to the interior of cells by the binding of receptor- 
ligand complexes to a series of membrane-localized GDP/GTP binding proteins 
known as G-proteins.
The gastrointestinal tract is the source of five named hormones and a large number of 
peptides whose range of functions and target tissues remain to be identified (Rehfeld 
1998; Holst et al., 1996). Gut peptides and hormones have effects in multiple tissues 
(Sancho et al., 2006; Yip et al., 2000). These peptides stimulate whole body 
metabolism through both direct and indirect pathways. Generally, the effects of the 
incretins, GLP-1 and GIP, in stimulating insulin secretion in response to an oral 
glucose load (Sancho et al., 2006), are mediated following activation of the GLP-1 
receptor (GLP-1 R) and GIP receptor (GIPR) respectively. Both GLP-1 R and GIPR 
are typical seven-transmembrane spanning receptors coupled to G-protein activation. 
GLP-1 R increased cAMP production and activation of PKA. However, there are also 
PKA-independent responses initiated through the GLP-1 R (Miki et al., 1996).
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Moreover, studies reported that GIPR has alternative modes of action, both dependent 
and independent of cAMP, in rat adipocytes (Ehses et al., 2002) and in non-adipose 
cell lines (Oben et al., 1991a; Beck et al., 1983; Beck et al., 1988).
The two newly discovered gastric mucosa-derived peptides, ghrelin and obestatin, 
appear to have opposing roles in the control of appetite (Zhang et al., 2005). Although 
both peptides derive from a common pre-prohormone, ghrelin is orexigenic whereas 
obestatin is anorexigenic. Differential post-translation events determine whether the 
signal to eat or not to eat predominates. Furthermore, ghrelin and obestatin peptides 
are activated by different receptors. The receptor for ghrelin is growth hormone 
secretagogue receptor (GHS-R) (Van der Lely et al., 2006) and the proposed receptor 
for obestatin is one of the orphan receptors, G-protein coupled receptor 39 (GPR39) 
(Zhang et al., 2005). It should be noted, however, that recent data question whether or 
not GRP-39 is, in fact, the endogenous receptor for obestatin (Holst et al., 2007; 
Lauwers et al., 2006). Therefore, the role of gut peptides in whole body metabolism 
extends beyond regulation of only gastrointestinal function. These peptides, with 
receptors located throughout the body, may play a more active role in whole body 
metabolism, appetite regulation and fuel preference than is currently appreciated.
Elucidation of the roles of gastrointestinal hormones in adipose tissue function may 
lead to further understanding of the mechanisms of obesity which in turn could allow 
more effective approaches to the prevention and treatment of obesity. Thus, if specific 
receptors for gut peptides can be found in adipose tissue one may infer that it is likely 
that they may have a direct effect on adipose tissue function. While specific receptors 
for GIP have been identified, studies have been inconclusive with regard to GLP-1 
and very little is known regarding ghrelin and obestatin.
Therefore, as a starting point in an examination of potential additional physiological 
actions of gut hormones in obesity, the expression of receptors from the gut were 
examined for the incretins, GIPR and GLP-1 R, the orexigenic peptide ghrelin, GHS- 
R, and the anorexigenic peptide obestatin, GRP39, in nonadipose and adipose mouse 
tissue, in two major human fat pad (subcutaneous and omental) and in cell culture 
systems of both mouse and human.
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3.2 Methods
3.2.1 Mouse tissue
Adult male CD-I mice, aged 8  wk, were obtained from Harlan Olac (Bicester, UK). 
The mice were housed on receipt for 2 wk at 21°C with a 12:12-h light-dark cycle 
(lights on at 0700) and fed a commercial rodent diet (CRM Diet, Labsure, Witham, 
UK) containing 19.2% protein and 4.3% lipid (wt/wt). Both food and water were 
available ad libitum. The mice were killed by cervical dislocation, and the following 
tissues were rapidly removed and frozen in liquid nitrogen: skeletal muscle, small 
intestine, liver, kidney, brain and various white fat depots (gonadal, mesenteric, 
omental, and subcutaneous). The omental depot, which is small and can be hard to 
localize in lean mice, is located alongside the inferior surface of the stomach and is 
distinct from the mesenteric fat. All tissues were stored at -80°C until analysis.
3.2.2 Human WAT
Abdominal subcutaneous and omental adipose tissue were provided by Dr S Wong 
(University of Liverpool) following gastroplasty of obese patients (aged 35-48 years, 
BMI>43 kg/m2); the subjects did not exhibit any other ongoing diseases. After 
removal, all tissues were immediately frozen in liquid nitrogen and stored at 
-80°C until analysis.
cDNA samples from human subcutaneous depots derived from 4 obese subjects (age, 
50 ± 16 yr; BMI 45 ±5 kg/m2) and 4 lean or nearly normal weight controls (age, 50 
±11 yr; BMI 24 ± 2.5 kg/m2) were kindly provided by Dr M Bullö (Universität Rovira 
I Virgili, Reus, Spain). The tissue was obtained by biopsies or during surgical 
procedures (cholecystectomy or abdominal hernia repair).
3.2.3 3T3-L1 cell culture
3T3-L1 cells were obtained from the American Type Culture Collection (Manassas, 
USA) and cultured at 37°C in a humidified atmosphere of 5% CO2 / 95% air as
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described in section 2.3.1. The cells were maintained in culture medium containing 
Dulbecco’s modified Eagle’s medium (DMEM), and 10% foetal calf serum (FCS). 
Differentiation of the cells was initiated 24 h after confluence by incubation for 2 days 
in culture medium containing dexamethasone, IBMX and insulin. This was followed 
by maintenance in feeding medium (renewed every 2 or 3 days) consisting of culture 
medium containing insulin. To investigate the time course of receptor gene expression 
during adipocyte differentiation, cells were collected every 2  days for up to 15 days.
3.2.4 SGBS cell culture
SGBS preadipocytes were kindly supplied by Professor Martin Wabitsch 
(University of Ulm, Germany). SGBS adipocytes were cultured as described in 
section 2.4.2. The preadipocytes were maintained in culture medium until they were 
totally confluent. Differentiation of the cells was initiated 24 h after post-confluence 
by exposing the cells to the adipogenesis cocktail for 4 days. After this step, the cells 
were maintained in feeding medium (containing insulin, cortisol and T3) for up to 18 
days and collected every 1-3 day for a time course study. The accumulation of lipid 
droplets in the differentiated SGBS cells was confirmed by viewing under a light 
microscope. More than 90% of preadipocytes differentiated into mature fat cells.
3.2.5 RT -PCR
RNA isolation was as described in section 2.6.1. The concentration of RNA was 
measured by spectrophotometry (Section 2.5.3). One pg of RNA was reverse 
transcribed to cDNA (Section 2.6.2) and stored at -20°C until being used for PCR 
(Section 2.7).
3.2.5 Western blotting
Protein extraction was performed using the methods described in section 2.11.1. The 
total protein was quantified using the BCA assay described in section 2.11.2. 
Samples containing 10-20 pg of total proteins were separated by 12% SDS-PAGE 
(Section 2.11.3).
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3.3 Results
3.3.1 Gut peptide receptor gene expression in mouse tissue
3.3.1.1 Incretin receptor gene expression in mouse tissue (adipose and 
nonadipose)
In initial studies, the presence of the mRNAs for GIPR and GLP-1R mRNA in the 
major fat depots and various nonadipose tissues of mice was examined by RT-PCR. A 
strong signal for GIPR mRNA was obtained in each of the four white adipose tissue 
sites examined (subcutaneous, gonadal, omental and mesenteric) and in the brain (Fig 
3.land Fig 3.2). A faint signal was discernible with the small intestine, but no signal 
was detected in skeletal muscle, liver or kidney (Fig 3.1A). By contrast, amplification 
of GLP-1R was widely detected in the entire nonadipose mouse tissues studied 
(skeletal muscle, small intestine, liver, kidney and brain) (Fig 3.1 A). On the other 
hand, GLP-1R mRNA expression was found only in omental and mesenteric fat 
depots but there was no detectable GLP-1 receptor gene expression in subcutaneous 
or gonadal fat (Fig 3.2). Sequence analysis of the PCR products confirmed the 
identity. Studies were limited with regard to GLP-1 receptor expression in the liver. 
The results from this section supported the outcome of a previous study (Schmidtler et 
al., 1994), in which the mRNA of GLP-1 R was detected in the rat liver using a 
combination of northern blot analysis and RT-PCR. For the subsequent experiment, a 
cDNA sample of human liver tissue was kindly provided by Dr. Stuart Wood 
(University of Liverpool). Importantly, this study showed that GLP-1 R gene 
expression was detectable in both mouse and human liver (Fig 3.IB).
3.3.1.2 GHS-R and GPR39 gene expression in mouse tissue (adipose and 
nonadipose)
The presence of GHS-R and GPR39 mRNA in four major WAT depots 
(subcutaneous, gonadal, omental and mesenteric) and also in skeletal muscle, small 
intestine, liver, kidney and brain of mouse was examined by RT-PCR.
There was widespread tissue expression of the GPR39 gene; GPR39 mRNA was 
present in all the adipose and nonadipose tissue examined (Fig 3.1 and Fig 3.2). In
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contrast, GHS-R gene expression was detected only in three major fat depots 
(subcutaneous, gonadal and omental) and in the brain of the mouse tissues (Fig 3.1 
and Fig 3.2). GHS-R mRNA was not detected in mesenteric fat, skeletal muscle, 
small intestine, liver or kidney by RT-PCR.
3.3.2 Gut peptide receptor gene and protein expression in human white adipose 
tissue
3.3.2.1 Incretin receptor gene and protein expression in human WAT
In the subsequent study, RT-PCR and western blotting were employed to examine 
whether the gene encoding incretin receptors are expressed in human WAT and 
whether the receptor protein is present. Expression of the genes encoding both GLP- 
1R and GIPR was examined in the major human WAT sites. Signals for GIPR mRNA 
were observed in both human depots examined, namely subcutaneous and omental 
fat; the signal was relatively strong in both WAT depots investigated (Fig 3.3A). A 
signal for GLP-1R mRNA was only observed in the omental fat depot; no signal for 
GLP-1R mRNA was detected in the subcutaneous tissue.
To investigate whether the mRNA coding sequence of GIPR and GLP-1R are 
translated into a functional protein, the expression of receptor proteins, both in human 
subcutaneous and omental fat pads, of two subjects was assessed by western blotting 
using specific polyclonal antiGIPR and antiGLP-lR antibodies respectively. 
Immunoreactivity was obtained with a band of a 53 kDa in both fat depots, consistent 
with the presence of GIPR. In contrast, GLP-1R protein expression was detected only 
in the omental fat depot of both human subjects, and was not detected in subcutaneous 
fat (Fig 3.3B).
3.3.2.2 GHS-R and GPR39 gene and protein expression in human WAT
The studies on GHS-R and GPR39 gene expression reported in the previous section 
(3.3.1.2) involved a range of nonadipose and four major adipose mouse tissues. RT- 
PCR was used to investigate whether the genes are also expressed in human WAT. 
Figure 3.4A shows that GHS-R and GPR39 mRNA was present in both human depots
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Figure 3.1 GLP-1R, GIP R, GHS-R and GPR39 expression in 
various nonadipose mouse tissues
A
328 bp 
489 bp 
217 bp 
355 bp 
463 bp
Mus SI Liv Br Ki
GLP-1R
GIPR
GHS-R
GPR39
P-actin
B
328 bp
GLP-1R (human liver)
GLP-1R (mouse liver)
(A) GLP-1R, GIPR, GHS-R and GPR39 gene expression using RT-PCR, in 
several nonadipose mouse tissues. (B) GLP-1 receptor gene expression in both 
mouse and human liver. Mus, skeletal muscle; SI, small intestine; Liv, liver; Br, 
brain; Ki, kidney. Cycle number for GLP-1 R, GIPR, GHS-R, GPR39 and fi-actin 
are 36, 32, 36, 32 and 25 cycles respectively
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Figure 3.2 GLP-1R, GIP R, GHS-R and GPR39 expression in major
mouse fat depots
328 bp 
489 bp 
217 bp 
355 bp 
463 bp
GHS-R
GPR39
P-actin
Sc Gon Om Mes
GLP-1R, GIPR, GHS-R and GPR39 mRNA is detected in four major mouse WAT 
depots using RT-PCR. Sc, subcutaneous; Gon, Gonadal; Om, omental; Mes, mesenteric. 
Cycle number for GLP-1R, GIPR, GHS-R, GPR39 and 6 -actin are 36, 32, 36, 32 and 25 
cycles respectively.
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studied, subcutaneous and omental, the signal was rather stronger, however, for the 
GPR39 gene compared to the GHS-R gene (Fig 3.3A).
In the subsequent studies, proteins were extracted from major human WAT depots, 
precisely subcutaneous and omental fat of two human subjects to explore GHS-R and 
GPR39 protein expression in human WAT by western blotting. Signals for GHS-R 
and GPR39 proteins were detected in both omental and subcutaneous fat depot of the 
two subjects, which paralleled the observation of GHS-R and GPR39 gene expression 
in these major human fat depots (Fig 3.3B).
3.3.3 Gut peptide receptor gene and protein expression in cell culture system
3.3.3.1 Incretin receptor gene expression in mouse 3T3-L1 cells
In the following experiments, cultured mouse 3T3-L1 cells were employed to 
investigate the expression of both GIPR and GLP-1R mRNA in adipocytes pre- and 
post- induction of differentiation using RT-PCR.
GIPR was not detected in undifferentiated 3T3- LI cells, but was evident by day 5 
after the induction of differentiation into adipocytes and the signal remained high 
over the following 10 days (Fig 3.4). A similar pattern was evident with GLP-1R, 
but this gene was expressed even later; mRNA was detected from day 8  post- 
differentiation and onwards (Fig 3.4).
100
Chapter 3
Figure 3.3 GLP-1R, GIP R, GHS-R and GPR39 gene and protein 
expression in major human fat depots
(A)
448 bp
268 bp 
320 bp
(B)
GIPR
GLP-1R
GHS-R
453 bp
SC Om
GPR39
Oml Om2 Scl Sc2
(A) GIPR, GLP-1R, GHS-R and GPR39 gene expression using RT-PCR in 
subcutaneous and omental WAT depots. Cycle number for GLP-1R, GIPR, 
GHS-R and GPR39 are 36, 34, 36 and 32 cycles respectively (B) Receptor 
protein examined by western blotting in two major human WAT depots 
(subcutaneous and omental) of two subjects (1-2). Sc, subcutaneous; Om, 
omental.
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3.3.3.2 GHS-R and GPR39 gene expression in mouse 3T3-L1 cells
In the next studies, 3T3-L1 cells were utilised before and after the induction of 
differentiation into adipocytes to assess whether GHS-R and GPR39 mRNAs are 
present by RT-PCR. GPR39 mRNA was undetectable in 3T3-L1 preadipocytes; 
however, a signal was immediately observed at day 1 post-induction and was 
present throughout the subsequent time course after the initiation of differentiation 
(Fig 3.4). In contrast to GPR39 mRNA, GHS-R mRNA was not detected before or 
shortly after the induction of differentiation; a signal was, however, present at day 8  
post induction and thereafter (Fig 3.4).
3.3.3.3 Incretin receptor gene and protein expression in human SGBS 
adipocytes
To further establish whether the incretin receptor genes are expressed in differentiated 
adipocytes, another adipocyte culture system (SGBS) was employed. SGBS cells are a 
human preadipocyte cell strain derived from the stromal-vascular fraction of the 
subcutaneous white adipose tissue of an infant with Simpson-Golabi-Behmel 
syndrome. The cell strain shows a high capacity for adipose differentiation, resulting 
in mature fat cells which are biochemically and functionally similar to human 
adipocytes (Wabitsch et al., 2001).
This study showed that GIPR gene expression was undetectable in preadipocytes; in 
contrast, a strong signal for GIPR mRNA was detected at day 4 and thereafter (Fig 
3.5). A similar pattern was evident with GLP-1R, but was expressed even later; 
mRNA was detected by day 8  post-differentiation and thereafter (Fig 3.5).
In the subsequent studies, the total protein was extracted from pre- and post- 
differentiated SGBS cells to explore the GLP-1R and GIPR protein expression in 
human adipocytes by western blotting. Signals from the GIPR protein began to be 
detected at day 4 and thereafter (Fig. 3.6). In contrast, GLP-1R protein signals were 
very faint, and were detected very late (day 8 ) after the induction of differentiation 
and onwards (Fig. 3.6). However, no signal for both incretin receptor proteins was 
identified in SGBS preadipocytes, which paralleled the observation of the receptor
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Figure 3.4 Receptor expression during the differentiation and development of
3T3L1 cells to adipocytes
-3 -1 0 1 2 3 4 6  8  10 12 15
Days post-differentiation
GLP-1R
GIPR
GHS-R
GPR39
(3-actin
GIP R, GLP-1R, GHS-R and GPR39 gene expression in cultured 3T3-L1 
cells pre- and post- differentiation assessed by RT-PCR. Differentiation was 
initiated on day 0. Cycle number for GLP-1R, GIPR, GHS-R, GPR39 and B- 
actin are 36, 32, 36, 32 and 25 cycles respectively.
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gene expression in the cells (Fig 3.5).
3.3.3.4 GHS-R and GPR39 gene and protein expression in human SGBS 
adipocytes
GPR39 mRNA was undetectable in SGBS preadipocytes; however, a signal was 
immediately observed at day 1 post-induction and was present throughout the 
subsequent time course (Fig 3.5). GFIS-R mRNA appeared much later, and signal was 
not detected in undifferentiated SGBS cells, but was evident by day 6  after the 
induction of differentiation into adipocytes (Fig 3.5).
To investigate the expression of GPR39 and GHS-R protein, both in pre- and post- 
differentiated SGBS cells, western blotting was employed using a specific polyclonal 
antiGPR39 and antiGHS-R antibodies, respectively. GPR39 protein was detectable in 
preadipocytes; a faint signal was immediately observed at day 0  and became stronger 
at day 2  post-differentiation and moreover was present throughout the subsequent 
time course (Fig 3.6). In contrast to GPR39, GHS-R protein was not detected before 
or shortly after the induction of differentiation; a signal was, however, present at day 
6  post induction and thereafter (Fig 3.6).
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Figure 3.5 Receptor gene expression in human SGBS adipocytes
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GIP R, GLP-1R, GHS-R and GPR39 gene expression in cultured SGBS cells pre- 
and post- differentiation assessed by RT-PCR. Differentiation was initiated on day 0. 
Cycle number for GLP-1R, GIPR, GHS-R, GPR39 and fi-actin are 36, 34, 36, 32 
and 23 cycles respectively.
105
Chapter 3
Figure 3.6 Receptor protein expression in human SGBS
adipocytes
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Western blotting was performed to detect GIPR, GLP-1R, GHS-R and 
GPR39 protein expression during differentiation and development of 
SGBS cells to adipocytes.
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3.3.4 Gut peptide receptor gene expression in WAT of obese subjects
The next experiments examined whether the mRNA of genes encoding the receptors 
for ghrelin (GHS-R), obestatin (GPR39), glucagon-like peptide-1 (GLP-1R) and 
glucose-dependent insulinotropic polypeptide (GIPR) are expressed in WAT of 
human obese subjects using RT- PCR.
This study was carried out by using the subcutaneous fat depots obtained from four 
morbidly obese individuals. Leptin mRNA was examined as a reference for the same 
obese subjects. Expression of all the above gut peptide receptor genes, together with 
that of the leptin gene, was detected in all four obese human (subcutaneous) WAT 
subjects (Fig 3.7A).
From the above observations, GPR39 and the other receptor genes expression are 
evidently expressed in obese human (subcutaneous) WAT. The mRNA of the GPR39 
gene was then examined again in subcutaneous fat of four lean individuals using RT- 
PCR. Although, GPR39 gene expression was found in subcutaneous fat of all four 
human obese subjects, no expression was evident for GPR39 in the lean subjects (Fig 
3.7B). For a reference, the mRNA levels of leptin in the same samples of lean and 
obese subjects were also examined using RT- PCR (Fig 3.7B).
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Figure 3.7 Incretins R, GHS-R and GPR39 expression in subcutaneous WAT
depot of obese human subjects
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(A) GIPR, GLP-1R, GHS-R and GPR39 gene expression using RT-PCR, 
in subcutaneous WAT of four (S1-S4) obese human subjects. Leptin 
expression was examined as a reference (B) Leptin and GPR39 were 
examined in subcutaneous fat of four human obese (Ob 1-4) and lean 
(Lnl-4) subjects. Cycle numbers for GLP-1R, GIPR, GHS-R, GPR39 
and Leptin are 36, 34, 36, 32 and 33 cycles respectively.
108
Chapter 3
3.4 Discussion
The literature review indicates that whether the gut hormone receptor(s) gene 
examined in this study including, the incretins GIP and GLP-1, ghrelin and obestatin, 
are expressed in white adipose tissue has been an issue of debate. The initial 
experiments set out to establish whether the genes encoding the receptors for the 
above gut peptides are indeed expressed in adipocytes. RT-PCR was performed on 
RNA extracted from several adipose and nonadipose tissues, including four major 
WAT depots (subcutaneous, gonadal, omental and mesenteric) in mice. In addition, 
subcutaneous and omental WAT samples of lean and obese human subjects, and 
adipocytes from cell culture systems (mouse 3T3-L1 and human SGBS cells) were 
examined. The receptor protein was determined in adipose tissues by using western 
blotting.
3.4.1 Gut peptide receptor gene expression in mouse tissue
In the present study, GLP-1R, GIPR, GHS-R and GPR39 gene expression was 
detected in the mouse brain, consistent with the observations of previous studies in 
rodent brain (Wei & Mojsov,1995; McKee et al., 1997; Rudovich et al., 2007). The 
presence of binding sites in the brain suggest that the above gut peptide receptor(s) 
may have a role as neurotransmitters. However the action of GIP and the more 
recently discovered peptide, obestatin, in the central nervous system remain 
uncertain.
Using RT- PCR the presence of GLP-1 R and GPR39 mRNA has been shown in a 
range of mouse tissue including skeletal muscle, small intestine, liver, kidney and 
brain. The tissue expression pattern of both GLP-1 R and GPR39 indicates that these 
receptors might be truly essential for the function of a number of metabolic organs, 
although this result was not quantitative.
Importantly, GLP-1 R gene expression was detected not only in mouse liver, but also 
in human liver tissue, which supports the outcome of other studies (Schmidtler et al., 
1994; Villanueva-Penacarrillo et al., 1995), in which the mRNA expression of GLP- 
1R was detected in mouse and rat liver using a northern blot analysis and RT-PCR
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respectively. The known insulin secretion-independent effect of GLP-1 on hepatic 
glucose uptake is consistent with the presence of specific GLP-1 receptors on liver 
cells. Binding of GLP-1 to these receptors could initiate intracellular signaling 
pathways which could target kinases and/or factors involved in glucose uptake and 
glycogen synthesis. Recent evidence suggests that GLP-1 is secreted into the hepatic 
portal vein through the presence of GLP-1 sensors or receptors in the hepato-portal 
region (Burcelin et al.t 2001). Because of the rapid degradation of GLP-1 in the 
plasma, the hepato-portal region may play a critical role in the generation of the full 
effects of GLP-1.
3.4.2 Gut peptide receptor gene expression in mouse and human WAT
The present study has identified receptors for multiple gut peptides in major white 
adipose tissue depots of both mice and humans. Whether any of these receptors have a 
normal physiological role in the control of fat metabolism remains to be determined. 
Differences in GLP-1 R gene expression between subcutaneous and visceral fat have 
been shown and this may explain why previous reports on the lipolytic or lipogenic 
activity of incretins in rodent adipocytes have been contradictory; some appear to 
support the notion of increased lipogenesis, while some oppose it.
GLP-1 R gene expression was found in omental and mesenteric, but not subcutaneous 
or gonadal WAT of mice. It is tempting to speculate about the significance of the 
absence of GLP-1 R mRNA in subcutaneous fat while being abundant in omental fat 
in humans. As discussed in Chapter 1, WAT contains mature adipocytes and the 
stromal-vascular (SV) fraction, which comprises macrophages, fibroblasts, vascular 
endothelial cells and preadipocytes (Hausman, 1985). The differences in GLP-1 gene 
expression could come from any component of these fat depots. Therefore, additional 
study is required to establish the cellular site not only of GLP-1 R, but also of GIPR, 
GHS-R and GPR-39 gene expression in adipose tissue.
Adipose tissue located within the abdominal cavity has been suggested to be 
functionally and metabolically distinct from that of the subcutaneous compartment 
and these differences could play a role in obesity-related complications (Vohl et al., 
2004). The findings presented here, however, could be the result of a different
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regulatory mechanism of subcutaneous and visceral fat gene expression by multi­
stimuli. Vohl et al. (2004), showed by using multiple array replicates, that the 
expression profiles of different genes involved in lipolytic stimuli and cytokine 
secretion, were altered in subcutaneous and visceral adipose tissues of obese men. 
Moreover, Tchkonia et al., (2006), demonstrated regional differences in the intrinsic 
characteristics of the preadipocytes in the different fat depots, with those of 
subcutaneous adipose tissue presenting greater differentiation and fat cell gene 
expression but less apoptosis than that of visceral fat tissue.
The regulation of GLP-1R expression in human fat tissue has until now not been 
investigated in detail. In recent years, it has been shown that the promoter region of 
the incretin receptor genes contains multiple Spl/Sp3 binding sites, which appear to 
be involved in the cellular expression of the receptor (Barth et al., 2002). However, 
Spl binding activity is enhanced during adipocyte differentiation and acts 
predominantly as an activator of G-protein coupled receptor activity, while Sp3 may 
also exert a repressor activity (Barth et al., 2002). Thus, fat depot-specific differences 
in GLP-1R gene expression may be explained via the depot-specific composition of 
slowly and rapidly replicating subtypes of preadipocytes (Tchkonia et al., 2005).
3.4.3 Gut peptide receptor gene and protein expression in adipocytes in cell 
culture
By using 3T3-L1 cells in culture, the current study further indicates, that not only the 
incretin receptor genes but also the GHS-R and GPR39 genes are expressed after 
differentiation, although not in preadipocytes. The signals for the GIP, GLP-1 and 
ghrelin receptor mRNAs are late post differentiation, emerging from day 4, day 8  and 
day 8 , respectively. However, a signal for the GPR39 gene was immediately observed 
at day 1 post-induction and was present throughout the subsequent time course shortly 
after adipocyte differentiation. This finding is partially consistent with previous 
reports suggesting that GIPR, GLP-1 R and GHS-R gene expression is detected in 
3T3-L1 cells at an even earlier stage (McIntosh et al., 1999; Egan et al., 1994; Kim et 
al., 2004). On the other hand, these are the first data which demonstrate that adipocyte 
cell culture systems of mice 3T3-L1 cells express the transcript coding for the 
proposed obestatin receptor (GPR39).
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The expression of gut peptide receptor genes in differentiated mouse adipocytes, but 
not in preadipocytes, was further supported by exploring GIPR, GLP-1R, GHS-R and 
GPR39 gene and protein expression in human SGBS adipocytes. GPR39 mRNA was 
undetectable in SGBS preadipocytes; however, a signal was observed at day 1 post­
induction and was present throughout the subsequent time course. In contrast to 
GPR39, GIPR, GLP-1R and GHS-R mRNA appeared much later. The early presence 
of GPR39 mRNA and protein during the development process of the adipocytes 
implies that GPR39 may be an early marker of the differentiation in SGBS 
adipocytes.
The presence of these gut peptide receptors in fat cells could be an indicative of the 
physiological nature of the effects mediated by these gut peptides in adipose tissue. 
To date, surprisingly little is known about these gut peptides interactions with 
adipocyte biology. However, Tnag et al., (2008), have recently evaluated the effect of 
obestatin on cell proliferation in primary cultures of piglet adipose cells. The results 
showed that this peptide induced cell proliferation in a dose-dependent manner with 
MEK/ERK 1/2 phosphorylation (Tnag et al., 2008). However, in another study 
obestatin did not increase the cell cycle or viability of the murine 3T3-L1 adipocyte 
cell line, other than that this peptide inhibited the proliferation and differentiation of 
3T3-L1 preadipocytes. Furthermore, the effect of obestatin was contrary to that of 
ghrelin on this adipocyte cell line (Zhang et al., 2007). These findings suggest that 
direct effects of obestatin on proliferation and or differentiation, in adipocytes may 
play a role in regulating body fat mass.
On the other hand, GLP-1 seems to exert differential, concentration-dependent effects 
on lipid metabolism in human adipocytes, which may be explained by the existence of 
different GLP-1-binding receptors (Villanueva-Penacarrillo et al., 2001). 
Furthermore, recent studies showed that ghrelin activates the mitogen-activated 
protein kinase pathway in vitro, which stimulates cellular proliferation and 
differentiation in cultured white adipocytes. (Kim et al., 2004; Zhang et al., 2004).
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3.4.4 Gut peptide receptor gene expression in WAT of obese subjects
Finally, in this section of the study, receptor mRNA was detected in subcutaneous 
WAT of four obese human subjects. In addition to expression of GIPR, GLP-1R and 
GHS-R genes, GPR39 was evidently present in all obese human WAT used.
The GLP-1R gene expression in subcutaneous fat of the 4 obese subjects was not 
similar to what was revealed in the previous section of this chapter in lean 
subcutaneous fat. It has been postulated that an exaggerated 'incretin' factor, that 
induces glucose-dependent insulin secretion from the pancreas when the meal is taken 
orally, may have a pathophysiological role in obesity. Moreover the hyper- secretion 
of GLP-1 may be the long sought 'incretin' factor in obesity. Molavi et al., (2006), 
suggested that obesity often produces a type 2 -like diabetic state, which resolves after 
weight loss (Molavi et al., 2006). That might explain the results in the current 
experiment in which the BMI of the 4 obese subjects used was 45 ±5 kg/m2. Since this 
is classified as morbidly obese, we can therefore hypothesise that the obese subjects 
might have either an expanded or contracted end organ receptor number for this 
peptide.
Importantly, GPR39 gene expression was found in the subcutaneous fat of all four 
human obese subjects, but no expression was evident in lean subjects. It could be 
hypothesised that high expression of the GPR39 gene in obese subjects is due to a 
decreased obestatin level in obesity. In a recent study, Huda et al., (2008) have shown 
that plasma obestatin concentrations are significantly lower in obese subjects when 
compared to lean controls. Nevertheless, the reduction of this peptide in obese 
humans is probably maladaptive and may further propagate the obese state. In another 
study, Catalan et al., (2007), revealed that the GPR39 receptor is present in adipose 
tissue and that it is down regulated in obese type 2  diabetes, but not in non-diabetic 
obese subjects.
The work described in this chapter now shows that genes encoding the receptors for 
ghrelin (GHS-R), obestatin (GPR39), glucagon-like peptide-1 (GLP-1R) and glucose- 
dependent insulinotropic polypeptide (GIPR) are expressed in the main WAT depots
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of mice and humans, and are indeed expressed in differentiated cell culture systems of 
both mice and human adipocytes.
114
CHAPTER 4
EFFECT OF GLP-1, GIP & GHRELIN ON ADIPOKINE 
GENE EXPRESSION IN HUMAN ADIPOCYTES
Chapter 4
4.1 Introduction
In Chapter 3, it was demonstrated that the receptors, encoding the incretins, GLP-1 
and GIP, and ghrelin, were expressed by human white adipose tissue, and that these 
gut receptors (mRNA and protein) were unambiguously detected in post differentiated 
3T3-L1 and SGBS adipocytes. The finding of receptor expression in SGBS cells 
provides an opportunity to further study the possible biological roles of GLP-1, GIP 
and ghrelin peptides in human adipocytes. In this chapter, studies focused on 
exploring the possible regulatory effect of GLP-1, GIP and ghrelin on key adipokines 
in adipocytes. The studies were carried out by treating cultured human adipocytes 
with recombinant human GLP-1, GIP or ghrelin peptides in vitro. As described in the 
previous chapter, SGBS cells can maintain their proliferation and differentiation 
capacity after repeated subculture; more importantly, the differentiated adipocytes are 
histologically and metabolically similar to the adipocytes derived from the SV 
fraction in primary culture (Wabitsch et al., 2001).
A limited number of investigations have demonstrated that gastrointestinal hormones 
may have an important role in the control of the pathways of lipid metabolism. For 
instance, GIP has been proposed to be an anabolic hormone for adipocyte lipid 
metabolism and stimulates lipoprotein lipase activity (Eckel et al., 1979), thereby 
promoting fat storage. GIP also promotes fatty acid incorporation into adipose tissue 
(Beck et al., 1983). GIP infusion promotes triglyceride clearance from the circulation 
in dogs (Wasada et al., 1981), and inhibits the lipolytic effect of glucagon on 
adipocytes (Hauner et al., 1988).
Unlike GIP, the effects of GLP-1 on the lipolytic or lipogenic activity in rodent 
adipocytes have been contradictory, some supporting the notion of increased 
lipogenesis (Oben et al., 1991; Egan et al., 1994; Perea et al., 1997), and some the 
opposite (Ruiz-Grande et al., 1992).
Recently, ghrelin has been found to activate the mitogen-activated protein kinase 
pathway in vitro (Kim et al., 2004; Zhang et al., 2004), which stimulates cellular 
proliferation and differentiation in cultured white adipocytes (Kim et al., 2004; Zhang 
et al., 2004).
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In this set of studies, synthetic GLP-1, GIP and recombinant ghrelin were used to 
investigate whether these peptides influence the expression of key adipokine genes in 
adipocytes. Little has been reported in regard to the regulation of adipokine 
production by incretins. However, a recent study has now examined the possibility 
that specific actions of GIP are mediated through the direct regulation of resistin 
release in 3T3-L1 adipocytes, resulting in increasing the activity of both PKB and 
LPL pathways (Kim et al., 2007). On the other hand, ghrelin directly suppresses 
adiponectin mRNA expression (Ott et al., 2002). In one study, intra-peritoneal 
injection of ghrelin increased both adiponectin and leptin expression in adipose tissue, 
but these effects did not reach statistical significance (Asakawa et al., 2003).
In this section, the effect of GLP-1, GIP and ghrelin on the gene expression of leptin, 
adiponectin, MCP-1 and IL-6 , was investigated in SGBS cells.
4.2 Methods
4.2.1 SGBS cell culture
SGBS cells were cultured as described in section 2.4.2. The preadipocytes were 
maintained in culture medium and differentiation of the cells was initiated 24 h post­
confluence by incubating the cells for 4 days in induction medium. The cells were 
maintained in feeding medium, which was renewed 2-3 times a week. At day 12, the 
cells were pre-incubated with cortisol and T3- free feeding medium for 24 h. All the 
human recombinant gut peptides explored in this set of studies were dissolved either 
in 100% DMSO or autoclaved water according to the protocol provided for each 
peptide, and the concentration of stock solutions for each peptide was 1 pM. Prior to 
treatment, incubation media were prepared by adding each peptide stock, to the 
cortisol and T3-free feeding medium. The final concentration of each gut peptide in 
the media were 2 nM for the low dose, 20 nM for the intermediate dose and 100 nM 
for the high dose. The media used for the cells as a control had their pre-incubation 
medium renewed. Cells were collected after 4 h or 24 h in 700 pi of TRI Reagent 
(Sigma). After the total RNA was isolated, it was treated with a DNA-free kit (Section 
2.5.2). The concentration o f RNA was measured by a spectrophotometer (Section
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2.5.3), and 1 pg of RNA was reverse transcribed to cDNA using the Reverse-iT First 
Strand Synthesis Kit (Section 2.6.).
The cDNA samples from treated groups and the control group were analysed by real­
time PCR using the qPCR Core kit and the Mx3005P™ QPCR System. The mRNA 
levels of each quantified gene were normalized to the value of human p actin, and the 
results were expressed as relative fold changes to control using the 2  AACt method 
(section 2.10.3.4).
4.2.2 Statistics
Data are presented as mean values ± S.E.M. Differences between groups (treatments 
vs. control) were analysed by one-way ANOVA with Dunnett's post-hoc test. All data 
were checked for normality. There were no differences in variance amongst groups. 
Differences were considered to be statistically significant when P<0.05.
4.3 Results
4.3.1 The effect of GIP on adipokine gene expression in human SGBS 
adipocytes
The SGBS adipocytes were used at day 14 post-induction. Three different 
concentrations of GIP were employed; 2 nM for the low dose, 20 nM for the 
intermediate dose and 100 nM for the high dose.
No effect was found on mRNA level in the case of leptin in both 4 h and 24 h of GIP 
treatment (Fig 4.1). However, with the 24 h treatment a 2-fold increase in adiponectin 
mRNA level was evident at the higher dose of GIP treatment, while there was no 
response to the low or the intermediate doses of GIP (Fig 4.2).
Moreover, GIP treatment for 24 h led to an increase in IL- 6  gene expression, with a 2- 
fold induction of IL- 6  mRNA level in response to low, intermediate and high doses of 
GIP, but there was no change with the 4 h treatment (Fig 4.3). Interestingly in a 
similar pattern, a 2-fold increase in MCP-1 mRNA level was detected at low, 
intermediate and high doses applied to the differentiated SGBS adipocytes after 24 h
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GIP treatment (Fig 4.4).
4.3.2 The effect of GLP-1 on adipokine gene expression in human SGBS 
adipocytes
In the next set of experiments, the effect of GLP-1 on the production of important 
adipokines was examined in SGBS adipocytes. Administration of recombinant human 
GLP-1 for 4 or 24 h had no effect on leptin gene expression in SGBS cells (Fig 4.5). 
However, after applying GLP-1 for 24 h there was a dose-dependent increase in 
adiponectin gene expression, with a 2.5-fold and 4-fold induction of adiponectin 
mRNA level in response to the intermediate and higher dose respectively, but these 
was no change with the 4 h GLP-1 treatment in SGBS cells (Fig 4.6). A very small 
stimulatory effect of GLP-1 on IL- 6  mRNA level was also observed at the higher 
dose only with both 4 and 24 h treatments, which caused a 70% increase (Fig 4.7). 
Whereas, neither the 4 nor 24 h GLP-1 treatment had any effect on MCP-1 gene 
expression in SGBS cells compared with the control (Fig 4.8).
4.3.3 The effect of ghrelin on adipokine gene expression in human SGBS 
adipocytes
To evaluate the effect of ghrelin on the key adipokines gene expression, SGBS 
adipocytes were treated with different concentrations of ghrelin for 4 and 24 h. Real 
time quantitative PCR analysis revealed that none of the doses of ghrelin influenced 
the mRNA expression of leptin, adiponectin and IL- 6  gene expression (Fig 4.9, Fig 
4.10; Fig 4.11).
Interestingly however, ghrelin treatment for 24 h under the same conditions exerted an 
inhibitory effect on MCP-1 gene expression. MCP-1 mRNA levels were reduced by 
50% with both intermediate and high doses (Fig 4.12); and these differences were 
statistically significant. However, MCP-1 mRNA level was not altered with the 4 h 
ghrelin-treated cells.
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Figure 4.1 Effect of GIP on leptin gene expression in human SGBS
adipocytes
Effect of GIP on leptin relative mRNA levels in SGBS cells. Differentiated human 
adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then incubated 
in medium containing either low dose (LD) 2 nM, intermediate dose (IMD) 20 nM 
or high dose (HD) 100 nM GIP for 4 and 24 h. Leptin mRNA levels were 
measured by real-time PCR and normalised to human (3 actin relative to the 
untreated control group. Treatment with GIP did not alter gene expession for leptin 
in both 4 h and 24 h. Results are mean values ± S.E.M for groups of 5-6; compared 
with controls.
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Figure 4.2 Effect of GIP on Adiponectin gene expression in human SGBS
adipocytes
sk
Effect of GIP on adiponectin relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM GIP for 4 and 24 h. Adiponectin mRNA 
levels were measured by real-time PCR and normalised to human P actin relative 
to the untreated control group. The 24 h treatment at the higher dose of GIP 
showed a 2-fold increase in adiponectin mRNA. Results are mean values ± S.E.M 
for groups of 5-6, *P < 0.05; compared with controls.
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Figure 4.3 Effect of GIP on IL-6 gene expression in human SGBS
adipocytes
3 ' *
Effect of GIP on IL- 6  relative mRNA levels in SGBS cells. Differentiated human 
adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then incubated 
in medium containing either low dose (LD) 2 nM, intermediate dose (IMD) 20 nM 
or high dose (HD) 100 nM GIP for 4 and 24 h. IL- 6  mRNA levels were measured 
by real-time PCR and normalised to human (B actin relative to the untreated control 
group. GIP treatment for 24 h led to an increase in IL- 6  gene expression however 
there was no change with the 4 h treatment. Results are mean values ± S.E.M for 
groups of 5-6, *P < 0.05; compared with controls.
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Figure 4.4 Effect of GIP on MCP-1 gene expression in human SGBS
adipocytes
Effect of GIP on MCP-1 relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM GIP for 4 and 24 h. MCP-1 mRNA levels 
were measured by real-time PCR and normalised to human p actin relative to the 
untreated control group. GIP treatment for 24 h led to an increase in MCP-1 gene 
expression but there was no change with the 4 h treatment. Results are mean values 
± S.E.M for groups of 5-6, *P < 0.05; compared with controls.
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Figure 4.5 Effect of GLP-1 on leptin gene expression in human SGBS
adipocytes
Effect of GLP-1 on leptin relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM GLP-1 for 4 and 24 h. Leptin mRNA 
levels were measured by real-time PCR and normalised to human (3 actin relative 
to the untreated control group. Treatment with GLP-1 did not alter gene expession 
for leptin in both 4 and 24 h. Results are mean values ± S.E.M for groups of 5-6; 
compared with controls.
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Figure 4.6 Effect of GLP-1 on adiponectin gene expression in human SGBS
adipocytes
7 -,
Effect of GLP-1 on adiponectin relative mRNA levels in SGBS cells. 
Differentiated human adipocytes at day 12 were deprived of cortisol and T3 for 24 
h and then incubated in medium containing either low dose (LD) 2 nM, 
intermediate dose (IMD) 20 nM or high dose (HD) 100 nM GLP-1 for 4 and 24 h. 
Adiponectin mRNA levels were measured by real-time PCR and normalised to 
human (3 actin relative to the untreated control group. There was a dose-dependent 
increase in adiponectin gene expression after applying GLP-1 for 24 h but there 
was no change with the 4 h GLP-1 treatment. Results are mean values ± S.E.M for 
groups of 5-6, *P < 0.05; compared with controls.
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Figure 4.7 Effect of GLP-1 on IL-6 gene expression in human SGBS
adipocytes
Effect of GLP-1 on IL- 6  relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM GLP-1 4 and 24 h. IL- 6  mRNA levels 
were measured by real-time PCR and normalised to human f3 actin relative to the 
untreated control group. A small stimulatory effect of GLP-1 on IL- 6  mRNA level 
was observed only at the higher doses for both 4 and 24 h treatments. Results are 
mean values ± S.E.M for groups of 5-6, *P < 0.05; compared with controls.
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Figure 4.8 Effect of GLP-1 on MCP-1 gene expression in human SGBS
adipocytes
3 i
Effect of GLP-1 on MCP-1 relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM GLP-1 4 and 24 h. MCP-1 mRNA levels 
were measured by real-time PCR and normalised to human p actin relative to the 
untreated control group. Treatment with GLP-1 did not alter gene expession for 
MCP-1 at both 4 and 24 h. Results are mean values ± S.E.M for groups of 5-6; 
compared with controls.
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Figure 4.9 Effect of ghrelin on leptin gene expression in human SGBS
adipocytes
Effect of ghrelin on leptin relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM ghrelin for 4 and 24 h. Leptin mRNA 
levels were measured by real-time PCR and normalised to human P actin relative 
to the untreated control group. Treatment with ghrelin did not alter gene expession 
for leptin at both 4 h and 24 h. Results are mean values ± S.E.M for groups of 5-6; 
compared with controls.
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Figure 4.10 Effect of ghrelin on adiponectin gene expression in human SGBS
adipocytes
Effect of ghrelin on adiponectin relative mRNA levels in SGBS cells. 
Differentiated human adipocytes at day 12 were deprived of cortisol and T3 for 24 
h and then incubated in medium containing either low dose (LD) 2 nM, 
intermediate dose (IMD) 20 nM or high dose (HD) 100 nM ghrelin for 4 and 24 h. 
Adiponectin mRNA levels were measured by real-time PCR and normalised to 
human p actin relative to the untreated control group. Treatment with ghrelin did 
not alter gene expession for adiponectin at both 4 h and 24 h. Results are mean 
values ± S.E.M for groups of 5-6; compared with controls.
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Figure 4.11 Effect of ghrelin on IL-6 gene expression in human SGBS
adipocytes
Effect of ghrelin on IL- 6  relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM ghrelin for 4 and 24 h. IL- 6  mRNA levels 
were measured by real-time PCR and normalised to human (3 actin relative to the 
untreated control group. Treatment with ghrelin did not alter gene expession for 
IL- 6  at both 4 h and 24 h. Results are mean values ± S.E.M for groups of 5-6; 
compared with controls.
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Figure 4.12 Effect of ghrelin on MCP-1 gene expression in human SGBS
adipocytes
Effect of ghrelin on MCP-1 relative mRNA levels in SGBS cells. Differentiated 
human adipocytes at day 12 were deprived of cortisol and T3 for 24 h and then 
incubated in medium containing either low dose (LD) 2 nM, intermediate dose 
(IMD) 20 nM or high dose (HD) 100 nM ghrelin for 4 and 24 h. MCP-1 mRNA 
levels were measured by real-time PCR and normalised to human p actin relative 
to the untreated control group. Ghrelin treatment for 24 h exerted an inhibitory 
effect on MCP-1 gene expression. Results are mean values ± S.E.M for groups of 
5-6, *P < 0.05; compared with controls.
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4.4 Discussion
The key adipokines investigated in this set of studies including adipocytes hormones, 
adiponectin and leptin, IL-6 , and MCP-1 are known for their role either locally, 
peripherally, or centrally in a variety of physiological processes including food intake, 
energy balance, insulin action, lipid metabolism, and homeostasis (Friihbeck et al., 
2001; Raj ala & Scherer, 2003; Trayhum & Beattie, 2001). Moreover, there is 
accumulating evidence to suggest that IL- 6  and MCP-1 are linked to inflammation 
and the inflammatory response (Rajala & Scherer, 2003). Leptin itself has also been 
linked with inflammation (Sarraf et al., 1997), whereas the other major adipocyte 
hormone, adiponectin, has an anti-inflammatory effect (Yokota et al., 2000). The 
major aim of the studies in this section therefore was to examine whether GLP-1, GIP 
and ghrelin influence the expression of inflammatory-related adipokine genes in 
human adipocytes.
The results obtained in the current studies indicate that neither the incretins, GLP-1 
and GIP, nor the ghrelin have effect on the regulation of leptin synthesis. However, 
both GLP-1 and GIP appears to have a small stimulatory effect on adiponectin 
mRNA levels at higher concentrations. Adiponectin is one of the most abundantly 
expressed adipose-specific proteins (Maeda et al., 1997), and it has been implicated 
in the pathogenesis of obesity and insulin resistance in rodents and in humans (Kim 
et al., 2002). Adiponectin levels are decreased in obese states and increased in 
individuals losing weight (Kim et al., 2002). Furthermore, it has been demonstrated 
that administration of adiponectin improves insulin resistance and fatty acid 
oxidation in mice (Yamauchi et al., 2002; Berg et al., 2001), and that disruption of 
the adiponectin gene results in diet-induced insulin resistance (Maeda et al., 2002).
In addition to the most remarkable ability of incretins to excite insulin secretion in the 
presence of glucose stimulatory concentrations (Kreymann et al., 1987), the incretins 
role in regulating glucose and lipid metabolism has been reported by others (Hauner et 
al., 1988; Wang et al., 1997). The present data reveals that incretins may modulate the 
production of adipocyte-derived adipokines, by increasing adiponectin mRNA level 
after applying high doses of either GLP-1 or GIP for 24 h in differentiated SGBS 
cells. However, It should be noted, that the effect of incretins on adiponectin
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expression is very small, and more work including the influence of both incretins on 
adiponectin release by fat cells is needed in the future.
MCP-1 is expressed primarily by immune cells, but it is also produced by human 
adipocytes (Gerhardt et al., 2001; Wang et al., 2005). MCP-1 has been recognized as a 
crucial signal governing the infiltration of macrophages into WAT in obesity (Xu et 
al., 2003). The increased secretion of MCP-1 by WAT in obesity (Bruun et al., 2005 ) 
may contribute to the inflammatory response and insulin resistance locally in adipose 
tissue (Dahlman et al., 2005). In the present study, the stimulation of MCP-1 by GIP 
indicates that GIP may be involved in the synthesis of this adipokine in adipocytes. 
However, This stimulatory effect contradicts the proposed anti-obesity function of 
GIP (Gault et al., 2003). Recently, studies have witnessed the development of a 
substantial number of designer enzyme-resistant 'super GIP' molecules with potent 
insulinotropic and anti-diabetic properties (Gault et al., 2003). Nevertheless, 
observations in transgenic GIP receptor deficient mice indicate that GIP directly links 
ovemutrition to obesity, therein playing a vital role in the development of obesity and 
related metabolic disorders (Miyawaki et al., 2002).
Moreover the present results with 24 h GIP treatment in human adipocytes, showed 
that IL-6 , another pro-inflammatory cytokine, gene expression was stimulated in a 
similar pattern. This indicates that GIP peptide is a regulatory agent that may have a 
role in the inflammatory response in white adipose tissue.
Unlike GIP, the data in regard to GLP-1 treatment, showed that the MCP-1 mRNA 
levels in human cell culture system did not change. However, a very small increase 
(although statistically significant) in IL- 6  mRNA levels was observed in the high 
dose of GLP-1, at both 4 and 24 h of treatment, whereas IL- 6  mRNA was not altered 
at the lower doses. The data has demonstrated that in general the regulation of 
incretins, GIP and GLP-1, in SGBS adipocytes is multi-factorial, and most likely the 
result of a complex interplay of different hormones and cytokines.
Little has been observed with regard to the regulation of adipokine production by 
ghrelin. However, a recent study has examined the possibility that ghrelin directly 
suppresses adiponectin mRNA expression in brown adipocytes, (Ott et al., 2002).
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The data here does not suggest such a role in SGBS (white) adipocytes.
Interestingly, however, ghrelin treatment for 24 h showed an inhibitory effect on 
MCP-1 mRNA levels by 50% in both intermediate and high doses, and these 
differences were statistically significant. Recent studies suggest that plasma 
concentrations of ghrelin are reduced in obese patients (Tschop et al., 2001). 
Moreover, obesity has been associated with elevated levels of pro-inflammatory 
cytokines (Das, 2001). The mechanisms responsible for enhanced pro-inflammatory 
cytokine production in obesity remain to be elucidated.
The present results were strengthened by an independent study in which ghrelin was 
shown to have a potent anti-inflammatory effect in human endothelial cells, likely 
mediated by inhibition of NF-kB activation (Li et al., 2004). This finding raises the 
possibility that reduction in endogenous ghrelin could potentially contribute to the 
pro-inflammatory state and the increased incidence of atherosclerosis in obese 
patients. Another study showed that peripherally administered ghrelin blocked IL-ip- 
induced anorexia (Asakawa et al., 2001) and produced a positive energy balance by 
promoting food intake and decreasing energy expenditure.
In summary, the present study has demonstrated that GIP may serve as a regulatory in 
the inflammatory response in human adipocytes. The results obtained in this study 
also indicates that ghrelin has an anti-inflammatory effect on pro-inflammatory 
cytokine expression (MCP-1) in SGBS cells. In addition treatment with different gut 
hormones like incretins, GIP and GLP-1, or ghrelin has a selective effect on the 
production of a number of adipokines, such as adiponectin, MCP-1 and IL-6 , in 
human adipocytes. However, it should be noted, that the effect of few tests revealed 
subtle differences (P-values P<0.05 or P<0.01) when multiple comparisons were 
made. There is a possibility that some of these differences have arisen by chance 
(Type 1 error). More work including the influence of incretins and ghrelin on 
adipokine expression by fat cells is needed in the future using larger sample sizes to 
justify that the effect did not just happen coincidentally. Nevertheless, this might 
constitute an important element in the pathogenesis of obesity.
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EFFECT OF OBESTATIN ON ADIPOKINE 
GENE EXPRESSION IN HUMAN ADIPOCYTES
Chapter 5
5.1 Introduction
In a previous Chapter it was established that the gene encoding the proposed receptor 
for obestatin (GPR39) is expressed in adipose and nonadipose tissues, including four 
major WAT depots (subcutaneous, gonadal, omental and mesenteric) of the mouse. It 
was also shown that the receptor is expressed in WAT (subcutaneous and omental) of 
human subjects and in adipocyte cell culture systems of mouse (3T3-L1) and humans 
(SGBS). The receptor mRNA and protein was determined by using RT- PCR and 
Western blotting methods respectively.
The studies reported in this Chapter focus on investigating the effects of obestatin (1- 
23) and the truncated form obestatin (11-23), on the gene expression of key 
adipokines in human adipocytes. In order to perform this study, adipocyte cell 
cultures were utilised.
Obestatin is a newly identified 23 amino acid gut peptide, which is associated with 
the ghrelin peptide (Zhang et al., 2005). Although both peptides originate from the 
same precursor (preproghrelin), they have opposing physiological roles. Obestatin 
exerts anorexigenic effects by decreasing food intake, gastric emptying, jejunal 
motility and weight gain by binding to the G-protein coupled receptor, GPR39. 
Zhang et al., (2005) proposed GPR39 as the target receptor of obestatin, but this has 
not been confirmed by other studies (Lauwers et al., 2006). In contrast, ghrelin 
(Kojima et al., 1999) has positive effects on energy balance, stimulating food intake, 
gastric acid secretion, gastrointestinal motility and increasing feelings of hunger in 
humans. Both peptide hormones require post-translational modification for full 
activity; for obestatin, post-translational amidation occurs at the C-terminus.
In the original obestatin study by Zhang et al, mass spectrometry analysis suggested 
that in addition to the obestatin peptide peak of 2516.3 kD, another peak was eluted. 
This had a molecular mass of 1.5 kD and represented the last 13 residues of amidated 
obestatin. Now known as truncated des (1-10) obestatin analogs, or obestatin (11- 
23), it exhibits lower affinity binding to GPR39 when compared to obestatin (Zhang 
et al., 2005).
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The direct effects of obestatin on peripheral tissues that may contribute to the 
regulation of body weight and energy homeostasis are controversial. Since white fat 
mass is a target organ in obesity, it was tempting for researchers to speculate on 
whether obestatin is one of the factors responsible for the regulation of storage and 
mobilisation of body fat mass that might interfere with the overweight condition. 
Several factors have been implicated in the regulation of adipocyte number. Insulin, 
IGF-1, PPAR-y ligands and corticosteroids have been found to increase adipocyte 
number, whereas TNF-a and leptin have been shown to decrease the number of these 
cells (Prins and O’Rahilly, 1997).
Tnag et al. have recently evaluated the effect of obestatin on cell proliferation in 
primary cultures of piglet adipose cells. The results showed that this peptide induced 
cell proliferation in a dose-dependent manner with MEK/ERK 1/2 phosphorylation 
(Tnag et al., 2008). However, in another study obestatin did not rouse the cell cycle or 
viability of the murine adipocytes cell line 3T3-L1, other than by inhibiting the 
proliferation and differentiation of 3T3-L1 preadipocytes. Furthermore, the effect of 
obestatin was contrary to that of ghrelin on this adipocyte cell line (Zhang et al., 
2007). These findings suggest that direct effects of obestatin on proliferation and or 
differentiation in adipocytes may play a role in regulating body fat mass.
In general, little is known about the regulation of adipokine production by gut 
peptides. Moreover, the effect of obestatin on the regulation of adipokines has not 
been explored to date. In this set of studies, recombinant obestatin (1-23) and the 
truncated form, obestatin (11-23), was used to investigate the possibility that these 
peptides influence the expression of key adipokine genes in adipocytes. The effect of 
obestatin on the gene expression of leptin, adiponectin, MCP-I and IL- 6  was therefore 
investigated in SGBS cells, as presented in the following section.
5.2 Methods
5.2.1 SGBS cell culture
SGBS cells were cultured as described in section 2.4.2. The preadipocytes were 
maintained in culture medium and differentiation of the cells was initiated 24 h after 
post-confluence by incubation for 4 days in induction medium. The cells were
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maintained in feeding medium, which was renewed 2-3 times a week. At day 11, the 
cells were pre-incubated with cortisol and T3 - free feeding medium for 24 h. The 
human recombinant obestatin peptides explored in this set of studies were dissolved in 
100% DMSO according to the protocol provided for this peptide, and the 
concentration of stock solutions for the peptide was 1 pM. Prior to treatment, 
incubation media were prepared by adding the peptide stock to the cortisol and T3 -free 
feeding medium. The final concentration of obestatin peptide in the media was 2 nM 
for the low dose, 20 nM for the intermediate dose and 100 nM for the high dose. The 
media used for the cells as a control had their pre-incubation medium renewed. Cells 
were collected after 4 or 24 h in 700 pi of TRI Reagent (Sigma).
In a separate set of studies, SGBS cells were incubated with human recombinant 
obestatin (1-23) from different sources (Peptides International, Peptide Institute or 
Alexis Biochemicals) as well as the truncated form, obestatin (11-23) (Peptide 
International). All peptides used in this set of studies were dissolved either in 100% 
DMSO, acetic acid or distilled water according to the protocol provided for each 
peptide. The final concentrations of each peptide in the media were 2 nM for the low 
dose and 100 nM for the high dose. The media used for the cells as a control had their 
pre-incubation medium renewed. Cells were then collected after 24 h in 700 pi of TRI 
Reagent.
5.2.2 Electrospray ionization mass spectrometry (ESI-MS)
The mass spectrometry study was kindly carried out by Mr Brian Green (VG 
BioTech/Fisons, Altrincham, England) using a VG BioQ mass spectrometer with 
electrospray (ES) ion source (section 2.13).
Initially, the obestatin amide sample was diluted 10-fold with water to give a stock 
solution. An aliquot of the stock solution was made up into aqueous acetonitrile 
solutions (50:50 v/v)/ 2% formic acid, with a final concentration of 25-50 pmol/ pL. 
Generally, a 10 pi aliquot of the analyte solution was injected, via a loop injector, into 
a stream of the same solvent mixture flowing at a rate of 5 pi /min. The mass 
spectrometer was then used to routinely scan over an appropriate m/z range 
determined experimentally. Generally several scans <15 were summed to obtain the
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final ESI-MS spectrum. Calibration of the m/z scale of the spectrometer was normally 
performed during each series of measurements using a solution of pure protein of 
known structure.
5.2.2 Statistics
Data are presented as mean values ± S.E.M. Differences between groups (treatments 
vs. control) were analysed by one-way ANOVA with Dunnett's post-hoc test. All data 
were checked for normality. There were no differences in variance amongst groups. 
Differences were considered to be statistically significant when P<0.05.
5.3 Results
5.3.1 The effect of Obestatin (Alexis) on adipokine gene expression in human 
SGBS adipocytes
In the first studies, the integrated effect of obestatin on the expression of the adipokine 
genes was examined in differentiated SGBS adipocytes, with relative mRNA levels 
quantified by real-time PCR. The adipocytes were used at day 14 post-induction. 
Three different concentrations of obestatin were employed, 2 nM for the low dose, 20 
nM for the intermediate dose and 100 nM for the high dose.
No effect was found on mRNA levels in the case of leptin at both 4 and 24 h of 
obestatin treatment (Fig 5.1). However, the 24 h obestatin treatment led to a dose- 
dependent decrease in adiponectin gene expression, with a 2-fold reduction of 
adiponectin mRNA levels in response to the intermediate and higher dose of 
obestatin, but there was no change seen after the 4 h obestatin treatment in SGBS cells 
(Fig 5.2).
In contrast, treatment with obestatin resulted in a marked increase in mRNA levels for 
both IL-6 and MCP-1 (Fig 5.3 and 5.4). The increase was approximately 10-fold, 15- 
fold and 20-fold for IL-6 in 4 h low, intermediate and high doses respectively, and 
10-fold in the 24 h obestatin treatments (Fig 5.3). The most substantial effect was on 
MCP-1 mRNA, the level of which was between 30 and 60-fold higher in both time 
courses (Fig 5.4).
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Figure 5.1 Effect of obestatin on leptin gene expression in human SGBS
adipocytes
Effect o f obestatin (Alexis) on leptin relative mRNA levels in SGBS cells. 
Differentiated human adipocytes at day 12 were deprived of cortisol and T3 for 24 
h and then incubated in medium containing obestatin either low dose (LD) 2 nM, 
intermediate dose (IMD) 20 nM or high dose (HD) 100 nM for 4 h and 24 h. 
Leptin mRNA level was measured by real-time PCR and normalised to human (3 
actin relative to the untreated control group. Treatment with obestatin did not alter 
gene expession for leptin at both 4 h and 24 h. Results are mean values ± S.E.M for 
groups o f 5-6; compared with controls.
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Figure 5.2 Effect of obestatin on adiponectin gene expression in human SGBS
adipocytes
2.5 i
Effect of obestatin (Alexis) on adiponectin relative mRNA levels in SGBS cells. 
Differentiated human adipocytes at day 12 were deprived of cortisol and T3 for 24 
h and then incubated in medium containing obestatin either low dose (LD) 2 nM, 
intermediate dose (IMD) 20 nM or high dose (HD) 100 nM for 4 h and 24 h. 
Adiponectin mRNA level was measured by real-time PCR and normalised to 
human (3 actin relative to the untreated control group. Obestatin treatment for 24 h 
exerted an inhibitory effect in adiponectin gene expression. Results are mean 
values ± S.E.M for groups of 5-6, *P < 0.05; compared with controls.
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Figure 5.3 Effect of obestatin on IL-6 gene expression in human SGBS
adipocytes
35
30
As
T
Effect of obestatin (Alexis) on IL- 6  relative mRNA levels in SGBS cells. 
Differentiated human adipocytes at day 12 were deprived of cortisol and T3 for 24 
h and then incubated in medium containing obestatin either low dose (LD) 2 nM, 
intermediate dose (IMD) 20 nM or high dose (HD) 100 nM for 4 h and 24 h. IL- 6  
mRNA level was measured by real-time PCR and normalised to human (3 actin 
relative to the untreated control group. Treatment with obestatin resulted in a 
marked increase on IL- 6  gene expression at both 4 and 24 h. Results are mean 
values ± S.E.M for groups of 5-6, **P<0.01, ***P<0.001; compared with controls.
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Figure 5.4 Effect of obestatin on MCP-1 gene expression in human SGBS
adipocytes
90 n
Effect of obestatin (Alexis) on MCP-1 relative mRNA levels in SGBS cells. 
Differentiated human adipocytes at day 12 were deprived of cortisol and T3 for 24 
h and then incubated in medium containing obestatin either low dose (LD) 2 nM, 
intermediate dose (IMD) 20 nM or high dose (HD) 100 nM for 4 h and 24 h. MCP- 
1 mRNA level was measured by real-time PCR and normalised to human p actin 
relative to the untreated control group. Treatment with obestatin resulted in a 
marked increase on MCP-1 gene expression at both 4 and 24 h. Results are mean 
values ± S.E.M for groups of 5-6, **P<0.01; compared with controls.
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5.3.2 The effect of obestatin (1-23) from different sources and des-obestatin i l l -  
23) on adipokine gene expression in human SGBS adipocytes
In a separate set of studies, SGBS cells were incubated for 24 h with human 
recombinant obestatin (1-23) from different sources: Peptides International (PI), 
Peptide institute (P), or Alexis Biochemicals (A), as well as the truncated form, des- 
obestatin (11-23) (D). The final concentrations of each peptide in the media were 2 
nM for the low dose, and 100 nM for the high dose. The expression of the adipokine 
genes was examined in differentiated human adipocytes, with relative mRNA levels 
quantified by real-time PCR. Although two different concentrations of the obestatin(s) 
were employed, low and high, there was in practice little difference in the results 
obtained.
Administration of recombinant human (1-23) obestatin (s) had no effect on leptin 
gene expression in SGBS cells (Fig 5.5). However, the obestatin (1-23) treatments 
showed a 2-fold decrease in adiponectin mRNA levels and this was only present at the 
higher dose of all the (1-23) obestatin(s) used: there was no response to the low doses 
(Fig 5.6).
Moreover, after incubating SGBS with (1-23) obestatin the results were inconsistent 
with those shown in the previous section. Even when using the original obestatin 
(Alexis), there was only a modest stimulatory effect on both MCP-1 and IL- 6  mRNA 
levels which was only observed at the higher doses, and caused only a 2  to 8 -fold 
increase (Fig 5.7 and 5.8 respectively). In contrast, the low dose (1-23) obestatin (s) 
treatment had no effect on MCP-1 or IL- 6  gene expression in SGBS cells compared 
with the control (Fig 5.7 and 5.8 respectively).
However, des-obestatin (11-23) showed a different response from those of the (1-23) 
obestatin. There was a marked increase in mRNA levels for leptin, adiponectin, IL- 6  
and MCP-1 (Figs 5.5, 5.6, 5.7 and 5.8). The increase was 2 to 3-fold in the case of 
leptin, adiponectin and MCP-1 and approximately 6 -fold for IL- 6  (Figs 5.5, 5.6, 5.7 
and 5.8 respectively).
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Figure 5.5 Effect of obestatin (1-23) from different sources and des-obestatin (11-23) 
on leptin gene expression in human SGBS adipocytes
Effect of obestatin (1-23) from different sources, Peptide Institute (P), Alexis 
Biochemicals (A), Peptides international (PI) and des-obestatin (D) on leptin 
relative mRNA levels in SGBS cells. Differentiated human adipocytes at day 12 
were deprived of cortisol and T3 for 24 h and then incubated in medium containing 
obestain either low dose (LD) 2 nM or high dose (HD) 100 nM for 24 h. Leptin 
mRNA level was measured by real-time PCR and normalised to human (3 actin 
relative to the untreated control group. Administration of recombinant human (1- 
23) obestatin (s) had no effect on leptin gene expression, however; des-obestatin 
showed a marked increase in mRNA levels for leptin at the high doses only. 
Results are mean values ± S.E.M for groups of 5-6, *P < 0.05; compared with 
controls.
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Figure 5.6 Effect of obestatin (1-23) from different sources and des-obestatin (11-23) 
on adiponectin gene expression in human SGBS adipocytes
Effect of obestatin (1-23) from different sources, Peptide Institute (P), Alexis 
Biochemicals (A), Peptides international (PI) and des-obestatin (D) on adiponectin 
relative mRNA levels in SGBS cells. Differentiated human adipocytes at day 12 
were deprived of cortisol and T3 for 24 h and then incubated in medium containing 
obestain either low dose (LD) 2 nM or high dose (HD) 100 nM for 24 h. 
Adiponectin mRNA level was measured by real-time PCR and normalised to 
human p actin relative to the untreated control group. The obestatin (1-23) 
treatments showed a clear decrease in adiponectin gene expression however; des- 
obestatin showed a marked increase in mRNA levels for adiponectin at the high 
dose only. Results are mean values ± S.E.M for groups of 5-6, *P < 0.05, 
**P<0.01; compared with controls.
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Figure 5.7 Effect of obestatin (1-23) from different sources and des-obestatin (11-23) 
on MCP-1 gene expression in human SGBS adipocytes
Effect of obestatin (1-23) from different sources, Peptide Institute (P), Alexis 
Biochemicals (A), Peptides international (PI) and des-obestatin (D) on MCP-1 
relative mRNA levels in SGBS cells. Differentiated human adipocytes at day 12 
were deprived of cortisol and T3 for 24 h and then incubated in medium containing 
obestain either low dose (LD) 2 nM or high dose (HD) 100 nM for 24 h. MCP-1 
mRNA level was measured by real-time PCR and normalised to human (3 actin 
relative to the untreated control group. Both obestatin (1-23) and des-obestatin 
groups showed a stimulatory effect on MCP-1 gene expression. Results are mean 
values ± S.E.M for groups of 5-6, *P < 0.05,**P<0.01, ***P<0.001; compared 
with controls.
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Figure 5.8 Effect of obestatin (1-23) from different sources and des-obestatin (11-23) 
on IL-6 gene expression in human SGBS adipocytes
Effect of obestatin (1-23) from different sources, Peptide Institute (P), Alexis 
Biochemicals (A), Peptides international (PI) and des-obestatin (D) on IL- 6  
relative mRNA levels in SGBS cells. Differentiated human adipocytes at day 12 
were deprived of cortisol and T3 for 24 h and then incubated in medium containing 
obestain either low dose (LD) 2 nM or high dose (HD) 100 nM for 24 h. IL- 6  
mRNA level was measured by real-time PCR and normalised to human (3 actin 
relative to the untreated control group. Both obestatin (1-23) and des-obestatin led 
to an increase in IL- 6  gene expression. Results are mean values ± S.E.M for groups 
of 5-6, *P < 0.05, **P<0.01; compared with controls.
148
Chapter 5
5.3.3 Obestatin detection by electrospray ionization mass spectrometry (ESI-MS)
Because of the inconsistency shown in the above set of results there was a question as 
why one specific obestatin (Alexis) behaving in an extreme way especially in regards 
with the production of the pro-inflammatory adipokines one possibility is that there 
were impurities which might lead to an inflammatory response. Therefore, to 
examine the purity of this specific sample the mass spectrometry study was performed 
and was kindly carried out by Mr Brian Green (VG BioTech/Fisons, Altrincham, 
England) using VG BioQ mass spectometer with electrospray (ES) ion source.
The obestatin amide sample was analysed by 10-fold diluting of the solution in 50% 
aqueous acetonitrile containing 0.2% formic acid. The result showed doubly and triply 
charged ions as major components that agreed with the elements composition within 
the experimental obestatin that calculated monoisotopic mass (Mr)= 2545.31. 
Moreover, the 2+ ion gave m/z 1273.68, which implies Mr = 2545.34 and there were 
also 1, 2 and 3 sodium adducts associated with this ion (Fig 5.9). While the 3+ ion 
gave m/z 849.48 which implies Mr = 2545.42 besides there was a DMSO adduct 
associated with this ion (Fig 5.10).
Furthermore, to ensure the absence of material-mediated pyrogenicity in the specific 
obestatin (Alexis), an endotoxin gel clotting technique was kindly performed by Mrs 
Janet Shaw (Dept of Microbiology, RLUF1, Liverpool, England). The results showed 
that no endotoxin was detected at levels between 6  EU/ml and 60 EU/ml. This 
concludes that the results obtained for obestatin (Alexis) were not due to chemical 
extractables (bacterial endotoxins).
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Figure 5.9 Obestatin detection by electrospray ionization mass spectrometry
(ESI-MS)
Graph showing doubly charged ions and the major components that agreed with the 
elements composition within the experimental obestatin (Alexis), calculated 
monoisotopic mass (Mr)= 2545.31, which was analysed by mass spectrometry. The 2+ 
ion gave m/z 1273.68, which implies Mr = 2545.34, and there were also 1, 2 and 3 
sodium adducts associated with this ion.
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Figure 5.10 Obestatin detection by electrospray ionization mass spectrometry
(ESI-MS)
Graph showing triply charged ions when analyzing the obestatin (Alexis) by mass 
spectrometry. The major components agreed with the elements composition within the 
experimental obestatin and the 3+ ion gave m/z 849.48 which implies Mr = 2545.42 
besides there was a DMSO adduct associated with this ion.
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5.4 Discussion
The major aim of the studies in this section was to examine whether obestatin 
influences the expression of key adipokine genes in human adipocytes. The results 
obtained indicate that obestatin has no effect on the regulation of leptin synthesis. 
However, obestatin appears to have a marked inhibitory effect on adiponectin mRNA 
levels after 24 h at the higher concentrations of obestatin administered.
This is the first study to demonstrate that obestatin triggers a robust sustained 
inhibition of adiponectin expression in differentiated adipocytes. Adiponectin 
production is suppressed in insulin resistance and obesity (Hu et al., 1996; Weyer et 
al., 2 0 0 1 ), and its expression is regulated by hormones and drugs influencing insulin 
sensitivity (Maeda et al., 2001). This suggests that obestatin could impair the insulin 
sensitivity by reducing adiponectin levels. A very recent in vivo study showed that 
fasting plasma concentration of obestatin is reduced in insulin resistance, and is 
positively associated with whole-body insulin sensitivity in non-diabetic humans. 
Furthermore, plasma obestatin is reduced by insulin in insulin-sensitive, but not in 
insulin-resistant persons (Anderwald-Stadler et al., 2007). However another study 
reported that obestatin peptide had no effect on insulin sensitivity as revealed by 
hypoglycaemic response when mice were co-administered with insulin (Green et al., 
2007).
Initially in this study, obestatin had a strong stimulatory effect on the expression of 
two inflammation-related adipokine genes (MCP-1 and IL-6 ) in human adipocytes.
The increase was approximately 20-fold and 15-fold for IL- 6  in both 4 h and 24 h 
respectively. The most substantial effect was on MCP-1 mRNA, the level of which 
was almost 50 to 60-fold higher in both time courses.
However, the initial promise of a new regulator on pro-inflammatory adipokines was 
limited by further convergent studies negating these findings. In a subsequent set of 
studies, SGBS cells were incubated for 24 h with human recombinant obestatin (1-23) 
from different sources: Peptides International (PI), Peptide institute (P), or Alexis 
Biochemicals (A). The results showed a small stimulatory effect on both IL- 6  and 
MCP-1 mRNA levels which was only observed at the higher doses. In contrast, the
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low dose (1-23) obestatin (s) treatment had no effect on IL- 6  or MCP-1 gene 
expression in SGBS cells compared with the control. Moreover, the results were 
inconsistent when repeated with the same obestatin (Alexis) as used in the previous 
section.
There is no exact explanation for the above results, especially after the certainty of the 
obestatin (Alexis) purity and pyrogenicity using mass spectrometry and endotoxin 
assays respectively. However, this study is one among many others that showed lack 
of reproducibility of the newly discovered gut peptide (Gourcerol. et al., 2006; Holst 
et al., 2007; Bassil et al., 2007).
Nevertheless, it is emphasised that the present results with 24 h obestatin treatments 
from different sources in human adipocytes showed a stimulatory effect in both pro- 
inflammatory cytokine, MCP-1 and IL-6 , mRNA levels in a similar pattern. This 
indicates that obestatin and des-obestatin peptides may act as regulatory agents that 
have a role in the inflammatory response in white adipose tissue. However, more 
work, including investigations on the influence of obestatin and des-obestatin on the 
inflammation-related adipokine release by fat cells, is needed in the future.
In this study whether the truncated form, obestatin (11-23), influences the gene 
expression of leptin, adiponectin, MCP-I and IL-6 , in SGBS cells was also 
investigated. The results again were different from those of the (1-23) obestatin; 
however des-obestatin (11-23) showed a marked increase in mRNA levels for leptin, 
adiponectin, IL- 6  and MCP-1. The increase was 2 to 3-fold in the case of leptin, 
adiponectin and MCP-1 and approximately 6 -fold for IL-6 .
Leptin is one of the best characterised adipokines and its expression and secretion are 
regulated by numerous factors, notably the activation of SNS, glucocorticoids, PPARy 
agonists and insulin (Fain et al., 2000; Havel, 2000; Rayner & Trayhum, 2001). The 
data presented in this study have suggested that production of leptin is induced in 
response to des-obestatin (11-23) but not to obestatin (1-23) administration, although 
this effect is small.
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Leptin has a pivotal role in the modulation of food intake and energy expenditure. 
Previous studies have shown that exogenous leptin administration results in the 
reduction of body fat (Chen et al., 1996) and the stimulation of lipolysis in cultured 
adipocytes of rodents (Wang et al., 1999). The present study may indicate a certain 
relationship between leptin and obestatin (1-23) or obestatin (11-23). However, a very 
recent in vivo study reported that plasma obestatin concentrations are negatively 
correlated with body mass index, insulin resistance index, and plasma leptin 
concentrations in obese humans (Nakahara et al., 2007). Of course, des obestatin is a 
small fragment of obestatin, and may be part of a system with multiple effector 
elements, which not only have opposite actions, but also regulate the action of each 
other.
In summary, the present study has demonstrated that obestatin (1-23) and obestatin 
(11-23) may have a regulatory effect on the production of a number of adipokines, 
such as adiponectin, IL-6 , MCP-1 and in the case of obestatin (11-23), leptin. 
However, it should be noted, that the effect of few tests revealed subtle differences (P- 
values P<0.05 or PO.Ol) when multiple comparisons were made. There is a 
possibility that some of these differences have arisen by chance (Type 1 error). More 
work including the influence of obestatin on adipokine expression by fat cells is 
needed in the future using larger sample sizes to justify that the effect did not just 
happen coincidentally.
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DO GUT HORMONES ENHANCE INSULIN- 
STIMULATED GLUCOSE METABOLISM IN HUMAN
ADIPOCYTES?
Chapter 6
6.1 Introduction
Disordered glucose metabolism is commonly observed in obesity. Kinetic studies of 
glucose utilization in obese patients have demonstrated a reduction in the 
disappearance rate and uptake of glucose from the blood.
There is now considerable evidence in support of the concept that the disordered 
glucose metabolism of obesity may be related to the presence of insulin resistance. 
Studies on the effects of obesity on adipose tissue glucose metabolism and perfusion 
in vivo have however given controversial results. When radioactive glucose was given 
with glucose either intravenously (Bjomtorp et al., 1971) or orally (Marin et al., 1987) 
its incorporation into adipose tissue was 1-4% of glucose given in lean individuals, 
and the incorporation was increased in the obese subjects (up to 20%)( Bjomtorp et 
al., 1971; Marin et al., 1987).
The amount of free glucose in the body is small, typically around 12 g in the 
circulation and extravascular space. When a meal containing 100 g carbohydrate is 
ingested, the influx of glucose could potentially increase the plasma glucose 
concentration eightfold. This does not happen, because coordinated mechanisms come 
into play to increase the disposal of glucose from plasma and to suppress the entry 
into the circulation of endogenous glucose (Fery et al., 1990). By these means, the 
exposure of tissues to hyperglycaemia are minimised. The main tissue involved in 
‘buffering’ the influx of glucose is the liver, absorbing the glucose and switching off 
glucose production. Skeletal muscle and to a lesser extent adipose tissue play a 
subsidiary role in taking up glucose under the influence of insulin.
After food ingestion, the digestion and absorption of nutrients is associated with 
increased secretion of multiple gut peptides that act on distant target sites to promote 
the efficient uptake and storage of energy. Plasma concentrations of most gut 
hormones rise briskly within minutes of nutrient intake and fall rapidly thereafter, 
mainly because they are cleared by the kidney and are enzymatically inactivated.
Incretin hormones, GIP and GLP-1, which cause an increase in the amount of insulin 
released from the (3 cells of the islets augment the magnitude of meal-stimulated
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insulin secretion from islet (3 cells in a glucose-dependent manner (Drucker, 2006). 
Incretin action facilitates the uptake of glucose by muscle tissue and the liver while 
simultaneously suppressing glucagon secretion by the a cells of the islets, leading to 
reduced endogenous production of glucose from hepatic sources.
Ghrelin also seems to have both physiological and pharmacological actions on the 
endocrine pancreas. Blocking the function of endogenous ghrelin with the use of an 
antagonist for its receptor markedly lowered fasting glucose concentrations, 
attenuated glycaemic excursion, and enhanced insulin responses during a glucose 
tolerance test, suggesting an inhibitory role for ghrelin in the control of insulin 
secretion (Dezaki et al., 2004).
The recent discovery of obestatin in (2005) means that many of its biological actions 
remain to be identified, including whether this peptide influences in vivo glucose 
homeostasis or insulin secretion. Since ghrelin raises blood glucose and lowers insulin 
secretion, a number of studies are investigating whether obestatin administration 
might exert opposite effects on glucose homeostasis and insulin secretion.
In Chapter 3 of this thesis, the presence of genes encoding the receptors for ghrelin 
(GHS-R), Obestatin (GPR39), glucagon-like peptide-1 (GLP-1R) and glucose- 
dependent insulinotropic polypeptide (GIPR) were examined in major fat depots of 
both mouse and human and in differentiated adipocytes. The existence of these 
receptors in fat cells is highly suggestive of physiological effects mediated by these 
gut peptides in adipose tissue.
Adipocytes are exquisitely sensitive to insulin; among the classical responses to 
insulin are an increase in glucose uptake, lipogenesis, and cellular proliferation and 
differentiation (Klein et al., 2002). Moreover, the transport and metabolism of glucose 
is central to the function of WAT and the tissue is known to express several members 
of the facilitative glucose transporter (GLUT) gene family (Wood et al., 2003; Wood 
and Trayhum 2003). One of these transporters, GLUT4, is responsible for the acute 
insulin-induced stimulation of glucose transport in 3T3-L1 adipocytes (Kaestner et al. 
1991, Czech et al. 1992). In addition to its acute effects, prolonged exposure to insulin 
has detrimental effects on glucose transport. Exposure of 3T3-L1 adipocytes to insulin
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or cAMP for 24 h causes a down-regulation of GLUT4, both at the mRNA and 
protein levels, and a decrease in insulin-mediated glucose transport (Kaestner et al. 
1991, Flores-Riveros et al. 1993).
In this series of experiments, the effects of a 24 h treatment with GLP-1, GIP, ghrelin 
and obestatin in the absence or presence of insulin, on glucose uptake and on the 
levels of expression of the facilitative glucose transporter, GLUT4, have been 
examined in SGBS adipocytes. The aim was to ascertain if prolonged exposure to 
these gut peptides has any modulatory effects by itself or on insulin action in cultured 
fat cells.
6.2 Methods
6.2.1 SGBS cell culture
SGBS cells were cultured as described in section 2.4.2. The preadipocytes were 
maintained in culture medium and differentiation of the cells was initiated 24 h after 
post-confluence by incubating the cells for 4 days in induction medium. The cells 
were maintained in feeding medium, which was renewed 2-3 times a week. At day 
11, the cells were pre-incubated with cortisol and T3 - free feeding medium for 24 h. 
All the human recombinant gut peptides explored in this set of studies were dissolved 
either in 100% DMSO or autoclaved water according to the protocol provided for 
each peptide, and the concentration of stock solutions for each peptide was 1 pM. 
Prior to treatment, incubation media were prepared by adding each peptide stock to 
the cortisol and T3-ffee feeding medium. The final concentration of each gut peptide 
in the media was 2 nM for the low dose and 100 nM for the high dose. The media 
used for the cells as a control had their pre-incubation medium renewed. Cells were 
collected after 24 h in 700 pi of TRI Reagent (Sigma). After the total RNA was 
isolated, it was treated with a DNA-free kit (Section 2.5.2). The concentration of 
RNA was measured by a spectrophotometer (Section 2.5.3), and 1 pg of RNA was 
reverse transcribed to cDNA using the Reverse-iT First Strand Synthesis Kit (Section 
2.6.). In this set of studies, GLUT-4 primers were kindly provided by Dr S Wood 
(University of Liverpool). Relative quantification of gene expression was measured 
by real-time PCR using SYBR Green (Core kit, Eurogentec) incorporating a melt 
curve analysis for each run. All samples were normalized to the values of human 0-
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2
actin, and the results were expressed as relative fold changes to controls using the 
AACt method (section 2.10.3.4). The QPCR products detected primer sequences are 
shown in table 2.3.
6.2.2 2-Deoxy-D-glucose uptake
A modification of a method by Bernier et al. (1988) was used for the measurements 
of 2-deoxy-D-glucose (2-DG) uptake as described in section 2.12. Briefly SGBS 
fibroblasts were grown and differentiated in 1 2 -well culture plates as described in 
section 2.4. After 24 h incubation with pretreatment medium in the presence or 
absence of 100 nM of human recombinant GLP-1, GIP, ghrelin or obestatin 
treatments, cells were washed twice and incubated with 950 pi of KRH buffer 
containing 1% BSA for 3 h at 37 °C, 5% CO2 . This was followed by the addition of 
different concentrations of insulin (0.1, 1, 10 and 100 nM).
In a separate set of experiments GLP-1 (0.1, 1 and 10 nM), GIP (0.1, 1 and lOOnM) 
or ghrelin (1,10 and 100 nM) were added without prior use of insulin. The cells were 
then incubated for 1 h at 37 °C (no insulin added for the basal uptake). 2-DG was 
added to a concentration of 60 pM containing 0.2 pCi/well of 2-deoxy-D-[l-3 H] 
glucose (Sp. Act 315 GBq/mmol, GE Healthcare) for 5 min at 37°C, 5% C 02. Uptake 
was stopped by the addition of 2 ml of ice-cold PBS containing 200 pM phloretin 
(Sigma). The cells were washed three times with PBS stop solution, and solubilised 
in 0.1 N NaOH for 10 min at 22 °C. The cell lysates were subjected to liquid 
scintillation counting using EcoScint A fluid (National Diagnostics). The uptake of 
2-DG was measured in the absence and presence of 40pM cytochalasin B to correct 
for non-specific uptake.
6.2.3 Statistics
The statistical significance of the difference between the means of two groups with 
equal variance was assessed by Student’s t-test. However, the alternate (Welsch) t-test 
was used for the groups with unequal variance. The statistical differences between 
more than two groups (treatments vs control) were evaluated through one-way 
ANOVA (Analysis of Variance) with Dunnett's post-hoc test. All data were checked
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for normality, and that there was no difference in variance amongst groups. 
Differences were considered to be significant when P<0.05. All results are presented 
as mean ± standard error of the mean (SE).
6.3 Results
6.3.1 Effects of GLP-1 on glucose uptake in adipocytes
The interaction between GLP-1 and 2-deoxy-D-glucose uptake was examined in the 
experiments depicted in Fig 6.1A. SGBS adipocytes were incubated with (100 nM) 
GLP-1. Cells were then washed twice and incubated with KRH buffer. This was 
followed by the addition of different concentrations of insulin for 1 h at 37 °C (no 
insulin added for the basal uptake). There was significant dose-response increase in 
acute insulin-stimulated glucose uptake when compared with control cells (Fig. 6.1 A). 
In the absence of insulin the glucose uptake was increased threefold with 100 nM 
GLP-1 treatment for 24 h when compared with control cells (P<0 001). (Fig. 6.1A)
In a separate experiment, the SGBS cells were incubated with pretreatment medium 
for 24 h in the absence of GLP-1. Cells were then washed twice and incubated with 
the buffer, then different concentrations of GLP-1 (0.1, 1 and 10 nM) was added to 
the cells for 1 h without prior use of insulin. Compared with untreated cells, again 
there was significant dose-response increase 2-fold, 2-fold and 3-fold respectively, in 
glucose uptake (Fig 6 .IB).
6.3.2 Effects of GIP on glucose uptake in adipocytes
In the subsequent studies, the effect of GIP on glucose uptake was examined in SGBS 
adipocytes. Administration of 100 nM GIP for 24 h in the presence of different 
concentrations of insulin had no effect on the glucose uptake compared with control 
cells (Fig. 6.2A).
The effect of GIP was further explored by monitoring its ability to enhance glucose 
uptake under basal conditions and in the absence of insulin. Different concentrations 
of recombinant GIP (0.1, 1 and 100 nM) were added to the SGBS cells for lh without
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the use of insulin. Compared with untreated cells, the glucose uptake was only 
induced by threefold with the 100 nM GIP treated adipocytes (Fig 6.2B); however, 
glucose uptake showed no changes in both 1 nM and 10 nM GIP treatment (Fig 6.2B).
6.3.3 Effects of ghrelin on glucose uptake in adipocytes
To examine the potential impact of ghrelin on glucose transport in differentiated 
SGBS adipocytes, 2-deoxy-D- glucose uptake assay was performed.
Applying 100 nM of ghrelin treatment for 24 h in the differentiated SGBS adipocytes 
significantly increased glucose uptake by fivefold in the absence of insulin. However 
after adding (0.1, 1, 10 and 100 nM) of insulin for 1 h to the treated cells; the glucose 
uptake was significantly down regulated compared with controlled untreated cells 
(Fig. 6.3A)
In a different experiment, pretreatment medium was applied to the SGBS adipocytes 
for 24 h in the absence of both ghrelin and insulin. Cells were then washed twice and 
incubated with the buffer, then different quantities of ghrelin (1, 10 and lOOnM) were 
added to the cells for 1 h. Compared with untreated cells, the ghrelin augmented 2- 
deoxy-D-glucose uptake in SGBS adipocytes and was significant at both intermediate 
and high doses, the increases being three and four fold respectively (P<0.001). (Fig. 
6.3B)
6.3.4 Effects of Obestatin on glucose uptake in adipocytes
The effects of a 24 h treatment with obestatin in the absence or presence of insulin on 
glucose uptake was measured in differentiated SGBS adipocytes.
Administration of recombinant 100 nM obestatin for 24 h in the presence of different 
concentrations of insulin (0.1, 1, 10 and 100 nM) showed a small significant increase 
(1.5-fold), in glucose uptake at 0.1 nM of insulin only (Fig. 6.4); however, glucose 
uptake showed no changes at the higher doses of insulin.
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6.3.5 Effects of GLP-lor Ghrelin on GLUT4 mRNA expression
Based on the results above, both GLP-1 and ghrelin have a robust effect on glucose 
uptake. By using real-time PCR their impact on GLUT4 gene expression in SGBS 
adipocytes was next assessed as described in section 6 .2 .1 .
In this set of experiments, GLUT4 gene expression was examined after 24 h 
incubation with the low (2 nM) and high (100 nM) doses of recombinant GLP-1 or 
ghrelin peptides. No treatment was added for the control group except their pre­
incubation medium was renewed. A minor decrease of GLUT4 mRNA levels was 
only observed in the low dose of GLP-1 treatment (Fig 6.5), whereas GLUT4 mRNA 
was not altered at the high GLP-1 dose or with the ghrelin treatment.
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Figure 6.1 Effects of GLP-1 on glucose uptake in SGBS adipocytes
A
□  Control
Insulin (nM) 0 0 0.1 0.1 1 1 10 10 100 100
GLP-1 (lOOnM) - + - + - + + - +
Effect of GLP-1 on 2-deoxy-D-glucose uptake in SGBS adipocytes at day 14 (postinduction 
of differentiation). Applying 100 nM of GLP-1 treatment for 24 h in the differentiated SGBS 
adipocytes significantly increased glucose uptake in the absence and presence of insulin 
(0.1, 1, 10 and 100 nM) for 1 h. The results were assessed by Student’s /‘-test/ Welsch /-test 
and expressed as mean values ± SE, (n = 6 ). * P < 0.05; **P < 0.01, *** P < 0.001, 
compared to adipocytes without treatment with GLP-1.
Control GLP-1 0.1 nM GLP-1 1 nM GLP-1 10 nM
SGBS cells were incubated with pretreatment medium for 24 h in the absence of 
GLP-1. When different concentrations of GLP-1 (0.1, 1 and 10 nM) were added to 
the cells for 1 h without prior use of insulin a significant dose-response increase 
was shown on 2-deoxy-D-glucose uptake. The results were assessed by ANOVA 
and expressed as mean values ± SE, (n = 6 ). **P < 0.01; compared to adipocytes 
without treatment with GLP-1.
163
Chapter 6
Figure 6.2 Effects of GIP on glucose uptake in SGBS adipocytes
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10 10
+
Effect o f GIP on 2-deoxy-D-glucose uptake in SGBS adipocytes at day 14 (postinduction 
of differentiation). Applying 100 nM of GIP treatment for 24 h in the differentiated SGBS 
adipocytes significantly increased glucose uptake in the absence and presence of insulin 
(0.1, 1, 10 and 100 nM) for 1 h. The results were assessed by Student’s r-test/ Welsch r-test 
and expressed as mean values ± SE, (n = 6 ), compared to adipocytes without treatment 
with GIP.
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SGBS cells were incubated with pretreatment medium for 24 h in the absence of GIP. 
When different concentrations of GIP (0.1, 1 and 100 nM) were added to the cells for 
1 h without prior use of insulin. The 2-deoxy-D-glucose uptake was only induced with 
the 100 nM GIP treated adipocytes. The results were assessed by ANOVA and 
expressed as mean values ± SE, (n = 6 ). *P < 0.05; compared to adipocytes without 
treatment with GIP.
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Figure 6.3 Effects of ghrelin on glucose uptake in SGBS adipocytes
400
Insulin (nM) 
Ghrelin(lOOnM)
□  Control 
S  Ghrelin
r
8S>
1
+
100 100
+
Effect of ghrelin on 2-deoxy-D-glucose uptake in SGBS adipocytes at day 14 
(postinduction of differentiation). Applying 100 nM of ghrelin treatment for 24 h in the 
differentiated SGBS adipocytes significantly increased glucose uptake in the absence and 
presence of insulin (0.1, 1, 10 and 100 nM) for 1 h. The results were assessed by Student’s 
Mest/ Welsch r-test and expressed as mean values ± SE, (n = 6 ). **P < 0.01, *** P <
0 .0 0 1 , compared to adipocytes without treatment with ghrelin.
SGBS cells were incubated with pretreatment medium for 24 h in the absence of 
ghrelin. When different concentrations of ghrelin (1,10 and 100 nM) were added to 
the cells for 1 h without prior use of insulin a significant dose-response increase was 
shown on 2-deoxy-D-glucose uptake. The results were assessed by ANOVA and 
expressed as mean values ± SE, (n = 6 ). **P < 0.01; compared to adipocytes without 
treatment with ghrelin.
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Figure 6.4 Effects of obestatin on glucose uptake in SGBS adipocytes
35 0
=■ 30 001
1  2 5 0
Insulin (nM ) 0 0 0.1 0.1
Obestatin(lO O nM ) -  +  +
□  Control 
B Obestatin
1 1  10 10
+ +
Effect o f obestatin on 2-deoxy-D-glucose uptake in SGBS adipocytes at day 14 
(postinduction of differentiation). Applying 100 nM of obestatin treatment for 24 h in 
the differentiated SGBS adipocytes significantly increased glucose uptake in the 
absence and presence of insulin (0.1, 1, 10 and 100 nM) for 1 h. The results were 
assessed by Student’s /-test/ Welsch /-test and expressed as mean values ± SE, (n = 6 ), 
compared to adipocytes without treatment with obestatin.
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Figure 6.5 Effects of GLP-lor Ghrelin on GLUT4 mRNA expression
Effect of GLP-1 and ghrelin on glucose transporter 4 (GLUT4) gene expression in 
human SGBS adipocytes. A minor decrease of GLUT4 mRNA levels was only 
observed in the low dose of GLP-1 treatment, whereas GLUT4 mRNA was not 
altered at the high GLP-1 dose or with the ghrelin treatment. Cells were harvested at 
day 14 (post-induction of differentiation) and incubated for 24 h in media containing 
GLP-1 or ghrelin. Total RNA was isolated and GLUT4 mRNA levels quantified by 
real-time PCR. The values were normalised to p-actin and expressed relative to 
controls. The results were assessed by ANOVA and expressed as mean values ± 
S.E.M for groups of 5-6, *P < 0.05; compared with controls.
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6.4 Discussion
Insulin, the most potent mammalian anabolic hormone (Saltiel and Kahn 2001), 
appears to have evolved from the need to maximise energy efficiency, obviating the 
requirement to forage continuously for food. Organisms expressing this important 
peptide hormone possessed a distinct survival advantage and flourished. During 
evolution, insulin biosynthesis translocated to the pancreas, possibly to protect p cells 
from enteric organisms, which then necessitated a messenger from the intestine to 
complete an entero-insular axis.
The eventual development of incretins (Tseng et al., 1996; Wang et al., 1995) and 
other recently discovered gut peptides fulfilled this requirement. The additional 
survival benefit offered by a specific gut hormone may have been the ability of those 
regulatory peptides to not only stimulate intestinal glucose absorption and maximally 
release insulin (Tseng et al., 1999) but to also possess insulin mimetic properties.
In this chapter, the effects of a 24 h treatment with GLP-1, GIP, ghrelin and obestatin 
in the absence or presence of insulin, on glucose uptake and on the levels of 
expression of the facilitative glucose transporter, GLUT4, in fully differentiated 
SGBS adipocytes were investigated.
6.4.1 Effects of incretins on glucose uptake in SGBS adipocytes
At 24 h GLP-1 treated SGBS adipocytes, showed a clear dose-dependent increase in 
glucose uptake with or without acute insulin-stimulation when compared with control 
cells.
One would suspect that GLP-1 might enhance several metabolic responses of insulin 
in target tissues. This study with differentiated SGBS adipocytes has contributed 
significantly toward this end. A previous study revealed that GLP-1 has acute effects 
on glucose metabolism in 3T3-L1 adipocytes (Egan et al. 1994), in which the actions 
of insulin to stimulate glucose uptake and its utilization for lipid synthesis were 
enhanced by the presence of GLP-1. They also showed that GLP-1 preferentially 
increases lipid synthesis without increasing glycogen synthesis. Furthermore, In vivo
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studies in humans have also shown that GLP-1 has effects on glucose disposal 
(D’Alessio et a l, 1994; Meier et al, 2006).
The results of this set of experiments, therefore, demonstrated that in addition to 
stimulating insulin release from pancreatic p cells, GLP-1 possesses insulin-mimetic 
properties in adipocytes. Like insulin, GLP-1 induces the activation that leads to 
enhanced adipocyte glucose uptake.
Although the insulin-releasing action of GIP makes a major contribution to its 
metabolic role, direct effects of GIP at extra-pancreatic sites, including stomach, liver 
and adipose tissue, have been suggested to contribute to the overall action of the 
hormone on post-prandial nutrient homeostasis (Fehmann et al. 1995).
Earlier studies had shown that GIP promotes the incorporation of glucose into 
extractable lipids (Hauner et a l, 1988). In addition, GIP has been found to regulate 
the function of lipoprotein lipase, which hydrolyses chylomicrons and very-low- 
density lipoproteins, thereby liberating fatty acids for uptake and storage within the 
adipocyte (Murphy et a l, 1995). These studies indicate that GIP may represent a 
major hormonal signal linking meal content and size to postprandial lipoprotein lipase 
activity (Eckel et al, 1979) and modulating circulating lipoprotein homeostasis.
The addition of 100 nM of GIP in to SGBS adipocytes for 24 h did not improve 
glucose uptake with or without the presence of diverse doses of insulin. Nevertheless, 
acute high dose administration of GIP without prior use of insulin caused the glucose 
uptake to rise by 2-fold. Because this experiment was performed in the absence of 
insulin, it was considered possible that the observed effects of GIP were a 
consequence of this absence. However, studies on the effect of insulin on GIP- 
stimulated glycerol release revealed that when cells were incubated in the presence of 
10' 10 M insulin, a concentration equivalent to that found circulating early 
postprandially, insulin resulted in a concentration-dependent inhibition of the GIP 
effect on lipolysis. (Flakoll et a l, 1996). This suggests that factors modulating 
glucose metabolism in vivo are not present in vitro and that in vivo factors are 
necessary for the full mechanism.
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6.4.2 Effects of Ghrelin on glucose uptake in SGBS adipocytes
Ott et al., (2002) reported that ghrelin does not stimulate glucose uptake without 
insulin in brown adipose tissue. The data in the present study, however, showed that, 
in SGBS adipocytes, insulin-independent (basal) glucose uptake is significantly 
increased in response to ghrelin and that administration of ghrelin without the 
presence of insulin augmented glucose uptake in a dose-dependent manner. 
Nevertheless, after applying different doses of insulin to the treated cells the glucose 
uptake was significantly down regulated compared with control untreated cells. This 
might indicate that ghrelin has a ‘insulin like’ rather than ‘insulin-sensitising’ effect. 
Besides, ghrelin did block the development of insulin sensitivity induced by acute 
exposure to varying concentrations of insulin.
Evidence is rapidly accumulating that indicates a pivotal role for ghrelin, not only in 
the regulation of growth hormone secretion but also in the control of energy 
homeostasis and food intake (Nakazato et al., 2001). However, peripheral actions of 
this stomach hormone particularly on tissues that contribute to the control of energy 
homeostasis are poorly understood, although a previous Chapter of this thesis showed 
that the ghrelin receptor is expressed in adipocytes. And other studies have described 
the stimulatory effect of ghrelin on pancreatic insulin secretion (Date et al., 2002) and 
insulin signaling in hepatoma cells (Murata et al., 2002).
A possible physiological action for ghrelin may be associated with the previous study 
that specific circulating fatty acids are essential for optimal glucose stimulation of 
insulin secretion following fasting (Stein et al., 1996). Ghrelin could be capable of 
stimulating lipolysis under conditions in which insulin levels are of insufficient 
magnitude to inhibit its action, and this may ensure that levels of circulating FFAs are 
optimal for glucose and ghrelin stimulated insulin secretion. Such a proposal is open 
to experimental verification. Horeover, additional in vitro and in vivo studies are 
required to investigate the physiological relevance of the effects of ghrelin on glucose 
uptake and or insulin signaling pathway in fat cells.
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6.4.3 Effects of Obestatin on glucose uptake in SGBS adipocytes
Obestatin stimulation alone did not have any effect on basal glucose uptake, 
Furthermore, pre-treated SGBS cells with 100 nM obestatin in the presence of 
different concentration of insulin did not alter the insulin-induced glucose uptake 
effect compared with the untreated adipocytes.
The data of this experiment do not support a role for obestatin on an adipocyte insulin 
activated endpoint such as glucose uptake. This finding is in agreement with a 
previous report (Green et a l, 2007) which observed that obestatin peptide has direct 
and indirect effects on food intake, but no direct actions on glucose homeostasis or 
insulin secretion in mice.
6.4.4 Effects of insulin and GLP-lor Ghrelin on GLUT4 mRNA expression
Having established the stimulatory effect of both GLP-1 and ghrelin on glucose 
uptake, whether this was mediated through increased expression of glucose 
transporter GLUT4 was examined.
This study demonstrated that a minor decrease of GLUT4 mRNA levels was only 
observed in the low dose GLP-1 treatment, whereas GLUT4 mRNA was not altered at 
the high GLP-1 dose or with the ghrelin treatment.
The considerable stimulatory effect of GLP-1 on glucose uptake in SGBS adipocytes 
is supported by a similar observation in murine 3T3-L1 cells (Egan et al. 1994). The 
presence of GLP-1 for 24 h was reported to nearly double the content of both GLUT4 
and GLUT1 protein levels in 3T3-L1 adipocytes compared with control cells; 
however, mRNA levels for both transporters was not altered.
It has been suggested that the prolonged exposure of cultured adipocytes to insulin 
results in decreased levels of GLUT4 mRNA (Flores-Riveros et a l, 1993) and down- 
regulation of GLUT4 glucose transporters at the plasma membrane (Kozka et al. 
1991). However, primary cultures of rat adipocytes also have reduced levels of
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GLUT4 even when no insulin is added to the medium (Hadjuch et al., 1992; Gerrits et 
al., 1993), indicating that insulin is not the only factor modulating facilitative glucose 
transporters.
This is the first demonstration of the stomach-derived hormone ghrelin on modulation 
of transporter GLUT4 in an insulin-sensitive tissue, SGBS adipocytes.
In summary, the studies presented in this chapter indicate that specific gut hormones, 
GIP, GLP-1, obestatin and ghrelin in addition to their well known effects on distant 
target sites to promote the efficient uptake and storage of energy, may have further 
effects on major targets of insulin action such as white adipose tissue. However, it 
should be noted, that the effect of several tests revealed subtle differences (P-values 
P<0.05 or P<0.01) when multiple comparisons were made. There is a possibility that 
some of these differences have arisen by chance (Type 1 error). More work including 
the influence of these gut peptides on glucose uptake by fat cells is needed in the 
future using larger sample sizes to justify that the effect did not just happen 
coincidentally.
Nevertheless, this study may assign a novel role for adipose tissue as an important 
relay station in mediating those gut hormone effects on adipocyte metabolism and on 
energy homeostasis.
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GENERAL DISCUSSION
Discussion
7.1 Introduction
The main work presented in this thesis was on the expression and action of a range 
of gut hormone receptors in human white adipose tissue. The results presented in 
Chapters 3 to 6 have shown that gut hormone receptor genes and proteins including 
these for the incretins, GIP, GLP-1, and for ghrelin and obestatin are expressed by 
both mouse and human white adipocytes, and this selection of gut peptides 
contribute to the regulation of a number of adipokines including classical hormones 
and cytokine gene expression in human adipocytes.
Additionally, GLP-1 and ghrelin appear to have effects on insulin action in white 
adipose tissue. The techniques utilized in the whole study included conventional RT- 
PCR and real-time PCR for analysis of receptor and adipokine gene expression 
respectively, western blotting for investigation of the receptor protein expression, 
electrospray ionization mass spectrometry for obestatin peptide molecular weight 
examination, and 2-deoxy-D-glucose for detection of the glucose uptake in human 
adipocytes.
7.2 ROLE OF INCRETINS IN WHITE ADIPOSE TISSUE
7.2.1 Incretin receptor gene expression in white adipose tissue
The present study demonstrates that GIPR mRNA was expressed in the major white 
adipose tissue depots of both mice and humans. On the other hand, differences in 
GLP-1 R gene expression between subcutaneous and visceral fat were shown in both 
mouse and human tissues. GLP-1 R gene expression was found in the omental but not 
the subcutaneous WAT of the human samples.
The findings presented here, however, could be the result of a different regulatory 
mechanism of subcutaneous and visceral fat gene expression by multiple stimuli. 
Adipose tissue located within the abdominal cavity has been suggested to be 
functionally and metabolically distinct from that of the subcutaneous compartment 
and these differences could play a role in obesity-related complications (Vohl et al.,
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2004). Tchkonia et al., (2006), demonstrated regional differences in the intrinsic 
characteristics of the preadipocytes in the different fat depots, with those of 
subcutaneous adipose tissue presenting greater differentiation and fat cell gene 
expression but less apoptosis than that of visceral fat tissue. Moreover, in recent years, 
it has been shown that the promoter region of the incretin receptor genes contains 
multiple Spl/Sp3 binding sites, which appear to be involved in the cellular expression 
of the receptor (Barth et al., 2002).
The present study also showed the presence of GLP-1R mRNA in a range of non­
adipose mouse tissues including skeletal muscle, small intestine, liver, kidney and 
brain. GLP-1R gene expression was detected not only in mouse liver, but also in 
human liver tissue, which supports the outcome of two studies (Schmidtler et al., 
1994; Villanueva-Penacarrillo et al., 1995). The known insulin secretion-independent 
effect of GLP-1 on hepatic glucose uptake is consistent with the presence of specific 
GLP-1 receptors on liver cells. Binding of GLP-1 to these receptors could initiate 
intracellular signaling pathways that could target kinases and/or factors involved in 
glucose uptake and glycogen synthesis.
Both incretin receptor genes are expressed in differentiated mouse and human white 
adipocytes. Western blot studies confirmed the expression of both GIP and GLP-1 
receptor proteins in SGBS adipocyte cultures similar to the mRNA data. The receptor 
genes are expressed after differentiation but not in preadipocytes. The signals for the 
GIP and GLP-1 receptor mRNA and protein are late post differentiation.
The presence of these gut peptide receptors in fat cells could be an indicator of 
physiological effects mediated by these gut peptides in adipose tissue. To date, 
surprisingly little is known about these gut peptides interactions with adipocyte 
biology. However, GLP-1 seems to exert differential, concentration-dependent effects 
on lipid metabolism in human adipocytes, which may be explained by the existence of 
different GLP-1-binding receptors (Villanueva-Penacarrillo et al., 2001).
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7.2.2 The regulation of adipokine production by the incretins
Incretins may modulate the production of adipocyte-derived adipokines; adiponectin 
mRNA level increased after applying high doses of either GLP-1 or GIP for 24 h in 
differentiated SGBS cells. Adiponectin is one of the most abundantly expressed 
adipose-specific proteins (Maeda et al., 1997), and is implicated in the pathogenesis 
of obesity and insulin resistance in rodents and humans (Kim et al., 2002).
In addition to the most remarkable ability of incretins to excite insulin secretion in the 
presence of glucose stimulatory concentrations (Kreymann et al., 1987), the role of 
incretins in regulating glucose and lipid metabolism has been reported by others 
(Hauner et al., 1988; Wang et al., 1997). The present data reveal that both GLP-1 and 
GIP appear to have a small stimulatory effect on adiponectin mRNA levels at higher 
concentrations in human fat cells. It should be noted, however, that the effect of 
incretins on adiponectin is very small, and further work is required on the influence of 
both incretins on adiponectin release by fat cells. Furthermore, it is important to 
determine whether the functional hormone is secreted from the adipocytes.
The stimulation of MCP-1 by GIP indicates that GIP may be involved in the synthesis 
of this adipokine in adipocytes. This stimulatory effect contradicts the proposed anti­
obesity function of GIP (Gault, et al., 2003). Moreover, observations from a recent 
study in transgenic GIP receptor-deficient mice indicated that GIP directly links 
ovemutrition to obesity, therein playing a vital role in the development of obesity and 
related metabolic disorders (Miyawaki et al., 2002). This study with differentiated 
SGBS adipocytes has contributed significantly towards research in this area.
The present results with 24 h of GIP treatment in human adipocytes, showed that the 
expression of IL-6, another pro-inflammatory cytokine, was stimulated in a similar 
pattern. This indicates that GIP peptide is a regulatory agent that may have a role in 
the inflammatory response in white adipose tissue.
GLP-1 treatment did not alter the level of MCP-1 gene expression in human cell 
culture systems. However, a very small but statistically significant increase in IL-6 
mRNA level was only observed with high doses of GLP-1 treatment, whereas IL-6
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mRNA remained unchanged at lower doses.
The data in this thesis may suggest that in general, regulation by incretins in SGBS 
adipocytes is multi-factorial, and most likely the result of a complex interplay of 
different hormones and cytokines.
7.2,3 The effect of Incretins on insulin sensitivity in SGBS adipocytes.
GLP-1 enhances the metabolic responses to insulin in white adipose tissue. This study 
with differentiated SGBS adipocytes showed that GLP-1 treatment had a clear dose- 
dependent increase in glucose uptake with or without acute insulin-stimulation when 
compared with control cells. This significant stimulatory effect of GLP-1 on glucose 
uptake in SGBS adipocytes is supported by a similar observation in murine 3T3-L1 
cells (Egan et al. 1994), indicating that the actions of insulin to stimulate glucose 
uptake and its utilization for lipid synthesis were enhanced by the presence of GLP-1. 
Furthermore, a very recent in vivo study in humans has also shown that GLP-1 has 
effects on glucose disposal (Meier et al., 2006).
The study also demonstrated a minor decrease of GLUT4 mRNA levels, which was 
only observed with low dose GLP-1 treatment. The presence of GLP-1 for 24 h was 
reported to almost double the content of both GLUT4 and GLUT1 protein levels in 
3T3-L1 adipocytes compared with control cells (Egan et al. 1994). However, mRNA 
levels for both transporters were not altered (Egan et al. 1994). Moreover, primary 
cultures of rat adipocytes also have reduced levels of GLUT4 even when no insulin 
was added to the medium (Hadjuch et al., 1992; Gerrits et al. 1993), indicating that 
insulin is not the only factor modulating facilitative glucose transporters.
Although the insulin-releasing action of GIP makes a major contribution to its 
metabolic role, in this study however the addition of 100 nM GIP to SGBS adipocytes 
for 24 h did not improve 2-deoxy-D-glucose uptake with or without the presence of 
different doses of insulin. Nevertheless, the acute administration of high dose GIP 
without prior use of insulin caused an increase in glucose uptake.
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Studies on the effect of insulin on GlP-stimulated glycerol release revealed that when 
cells were incubated in the presence of insulin, a concentration equivalent to that 
found circulating early postprandially, insulin resulted in an inhibition of the GIP 
effect on lipolysis. (Flakoll et al., 1996). This study suggests that factors modulating 
glucose metabolism in vivo are not present in vitro and that in vivo factors are 
necessary for the full response.
In conclusion, both incretin hormones, GIP and GLP-1, appear to interact with 
adipocyte functions. Regulation of endocrine adipocyte function and enhancement of 
insulin action may be an important direct effect.
7.3 ROLE OF GHRELIN IN WHITE ADIPOSE TISSUE
7.3.1 Ghrelin receptor gene expression in white adipose tissue
Ghrelin receptor, GHS-R, gene expression was detected in the mouse brain and in 
major white adipose tissue depots of both mice and humans, which is consistent with 
the observations of previous studies (Korbonits et al., 2004; Kojima et al., 1999; Kim 
et al., 2004).
By using 3T3-L1 cells in culture, the current study indicated that the GHS-R gene is 
expressed after differentiation, although not in preadipocytes and these findings were 
further supported by exploring GHS-R gene and protein expression in human SGBS 
adipocyte cultures. The signals for the GHS-R mRNA were late post differentiation; 
emerging from day 8 and onwards.
To date, surprisingly little is known about the interaction of ghrelin with adipocyte 
biology. However, recent studies have shown that ghrelin activates the mitogen- 
activated protein kinase pathway in vitro, which stimulates cellular proliferation and 
differentiation in cultured white adipocytes (Kim et al., 2004; Zhang et al., 2004). In 
contrast, using brown adipocytes, ghrelin does not seem to affect adipocyte 
differentiation (Ott et al., 2002).
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7.3.2 The regulation of adipokine production by ghrelin
Little is known concerning the regulation of adipokine production by ghrelin. 
However, a recent study has examined the possibility that ghrelin directly suppresses 
adiponectin mRNA expression in brown adipocytes (Ott et al., 2002). The data in 
this thesis does not support such a role in the case of white fat cells.
Interestingly, however, ghrelin treatment for 24 h resulted in a statistically significant 
inhibitory effect on MCP-1 mRNA levels by 50% in both intermediate and high 
doses. The results in this thesis were further strengthened by an independent study, in 
which ghrelin was found to have potent anti-inflammatory effects in human 
endothelial cells, which are likely to be mediated by inhibition of NF-kB activation 
(Li et al., 2004). These findings raise the possibility that reduction in endogenous 
ghrelin could potentially contribute to the pro-inflammatory state and the increased 
incidence of atherosclerosis in obese patients.
The present data demonstrate an inhibitory effect of ghrelin on the expression of pro- 
inflammatory cytokine, MCP-1 in human adipocytes supporting a possible regulatory 
role for ghrelin in a range of inflammatory conditions associated with obesity.
7.3.3 The effect of ghrelin on insulin sensitivity in SGBS adipocytes.
The data in this thesis support a direct role for ghrelin in enhancing insulin- 
independent glucose uptake in SGBS adipocytes. A significant increase in 2-deoxy- 
D-glucose uptake occurred at high ghrelin concentration; nevertheless, after applying 
different doses of insulin the glucose uptake was significantly down-regulated 
compared with control untreated cells.
The present study also showed that acute administration of ghrelin without the 
presence of insulin augmented glucose uptake in SGBS adipocytes in a dose- 
dependent manner and was significant at the higher doses. This suggests that ghrelin 
has ‘insulin-like’ rather than ‘insulin-sensitising’ effects. Ott et al., (2002) reported 
that ghrelin did not stimulate glucose uptake without insulin. However; the study in 
this thesis suggested the opposite.
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A possible physiological action of ghrelin might be the stimulation of lipolysis under 
conditions in which insulin levels are inadequate magnitude to inhibit its action, and 
this may ensure that levels of circulating FFAs are optimal for glucose and ghrelin 
stimulated insulin secretion. Such a proposal is open to experimental verification.
Moreover, the current study showed no change in GLUT4 mRNA levels, with ghrelin 
treatment. It was not possible to identify the precise mechanism by which ghrelin 
stimulates glucose uptake. Follow-up work would need to investigate the signal 
transduction pathway using cultured cells.
7.4 ROLE OF OBESTATIN IN WHITE ADIPOSE TISSUE
7.4.1 Obestatin receptor gene expression in white adipose tissue
The gene expression of the putative receptor for the anorexigenic peptide obestatin, 
GPR39, occurred in a range of mouse tissue including skeletal muscle, small intestine, 
liver, kidney and brain, as well as white adipose tissue of both mice and humans. The 
tissue expression pattern of GPR39 indicates that this receptor might be truly essential 
for the function of a number of metabolic organs.
The current study further indicates that the GPR39 gene is indeed expressed after 
differentiation but not in preadipocytes in cell culture systems (mouse 3T3-L1 and 
human SGBS cells). The signal was immediately observed at day 1 post-induction and 
was present throughout the subsequent time course shortly after differentiation. This 
finding is consistent with GPR39 protein expression in human SGBS adipocytes.
The G-protein coupled receptor, GPR39, has been proposed to be the target receptor 
of obestatin (Zhang et al., 2005). However, this has not been confirmed by other 
studies (Holst et al., 2007; Lauwers et al., 2006). This is the first occasion in which 
both mouse and human adipocytes cell culture systems were found to express the 
transcript coding for the proposed obestatin receptor (GPR39). Moreover, these pre­
adipocyte cell culture systems provide a valuable model for analysing ligand 
signalling by obestatin, for testing different obestatin agonists and antagonists and for 
the physiological nature of the effects mediated by obestatin in adipose tissue.
180
Discussion
Although, Tnag et a l (2008) demonstrated that obestatin induced cell proliferation in 
a dose-dependent manner with MEK/ERK 1/2 phosphorylation in primary cultures of 
piglet adipose cells, another study showed that obestatin did not stimulate cell cycle or 
viability of the murine adipocytes cell line 3T3-L1 and inhibited the proliferation and 
differentiation of 3T3-L1 preadipocytes (Zhang et a l, 2007). Furthermore, the effect 
of obestatin was contrary to that of ghrelin on these adipocyte cell line (Zhang et a l, 
2007).
7.4.2 The regulation of adipokine production by the obestatin
Surprisingly only two previous studies have evaluated the effect of obestatin in 
adipocyte biology. No information has been reported on the relationship between 
obestatin and adipokine production. However, the present results with 24 h treatment 
with obestatin from different sources in human adipocytes, including des-obestatin 
(11-23), showed a stimulatory effect in pro-inflammatory adipokine (MCP-1 and IL- 
6) mRNA levels. This indicates that obestatin and des-obestatin peptides may act as 
regulatory agents that have a role in the inflammatory response in white adipose 
tissue. However, more work, including investigations on the influence of obestatin 
and des-obestatin on inflammation-related adipokine release by fat cells is needed in 
the future.
Des-obestatin (11-23) showed a marked stimulation of mRNA levels for leptin and 
adiponectin. A very recent in vivo study reported that plasma obestatin concentrations 
are negatively correlated with body mass index, insulin resistance index, and plasma 
leptin concentrations in obese humans (Nakahara et al., 2007). Of course, des- 
obestatin is a small fragment of obestatin, and may be part of a system with multiple 
effector elements, which not only have opposite actions, but also regulate the action 
of each other.
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7.4.3 The effect of obestatin on insulin sensitivity in SGBS adipocytes.
Obestatin stimulation alone did not have any effect on basal glucose uptake in human 
SGBS adipocytes. Furthermore, pre-treated SGBS cells with obestatin in the presence 
of different concentrations of insulin did not alter the insulin-induced glucose uptake 
effect compared with the untreated adipocytes.
The current data do not support a role for obestatin in adipocyte insulin activated 
endpoints such as glucose uptake. This finding is in agreement with a previous report 
(Green et al., 2007), which observed that obestatin peptide has direct and indirect 
effects on food intake, but no direct actions on glucose homeostasis or insulin 
secretion in mice.
7.5 ROLE OF GASTROINTESTINAL HORMONES IN OBESITY
The expression of the GIPR, GLP-1R, GHS-R and GPR39 genes was evident in four 
obese human (subcutaneous) WAT.
The presence of GLP-1R expression in subcutaneous fat of obese subjects suggests 
that an exaggerated 'incretin' factor may have a pathophysiological role in obesity. 
Moreover, the hyper-secretion of GLP-1 may be the long sought 'incretin' factor in 
obesity. Studies suggest that obesity often produces a type 2-like diabetic state, which 
resolves after weight loss (Molavi et al., 2006).
Importantly, the putative obestatin receptor, GPR39, gene expression was found in the 
subcutaneous fat of all four human obese subjects, but no expression was evident in 
lean subjects. It could be hypothesised that high expression of the GPR39 gene in 
obese subjects is due to a decreased obestatin level in obesity. In a recent study, Huda 
et al., (2008) have shown that plasma obestatin concentrations are significantly lower 
in obese subjects when compared to lean controls. Nevertheless, the reduction of this 
peptide in obese humans is probably maladaptive and may further propagate the obese 
state.
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Obesity has emerged as a low-grade inflammatory state and it is still unclear whether 
adipocytes or the SV fraction in WAT have a more prominent role in the secretion of 
the major pro-inflammatory factors (Fain et a l, 2004). A remodelling of WAT by 
cross-talk between these two fractions is likely to mediate the low-grade inflammatory 
response in obesity.
7.6 CONCLUSION AND PERSPECTIVES
The studies described in this thesis have established that the genes encoding the 
receptors for ghrelin (GHS-R), obestatin (GPR-39), glucagon-like peptide-1 (GLP- 
1R) and glucose-dependent insulinotropic polypeptide (GIPR) are expressed in major 
white adipose tissue depots and are indeed expressed in adipocytes. The foundation 
has been laid for future work, which, in first instant, could involve further and more 
detailed examination of the metabolic role of these gut hormones in WAT using a 
multiplicity of approaches.
Furthermore, the relationship between obesity and gut hormones remains to be 
clarified; additional studies could be aimed both in vivo and in vitro. It is very 
important to elucidate the relationship between the serum levels of these gut 
hormones and adiposity in both obese and lean subjects.
The data in this thesis also suggest that GLP-1, in addition to its well-known effects 
on insulin secretion by pancreatic p cells and glucagons secretion by a cells, may have 
effects on major targets of insulin action sites such as white adipose tissue. The 
presence of mRNA for the GLP-1 receptor in liver, skeletal muscle as well as adipose 
tissue raises the possibility that binding of GLP-1 to these receptors could initiate 
intracellular signaling pathways that could target kinases and/or factors involved in 
glucose uptake and glycogen synthesis.
The current study has provided evidence for selective effects of ghrelin on adipocyte 
function and thus proposes a role for adipose tissue as a novel mediator of ghrelin’s 
effects on energy balance and glucose homeostasis. Moreover, the fact that this 
peptide can inhibit the production of pro-inflammatory “MCP-1” in human fat cells
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suggests a potential mechanism through which ghrelin may protect against pathologic 
inflammatory conditions in obesity. However, it should be noted, that appetite is 
regulated by numerous factors that may interact with and compensate for each other. 
Therefore the effectiveness of such an approach has to be directly shown in clinical 
studies. Further research is required to investigate whether ghrelin antagonists or 
agonists might be viable anti-obesity or malnutrition-treating drugs that can be used in 
wide clinical practice.
It is now recognised that adipose tissue is an active endocrine organ, secreting a wide 
range of adipokines and other factors, which can act locally within the tissue and may 
also be released into the general circulation, with effects on multiple organs and 
systems. The work presented in this thesis provided some evidence that incretins, 
obestatin and ghrelin regulate the expression and release of key adipokines and 
thereby play a significant role in adipose tissue as part of the cross-talk between the 
gut and adipose tissue.
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Appendix
Part of the work in this thesis has been presented in the following publications and 
oral communications:
Publications
1. Al-naimi S, Ranganath LR, Shenkin A & Trayhum P (2006). Do white 
adipose adipocytes express receptors for gut hormones? (Abstract). Ann Clin 
Biochem (Supplement) 43, S14
2. Al-naimi S, Ranganath LR & Trayhum P (2007). Ghrelin and Obestatin and 
the white adipose tissue. (Abstract). Ann Clin Biochem (Supplement) 44, S77
Oral presentation
1. “Do white adipose adipocytes express receptors for gut hormones?” (2006) 
Focus, The Association of clinical Biochemistry, Annual national meeting, 
Brighton, UK.
2. “White Adipocytes Express Receptors for the Gut Hormones Ghrelin, GIP, 
GLP-1 and Obestatin” (2006) International Congress on Obesity, Sydney, 
Australia.
3. “Ghrelin and Obestatin and the white adipose tissue”(2007) Focus, The 
Association of clinical Biochemistry, Annual national meeting, 
Manchester,UK.
4. “Gut Hormones ,Ghrelin and Obestatin in the white adipose tissue”(2008) The 
Association of clinical Biochemistry, NW ACB Ian Ward Meeting, Birchwood 
centre, Warrington, UK.
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